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Abstract 
 
Variation in the calpain-10 gene has been linked to a three-fold 
increased risk for type 2 diabetes in Pima Indian and some European 
populations.  Furthermore, reduced skeletal muscle expression of 
calpain-10 is associated with reduced insulin mediated glucose disposal 
and carbohydrate oxidation.  The skeletal muscle specific calpain-3 
plays a key role in skeletal muscle integrity and has also been linked to 
insulin resistance in humans and rodents.   
 
The major aims of this thesis were to 1) investigate the hypothesis that 
alterations in insulin sensitivity in healthy humans would lead to 
significant changes in the mRNA and protein expression of calpain-10 
and -3, 2) investigate the effect of hyperinsulinaemia and lipid 
availability on calpain-10 and -3 expression, 3) further address the role 
of genetic variation in the calpain-10 gene on glucose utilisation in 
humans and finally 4) investigate the expression of calpain-10 in 
skeletal muscle of type 2 diabetic patients.   
 
The studies in this thesis show for the first time that insulin resistance 
as a result of short term fasting or high fat availability is not associated 
with changes in calpain-10 and -3 mRNA and protein expression, 
providing evidence against an adaptive role for these genes in the 
development of fasting- and lipid-induced insulin resistance.   
 xii 
Analysis of human skeletal muscle protein demonstrated, also for the 
first time, the expression of multiple calpain-10 isoforms and revealed 
that calpain-10 is highly localised to the nucleus and plasma 
membrane.  Whilst short-term physiological hyperinsulinaemia was 
found to negatively regulate calpain-10 mRNA and protein, acute 
exercise did not lead to changes in calpain-10 and -3 expression.  
Genetic variation in the calpain-10 gene, previously linked to type 2 
diabetes, was not associated with insulin mediated glucose disposal or 
rates of carbohydrate and fat oxidation in healthy humans.  Finally, total 
calpain-10 protein expression was found to be lower in the skeletal 
muscle of type 2 diabetic patients when compared to age matched 
endurance trained, but not sedentary, control subjects.  These findings 
are highly relevant for studies into the underlying genetic causes of 
diabetes and for the ongoing search for diabetes linked genes.   
 xiii 
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 1 
1 Introduction 
 
1.1 In perspective 
 
Diabetes is characterised by abnormally high levels of sugar (glucose) 
in the blood.  Under normal physiological conditions, a rise in blood 
glucose triggers the release of the anabolic hormone insulin from the 
pancreas.  The major role of insulin is to stimulate muscle and fat cells 
to remove excess glucose from the blood, and to stimulate the liver to 
metabolise glucose, thereby causing the blood sugar level to return to 
normal fasting values.  In people with diabetes, blood sugar levels 
remain elevated.  This may be because insulin is not being produced, is 
not made at sufficient levels, or is not as effective as it should be.  The 
two major forms of diabetes are type 1 diabetes (5%), which is primarily 
an autoimmune disorder, and type 2 diabetes (95%), which is 
commonly associated with obesity. 
 
Type 2 diabetes is the most common disease in the world (King and 
Rewers, 1993; King et al., 1998; Mokdad et al., 2001a; Mokdad et al., 
2001b) and in the United States alone, it is a leading cause of blindness 
(Klein et al., 1995; Porta and Allione, 2004), kidney disease (Cowie et 
al., 1989) and nontraumatic loss of limb (Reiber and Raugi, 2005).  The 
associated health care costs in the United States are estimated to be in 
excess of $130 billion a year.  In the UK, approximately 1.6 million 
 2 
people have been diagnosed with diabetes and the associated costs to 
the National Health Service are approximately £5.2 billion a year.  On a 
wider scale, type 2 diabetes is set to become a global pandemic with an 
estimated 300 million individuals affected by the year 2025 (King et al., 
1998).   
 
Despite the fact that type 2 diabetes has been known for approximately 
2000 years, the precise mechanisms underlying the disease remain 
largely unknown.  The pathogenesis of type 2 diabetes is undoubtedly 
complex but it is clear from studies on twins that genetic predisposition 
is an important factor in the development of the disease (Froguel et al., 
1993; Guillausseau et al., 1997; Medici et al., 1999; Newman et al., 
1987).  However, the pattern of inheritance for the vast majority of type 
2 diabetic patients reflects varying penetrance or a polygenic nature.   
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1.2 Insulin and the regulation of blood glucose 
 
1.2.1 Insulin signalling 
 
Insulin is essential for maintaining normal physiological levels of 
glucose in the blood, or euglycaHPLDDQGLVUHOHDVHGIURPWKHȕ-cells of 
the pancreas in response to a glucose load.  Insulin exerts its effects by 
binding to and activating the membrane bound insulin receptor (IR) 
tyrosine kinase.  Insulin receptors are widely expressed throughout the 
human body, but insulin exerts most of its effects through three major 
target tissues - skeletal muscle, adipose tissue and the liver.   
 
In the skeletal muscle, which is the focus of this thesis, binding of 
insulin to the IR activates a cascade on intracellular events that leads to 
the removal of glucose from the blood into the cell.  In the presence of 
insulin, the insulin receptor phosphorylates insulin receptor substrate 
proteins (IRS), which are linked to the activation of the 
phosphatidylinositol 3-kinase (PI3K)-AKT/protein kinase B (PKB) 
pathway, which is responsible for a large majority of the metabolic 
actions of insulin. 
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1.2.1.1 The IR and IRS proteins 
 
The IR is the first point of contact between circulating insulin and an 
insulin response.  The importance of the IR has been demonstrated 
through the use of knock-out mice.  Targeted disruption of the insulin 
receptor gene (Insr) in mice resulted in marked hyperglycaemia and 
hyperinsulinaemia, ketoacidosis and growth retardation and finally 
death seven days after birth (Joshi et al., 1996).  In humans there have 
been just four case reports of homozygous Insr mutations (Tritos and 
Mantzoros, 1998).  Skeletal muscle specific IR knock out (MIRKO) 
leads to impaired insulin signalling and decreased insulin dependent 
glucose transport but not whole body insulin resistance (Bruning et al., 
1998).   
 
The insulin receptor satellite proteins known as IRS are activated by 
phosphorylation and mediate binding of intracellular effectors.  To date, 
six IRS proteins have been identified and it is IRS1 and IRS2 which 
appear to be the most important.  The IRS proteins associate with the 
IR via N-terminal plekstrin-homolgy domains (PH) and phosphotyrosine-
binding domains (PTB).  They associate with intracellular molecules 
containing Src-homology-2 domains (SH2) following the tyrosine 
phosphorylation of up to twenty sites located in the central and C-
terminal regions of IRS proteins.  Perhaps the best-studied SH2 protein 
is the regulatory subunit of phosphatidylinositol 3-kinase (PI3K) (Van 
Obberghen et al., 2001, Taniguchi et al., 2006).  
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1.2.1.2 Phosphatidylinositol 3-kinase (PI3K)        
 
Phosphorylation and activation of the IR and IRS leads to the activation 
of PI3K.  The importance of PI3K is clear as transfection with dominant-
negative PI3K blocks many of insulin’s actions (Cheatham et al., 1994).  
The PI3K enzyme consists of a regulatory and catalytic subunit; the 
activation of the catalytic subunit depends on the interaction of the two 
SH2 domains in the regulatory subunit with specific phosphotyrosine 
motifs in the IRS proteins (Shepherd et al., 1998).  PI3K exerts it effects 
by catalysing the formation of the lipid second messenger 
Phosphatidylinositol (3,4,5)-triphosphate  (PIP3), which is able to bind 
and activate additional proteins via their PH domains (Shepherd et al., 
1998).  One of the most important group of proteins that bind to PIP3 in 
this way is the AGC superfamily of serine/threonine protein kinases.  
The most critical of these proteins is the 3-phospoinositide-dependent 
protein kinase 1 (PDK1), which is responsible for the activation of 
AKT/protein kinase B (PKB) (Alessi et al., 1997).  AKT/PKB requires 
phosphorylation at two sites for its activation – Thr308 and Ser473; 
PDK1 enhances the activity of AKT/PKB by phosphorylation of Thr308 
only (Alessi et al., 1997).  Thus for full activation of AKT/PKB, it has 
been suggested that there is a PDK2 which phosphorylates Ser473.  
Indeed recent evidence suggests that this might be the rapamycin-
insensitive companion of mTOR (rictor) - mammalian target of 
rapamycin (mTOR) complex (Sarbassov et al., 2005).  The positive 
actions of PI3K can be negatively regulated at the level of PIP3 by 
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phospholipid phosphatases, such as phosphatase and tensin 
homologue (PTEN) which dephosphorylates and inactivates PIP3 
(Maehama and Dixon, 1999).   
 
1.2.1.3 AKT/PKB         
 
AKT/PKB mediates most of the PI3K – dependent metabolic actions of 
insulin, through the phosphorylation of many substrates including other 
kinases, signalling proteins and transcription factors.  One of the major 
roles of the AKT/PKB pathway is to stimulate glucose uptake into the 
cell and upregulate glycogen synthesis.  AKT/PKB appears to regulate 
glucose uptake by phosphorylating and inhibiting the Rab-GTPase-
activating protein AS160 (Kane et al., 2002; Sano et al., 2003).  This 
may trigger the activation of Rab small GTPases that are important for 
the cytoskeletal re-organisation that is required for the translocation of 
the glucose transporter GLUT4 to the plasma membrane (see 1.2.1.4).  
Phosphorylation of glycogen synthase kinase-3 (GSK3) by AKT/PKB 
decreases its activity towards glycogen synthase and thereby increases 
glycogen synthesis (Frame and Cohen, 2001) (see 1.3.3).  AKT/PKB 
also activates the mTOR pathway, possibly via phosphorylation and 
inhibition of tuberin, or tuberous sclerosis complex-2 (TSC2), which is in 
complex with hamartin (TSC1) (Harris and Lawrence, 2003).  The 
mTOR pathway regulates protein synthesis by phosphorylating the 
proteins p70 ribosomal protein S6 kinase (p70S6K) and eukaryotic 
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translation initiation factor 4E binding protein-1 (short, 4EBP1) (Harris 
and Lawrence, 2003). 
   
Finally, AKT/PKB regulates the expression of gluconeogenic and 
lipogenic enzymes by controlling the activity of the forkhead (FOX) 
class of transcription factors – a family of around 100 members, several 
of which may be critical for insulin action.  For example, FOXO1 
activates gluconeogenic genes in the liver and inhibits adipogenesis, 
actions which are inhibited by insulin through AKT/PKB mediated 
phosphorylation of FOXO1, which inhibits its transcriptional activity.  
FOXO1 may also have an important role in the regulation of 
carbohydrate and fat oxidation via actions on the pyruvate 
dehydrogenase complex (PDC) (1.3.4) (Taniguchi et al., 2006).  
 
1.2.2 Insulin signalling and glucose uptake 
 
Activation of the insulin signalling pathway through AKT/PKB leads to 
the translocation of intracellular glucose transporters to the plasma 
membrane where they facilitate glucose uptake into the target tissue.  
Whilst there are five major glucose transporters with distinct tissue 
distributions (Shepherd and Kahn, 1999; Joost et al., 2002; Bell et al., 
1990), the most abundant in insulin sensitive tissues is GLUT4.  GLUT4 
has a glucose Km of ~ 5 mM, which is close to the plasma glucose 
concentration of a healthy human.  In skeletal muscle and adipose 
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tissue, the concentration of GLUT4 at the plasma membrane increases 
markedly in response to insulin.   
 
In unstimulated muscle and adipose tissue, it is thought that GLUT4 
constitutively cycles to and from the plasma membrane through slow 
endocytosis and fast exocytosis, and it is thought that insulin stimulates 
the exocytic arm and reduces the endocytic arm of this cycling (Bryant 
et al., 2002; Dugani and Klip, 2005).  Whilst the exact mechanisms that 
lead to GLUT4 translocation following stimulation by insulin are not fully 
understood, it is currently thought that AKT/PKB (and possibly protein 
kinase C, 1.2.1.5) regulates GLUT4 translocation and glucose uptake 
by phosphorylating and inhibiting the Rab-GTPase-activating protein 
AS160 (Sano et al., 2003) as mentioned above.  In addition to 
stimulating the translocation of GLUT4, insulin derived signals also 
facilitate the fusion of GLUT4 containing vesicles with the plasma 
membrane.  AKT/PKB can target components of the vesicle – plasma 
membrane fusion machinery, which comprises the vesicle-associated 
membrane protein-2 (VAMP2), the N-ethylmaleimide-sensitive 
attachment protein-23 (SNAP23) and the membrane-associated SNAP 
protein (SNARE) syntaxin-4 as well as synip, tomosyn and munc18 that 
bind syntaxin4 to modulate the insulin dependent gain in membrane 
associated GLUT4 (Dugani and Klip, 2005).       
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1.2.3 Atypical protein kinase C (PKC) and glucose uptake 
 
A number of PKC isoforms have been linked to the regulation of the 
insulin signalling pathway, both in a negative (see 1.3.1.4) and a 
positive fashion.  The term protein kinase C (PKC) actually describes a 
family of protein kinases consisting of approximately 10 isozymes.  
They are commonly further subdivided into conventional (classical), 
nRYHO DQG DW\SLFDO IRUPV  &RQYHQWLRQDO 3.&V F3.& FRQVLVW RI Į ȕ
and Ȗ LVRIRUPV DQG UHTXLUH FDOFLXP GLDF\OJO\FHURO '$* DQG D
SKRVSKROLSLG IRUDFWLYDWLRQ 7KHQRYHO3.&VQ3.&FRQVLVWRIįİȘ
DQGșLVRIRUPVDQGUHTXLUH'$*EXWQRWFDOFLXPIRUWKHLr activation.  In 
FRQWUDVWWKHDW\SLFDO3.&VD3.&LQFOXGHȗDQGȜ\ȚLVRIRUPVEXWWKHVH
do not require either calcium or DAG for activation and are similar to 
AKT/PKB, which require PIP3 and PDK1/PDK2 phosphorylation (Dey et 
al., 2006).   
 
In addition to the phosphorylation and activation of AKT/PKB, it has 
been demonstrated that an additional target of PDK1 is PKC-ȗDQG-Ȝ\Ț 
and there is now evidence to suggest that these aPKC isoforms serve 
as molecular switches that participate in turning on glucose transport 
responses during insulin action (Farese, 2002).  The aPKCs exist in 
cells in a folded state and, upon activation by acidic lipids (e.g. PIP3), 
unfold and become active through a number of complementary 
mechanisms, including PDK1 phosphorylation, autophosphorylation and 
relief of auto-inhibition, suggesting that mechanism exist to activate 
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aPKC independent of phosphorylation and PDK1 (Farese, 2002).  
Following unfolding, aPKCs may become exposed to protease activity 
and are then converted to short lived, constitutively active M-type 
kinases (see 1.8.2.5). 
 
Defects in insulin mediated aPKC activation have consistently been 
reported in the muscle and adipocyte of type 2 diabetic patients 
(Beeson et al., 2003; Kim et al., 2003) and in a number of animal 
models of insulin resistance (Standaert et al., 2002; Kanoh et al., 2001).  
Stable expression of kinase inactive aPKC in myotubes inhibits insulin 
mediated GLUT4 translocation, whereas overexpression of 
constitutively active aPKC mimics the action of insulin on GLUT4 
translocation (Bandyopadhyay et al., 1997).  Furthermore, embryonic 
stem (ES) cells which lack PKC-ȜDQGZKLFKDUHWKHQGLIIHUHQWLDWHGWR
adipocytes, insulin fails to stimulate glucose transport (Bandyopadhyay 
et al., 2004).  Together, these studies strongly suggest that aPKCs play 
an important role in glucose uptake/GLUT4 translocation in skeletal 
muscle and adipose tissue.  There is currently no evidence to suggest 
that the conventional or novel PKC isoforms play a similar role in insulin 
stimulated glucose transport/GLUT4 translocation.  Indeed, as 
mentioned above, they appear to be more relevant in states of insulin 
resistance (see 1.3.1.4).    
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1.2.4 Glucose phosphorylation 
 
Once glucose has successfully entered the cell, isoenzymes of 
hexokinase (HK) catalyse the conversion of glucose to glucose-6-
phopshate – essentially trapping glucose within the cell.  HKI, HKII and 
HKIII are single chain peptides that have a number of properties in 
common, including a high affinity for glucose and inhibition by glucose-
6-phosphate.  HKII is expressed in insulin sensitive tissues (adipose 
and muscle tissue) whereas HKI is expressed in brain and erythrocytes.  
HKIV, also known as glucokinase, can be further subdivided into 
HKIVB, which is believed to be the glXFRVH VHQVRU LQ WKH ȕ-cell, and 
HKIVL, which is important for hepatic glucose metabolism (Katzen et 
al., 1970; Wilson et al., 2003). 
 
1.2.5 Glycogen metabolism – non oxidative glucose disposal 
 
During rest, storage of glucose as glycogen is enhanced by insulin 
stimulation of glucose uptake.  Following phosphorylation to glucose-6-
phosphate (G-6-P) by HKII, glucose may enter glycolysis to produce 
ATP or be converted to glucose-1-phosphate for glycogen synthesis.  
Glycogen synthase (GS) is one of the key enzymes controlling the rate 
of muscle glycogen synthesis and utilises UDP-glucose to add glucose 
PROHFXOHV E\ Į – 4 linkages – the rate limiting step in glycogen 
synthesis.   
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The activity of GS is controlled by covalent modification 
(phosphorylation/dephosphorylation), allosteric activation and enzyme 
translocation.  The enzyme is phosphorylated on up to nine residues by 
several kinases, resulting in enzyme deactivation and decreased 
sensitivity to allosteric activators.  These kinases include cAMP-
dependent protein kinase (PKA), calmodulin-dependent kinases, 
adenosine monophosphate kinase (AMPK) and glycogen synthase 
kinase 3 (GSK3).  Conversely, the dephosphorylation and activation of 
GS is controlled by protein phosphatase 1 (PP1).  These enzymes 
themselves are also closely regulated: GSK3 can be negatively 
regulated by phosphorylation by AKT/PKB following stimulation by 
insulin and positively regulated by cAMP following adrenergic 
stimulation.   Similarly, PP1 can be upregulated by insulin via complex 
mechanisms leading to dephosphorylation and activation of GS.  The 
relative contribution of GSK3 and PP1 to GS activity is not clear but 
recent reports on transgenic mice have questioned the ability of insulin 
to activate GS via PP1 (Suzuki et al., 2001; Walker et al., 2000).  
 
Alternative mechanisms exist to regulate GS activity in addition to 
phosphorylation/dephosphorylation.  For example, binding of G-6-P to 
GS unfolds the enzyme resulting in allosteric activation and causes 
conformational changes in GS that favour dephosphorylation of the 
enzyme.  Furthermore, translocation of GS to glycogen particles in 
response to stimuli (i.e. insulin) is an additional mechanism whereby GS 
activity is regulated (Greenberg et al., 2006).   
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During exercise muscles rely on glycolytic pathways to provide ATP for 
continued contraction.  Glycogen breakdown is controlled by the 
enzyme glycogen phosphorylase, which in turn is activated by a number 
of stimuli related to muscle contraction (e.g. calcium) thereby allowing 
glycogen breakdown to change in parallel with the energy demands 
during exercise. 
 
Repletion of glycogen stores involves an increase in GS activity after 
exercise.  However, despite net glycogen breakdown during exercise, 
mechanisms exist to activate GS and therefore increase glycogen 
synthesis during exercise in an insulin-independent manner.  An 
increase in GS activity in exercise appears to be dependent on the 
mode, duration and intensity of the exercise as some studies have 
demonstrated a reduction in GS activity during high intensity exercise.  
The insulin independence of GS activation during exercise suggests 
that exercise and insulin utilise different signalling pathways to activate 
GS.  These mechanisms may be related to glycogen levels themselves, 
phosphatase (PP1) and kinase (GSK3, PKA, AMPK) activation and 
allosteric factors (G-6-P) (Nielsen and Richter, 2003).   
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1.2.6 Carbohydrate oxidation – oxidative glucose disposal 
 
The PDH enzyme is part of the multi-enzyme pyruvate dehydrogenase 
complex (PDC), which catalyses the physiologically irreversible 
decarboxylation of pyruvate to acetyl CoA and is often referred to as a 
“gatekeeper” in the oxidation of carbohydrate.  Therefore PDC links the 
degradation of intracellular glycogen and extracellular glucose via 
glycolysis, as well as the oxidation of extracellular pyruvate and lactate, 
to the energy requirements of the cell (Holness and Sugden, 2003).  
Moreover, when the glucose supply is high, the combination of acetyl 
CoA with oxaloacetate provides a precursor for malonyl-CoA 
production.  Malonyl-CoA can limit the mitochondrial uptake (and 
therefore oxidation) of FFA via inhibition of carnitine 
palmitoyltransferase I (CPT1).  On the other hand, when glucose 
availability is low or FFA supply and oxidation is sufficient to meet the 
cellular energy demands, PDC activity is suppressed, limiting the 
conversion of pyruvate to acetyl-CoA.  This response to glucose 
scarcity may be crucial for glucose conservation (Holness and Sugden, 
2003).  Flux through the PDC is tightly regulated to maintain glucose 
homeostasis during both the fed and fasting states.  This regulation is 
achieved via a combination of three major mechanisms: 1) reversible 
phosphorylation/dephosphorylation, 2) modifications of the activities of 
the regulatory components by the redox state and acetyl CoA/CoA ratio 
and 3) transcriptional regulation of the regulatory components (Patel 
and Korotchkina, 2006). 
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The PDC complex contains two specific regulatory enzymes, pyruvate 
dehydrogenase kinase (PDK) and pyruvate dehydrogenase 
phosphatase (PDP).  These two enzymes catalyse a 
phosphorylation/dephosphorylation cycle involving specific serine 
residues on the PDH enzyme (Sugden and Holness, 2003).  The 
phosphorylation of the PDH completely inactivates the PDC and 
therefore the activity of PDC reflects the balance between the activities 
of PDK (which phosphorylates and inactivates PDH) and PDP (which 
dephosphorylates and activates PDH) (Linn et al., 1969).  The 
regulation of these enzymes is also tightly regulated.  The PDP 
enzymes (PDP1 and PDP2) are variably expressed in tissues but the 
dominant PDP1 enzyme in skeletal muscle requires magnesium and is 
stimulated by calcium (Huang et al., 1998).  Short term regulation of 
PDK includes its inhibition by pyruvate and its activation by acetyl CoA 
and NADH – products of the PDC reaction and FFA oxidation (Kerbey 
et al., 1976).  To date, four isoforms of PDK have been identified 
(PDK1-4) and each exhibits tissue specific regulation.  PDK1 is found in 
the heart, pancreas and skeletal muscle; PDK2 is ubiquitously 
expressed in the fed state; PDK3 has a limited tissue distribution and 
PDK4 is expressed at high levels in the heart, skeletal muscle, kidney, 
liver and pancreas (Bowker-Kinley et al., 1998).  The relative catalytic 
activity of the PDK isoforms towards PDH varies such that PDK2 and 
PDK4 exhibit the highest activity (Bowker-Kinley et al., 1998).  In 
addition, each isoform is differentially affected by short term regulatory 
metabolites.  For example, PDK2 is most sensitive to inhibition to 
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pyruvate where as PDK4 is relatively insensitive to pyruvate but instead 
is more sensitive to an increase NADH:NAD ratio (Bowker-Kinley et al., 
1998).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 17 
1.3 Cellular mechanisms of insulin resistance 
 
Insulin resistance, defined as a state of reduced responsiveness to 
normal circulating levels of insulin, plays a major role in the 
development of type 2 diabetes.  Historically, insulin resistance has 
been viewed in terms of the effects of insulin on glucose metabolism.  
As such, early studies focused on the reduction in early insulin 
signalling events including those affecting the structure and number of 
insulin receptors itself to those affecting the phosphorylation of early 
effectors of the insulin signalling cascade.  However, more recent 
analysis has revealed that insulin resistance also involves impairments 
in the enzymes that regulate glycogen synthesis and fat and 
carbohydrate metabolism, which lie downstream of insulin signalling 
pathways.  In this section, a discussion of the cellular mechanisms 
involved in insulin resistance begins with an overview of the defects 
along the insulin signalling pathway and then progresses to consider 
mechanisms further downstream of these pathways, including glycogen 
synthesis and substrate oxidation, that may influence insulin resistance.  
At the end of this section (see 1.4), a summary is provided which 
attempts to collate all the currently available data and postulate an all-
encompassing hypothesis for the mechanisms that may determine 
insulin resistance.   
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1.3.1 Insulin resistance and insulin signalling pathways 
 
1.3.1.1 Insulin receptor number and affinity 
 
Some early studies documented a small reduction in insulin binding in 
type 2 diabetic patients, due to a reduction in the number of insulin 
receptors (Freidenberg et al., 1987; Caro et al., 1986, 1987).  In 
addition, defects in insulin receptor internalisation and processing in 
monocytes have been reported (Trischitta et al., 1989).  These data are 
far from consistent however, and it should be noted that these defects 
in insulin receptor number and affinity have not always been reported in 
the two most important tissues for glucose disposal - muscle and liver 
(Klein et al., 1995).  Sequencing of the insulin receptor gene has not 
revealed any physiologically significant mutations in type 2 diabetics, 
excluding the possibility of a structural gene abnormality in type 2 
diabetic subjects (Moller et al., 1989).  However, mutations of the insulin 
receptor gene have been reported in some rare genetic syndromes with 
severe insulin resistance (Moller et al., 1990; Hashiramoto et al., 2005; 
Taylor et al., 1992).  
 
1.3.1.2 Insulin receptor phosphorylation  
 
Most studies have found reduced tyrosine kinase activity of the insulin 
receptor in insulin resistance and type 2 diabetics, either in the form of 
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reduced substrate phosphorylation or autophosphorylation (Comi et al., 
1987; Sesti et al., 2001; Haring et al., 1982; Nyomba et al., 1990; Nolan 
et al., 1994).  This may be an acquired defect as insulin receptor activity 
can be improved following normalisation of fasting plasma glucose (for 
example by weight loss) (Freidenberg et al., 1988).  In humans in vivo, 
studies employing the hyperinsulinaemic-euglycaemic clamp technique 
have demonstrated a large reduction in insulin receptor tyrosine 
phosphorylation and increased serine phosphorylation in type 2 
diabetics (Dresner et al., 1999; Griffin et al., 1999).  There are over 70 
potential serine phosphorylation sites in IRS1 and, in general, this 
serine phosphorylation seems to negatively regulate insulin signalling 
suggesting that it may have a role in the pathogenesis of insulin 
resistance.  Many IRS kinases including extracellular signal-regulated 
kinase (ERK) (Bouzakri et al., 2003), S6 kinase (Harrington et al., 2004) 
and c-jun-N-terminal kinase (JNK) (Miller et al., 1996) are activated by 
insulin suggesting that serine phosphorylation may be related to 
negative feedback of the insulin signalling pathway.  In particular, serine 
phosphorylation of the insulin receptor in insulin resistance may be 
linked to fat metabolites and nPKC activation (see 1.3.1.4) (Savage et 
al., 2005).  The activation of Nuclear Factor țB (NF-țB) mediated 
pathways also have been shown to inhibit insulin signalling through 
increased serine phosphorylation of IRS1 and may be a mechanisms 
that mediates cross talk between signalling pathways (Kim et al., 2001; 
Itani et al., 2002).    
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1.3.1.3 Glucose transport 
 
Glucose transporter activity in type 2 diabetic patients has consistently 
been shown to be lower in both adipocytes (Kashiwagi et al., 1983) and 
muscle (Zierath et al., 1996; Krook et al., 2000).  However, GLUT4 
mRNA levels in muscle tissue extracted from type 2 diabetics are 
unchanged, or in some cases are increased when compared to control 
subjects (Pedersen et al., 1990; Kahn et al., 1991), whereas GLUT4 
mRNA in adipose tissue is markedly reduced in type 2 diabetic humans 
and rodent models of diabetes (Kahn et al., 1991), suggesting that 
GLUT4 expression is subject to tissue specific regulation.  
 
1.3.1.4 Novel PKCs and insulin resistance 
 
A number of the novel PKC isoforms have been associated with the 
negative regulation of the insulin signalling pathway.  This is in contrast 
to the positive effects of the aPKCs on GLUT4 translocation and 
glucose uptake (see 1.2.3).  As mentioned above, these nPKCs include 
į İ Ș DQG ș LVRIRUPV DQG UHTXLUH '$* EXW QRW FDOFLXP IRU WKHLU
activation, and as such have consistently been linked to insulin 
resistance associated with increased lipid availability.  Lipid infusion in 
rats and humans impairs insulin stimulated glucose disposal in muscle 
and is associated with concomitant activation of PKC-įDQG–ș,WDQL et 
al., 2002; Yu et al., 2002; Dey et al., 2006; Shulman, 1999).  It has been 
suggested that one mechanism whereby PKC-įDQd –șUHGXFHLQVXOLQ
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sensitivity is via serine phosphorylation of the IRS and this has recently 
been demonstrated in vitro (Greene et al., 2004).  This serine 
phosphorylation may reduce the ability of IRS to activate PI3K and thus 
contribute to a reduction in insulin stimulated glucose uptake (see 1.2.2) 
and glycogen synthesis (see 1.2.5).  An additional nPKC, PKC- İKDV
recently been shown to be upregulated in the skeletal muscle of the 
diabetic Psammomys obesus rat (Ikeda et al., 2001).   
 
1.3.2 Insulin resistance and glucose phosphorylation 
 
HKII is regulated by insulin and, in response to physiological 
hyperinsulinaemia, HKII activity, protein and mRNA content are all 
increased in healthy non-diabetic subjects (Mandarino et al., 1995).  It 
has been reported that in type 2 diabetes, glucose phosphorylation by 
HKII is reduced under basal conditions and in response to insulin 
infusion (Kruszynska et al., 1998).  However, in the same study, basal 
and insulin mediated HKII activity was not reduced in insulin resistant 
obese subjects, suggesting that a reduction in HKII activity is probably 
secondary to the diabetic state (Kruszynska et al., 1998).  This idea is 
consistent with animal models of induced diabetes in which HKII activity 
can be partly restored by insulin therapy (Braithwaite et al., 1995; Frank 
and Fromm, 1986).  
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1.3.3 Insulin resistance and glycogen metabolism 
 
The importance of GSK3 to GS activation and insulin resistance is 
supported by several lines of evidence.  Firstly, in poorly controlled type 
2 diabetics, GSK3 protein expression and activity is upregulated 
(Nikoulina et al., 2000).  However, in better controlled type 2 diabetics, it 
has recently been shown that GSK3 activity is normal despite insulin 
mediated activation of GS being almost absent (Hojlund et al., 2003), 
suggesting that increased GSK3 activity is more a feature of severe 
insulin resistance.  In that study, insulin mediated dephosphorylation of 
GS at sites 3a + 3b was the same in normal and diabetic subjects but 
this dephosphorylation was counteracted in the diabetics by an insulin 
mediated phosphorylation of sites 2 + 2a on GS (Hojlund et al., 2003).  
Interestingly, alternative kinases associated with insulin resistance (e.g. 
PKC, 1.3.1.4) are able to phosphorylate GS on these sites (Ahmad et 
al., 1984).   
 
More consistent evidence for a role of GSK3 in insulin resistance comes 
from studies employing GSK3 inhibitors.  The administration of a 
number of chemical compounds, including lithium, malemides, 
aminopyridine derivatives and phosphopeptide pseudosubstrates, both 
acutely and chronically, has been shown to activate GS and lead to 
improvements in insulin action (reviewed in Cohen and Goedert, 2004).  
These studies suggest that GSK3 inhibitors may be a useful target in 
the treatment of type 2 diabetes. 
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In type 2 diabetics, exercise may improve blood glucose levels and 
overcome insulin resistance and this effect has been attributed, in part, 
to an increase in glycogen synthesis (Perseghin et al., 1996; Price et 
al., 1996) as a result of increased GS mRNA (Dela et al., 1995) and GS 
activity in the post exercise period (Christ-Roberts et al., 2003, Cusi et 
al., 2001).  These studies suggest that therapies which mimic the 
effects of exercise on carbohydrate metabolism could prove to be 
potent therapeutic tools in the treatment of type 2 diabetes.    
 
1.3.4 Insulin resistance and substrate oxidation 
 
Carbohydrate and fat are the primary fuel sources for mitochondrial 
ATP production in human skeletal muscle.  An interaction between the 
oxidation of these two fuels has historically been suggested as a 
potential mechanism underlying insulin resistance in skeletal muscle.  
Randle and colleagues proposed the concept of the “glucose-fatty acid 
cycle” in the 1960’s whilst studying rat heart and diaphragm muscle 
(Randle et al., 1963).  The main features of this concept were that 
increased fat oxidation in muscle would inhibit both pyruvate 
dehydrogenase (PDH) and phosphofructokinase (PFK) by accumulation 
of acetyl CoA and citrate, respectively.  Inhibition of these enzymes 
would lead to reduced flux through the glycolytic pathway and thus an 
increase in glucose 6-phosphate concentrations, inhibiting HK and 
resulting in reduced glucose uptake and oxidation.  
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Insulin resistance is associated with increased PDK activity and 
subsequent reductions in PDC flux.  PDK activity is increased in several 
oxidative tissues in vivo in response to nutritional manipulations that 
increase lipid supply and oxidation.  For example, PDK expression and 
/or activity increases with starvation (Wu et al., 1998; Spriet et al., 2004; 
Pilegaard et al., 2003), insulin resistance induced by high fat feeding 
(Peters et al., 2001) and streptozotocin induced diabetes (Wu et al., 
1998) and this has originally been attributed to an increase in FFA.  
However, recent studies have shown that PDK4 expression is 
downregulated by insulin independently of FFA (Lee et al., 2004) and 
as the above states of insulin resistance are characterised by insulin 
deficiency, it is possible that the increase in PDK4 is a consequence of 
the inability of insulin to suppress PDK4 expression (Kim et al., 2006).  
Recent studies have implicated FOXO1 in the regulation of PDK4 by 
insulin (Kwon et al., 2004; Furuyama et al., 2003; Kim et al., 2006) (see 
1.2.1.3).  FOXO1 is expressed in insulin sensitive tissues including the 
liver and skeletal muscle and is phosphorylated by AKT/PKB through 
the insulin signalling pathway and then translocates from the nucleus to 
the cytosol resulting in reduced transcriptional activity.  Therefore, a 
reduction in insulin signalling due to insulin resistance would activate 
FOXO1 and lead to an increase in PDK4 expression.  These pathways 
may provide a possible link between the insulin signalling pathways and 
the control of carbohydrate and fat oxidation and thereby provide an 
integrative model of insulin resistance.        
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1.4 Summary – The metabolic basis of insulin resistance 
 
From the discussions above, it is apparent that insulin resistance can 
be influenced by any one of many mechanisms, ranging from insulin 
receptor tyrosine phosphorylation to glycogen synthesis to fat and 
carbohydrate oxidation.  The question that remains is which of the 
mechanisms described above are the most important and which of 
them underlie insulin resistance?   
 
A hypothesis to explain insulin resistance in a way which integrated 
many of these pathways was suggested by Randle in the early 1960’s 
(Randle et al., 1963).  Initial attempts to confirm this model in humans 
demonstrated that increasing plasma FFA levels during a 
hyperinsulinaemic clamp (e.g. by lipid infusion) reduced carbohydrate 
oxidation, increased fat oxidation and inhibited insulin stimulated 
glucose uptake (e.g. Bonadonna et al., 1989).  However, it was later 
shown in more detailed studies that although lipid infusion did increase 
fat oxidation and reduce carbohydrate oxidation in vivo, there was no 
change in citrate or G-6-P in muscle or in glucose disposal for at least 3 
h (Boden et al., 1991).  In other words, the long delay between the rise 
in fat oxidation and the fall in glucose disposal and the lack of an 
increase in citrate and G-6-P could not be explained by the traditional 
Randle hypothesis.   
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It was also shown that glucose oxidation was increased (not decreased 
as would be expected) in the leg muscle of type 2 diabetic subjects 
studied postabsorptively under conditions of fasting hyperglycaemia 
(Kelley and Mandarino, 1990).  In retrospect, these findings perhaps 
were not surprising considering that in the skeletal muscle of healthy 
subjects, lipid, not carbohydrate, is the dominant oxidative fuel (Andres 
et al., 1956).  Around the same time, it was shown that increased 
muscle glucose metabolism in skeletal muscle increased malonyl-CoA 
concentrations, which inhibited carnitine palmitoyl transferase (CPT)-1 
and blocked FFA entry into the mitochondria (Winder et al., 1990).  
Reduced entry of FFA into the mitochondria might lead to an 
accumulation of activated FFA, or long-chain acyl-CoA concentrations, 
in the cell.  An increase in the concentrations of fatty acyl CoAs can 
lead to increased DAG concentrations and, as outlined above, this can 
lead to nPKC activation.  This PKC activation could lead to an 
increased serine phosphorylation of IRS1 and a reduction in PI3K and 
AKT/PKB activation leading, eventually, to a reduction in GLUT4 
trafficking, reduced glucose uptake and reduced glycogen synthesis.  
Under this hypothesis, it appears that the rate-limiting step governing 
insulin resistance is indeed GLUT4 mediated glucose uptake.  
 
Therefore, there is now increasing evidence to suggest that it is not 
increasing fat oxidation that produces insulin resistance, but instead 
that abnormalities in insulin action may arise as a result of an 
accumulation of various lipid species in skeletal muscle.  In other words, 
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insulin resistance may begin with an accumulation of fatty acid 
metabolites and these metabolites may negatively regulate the insulin 
signaling pathway via mechanisms linked to DAG mediated PKC 
activation for example.  Glucose oxidation could also contribute to 
insulin resistance at the same time via FOXO1 mediated PDK4 
upregulation, leading to inhibition of PDH.  Under this mechanism it is 
apparent that a reduction in glucose oxidation would be secondary to 
reduced insulin signalling.  It is also possible to envisage the opposite;   
that an increase in lipid supply could lead tRDQLQFUHDVHLQȕ-oxidation 
and increased acetyl CoA and NADH concentrations, leading to 
increased PDK4 activity, reduced carbohydrate oxidation and insulin 
resistance, although this idea is more consistent with the original 
Randle hypothesis.  In summary, whilst the exact mechanisms that 
underlie insulin resistance are still under intense debate, current 
thinking points to an integration of the pathways that govern 
carbohydrate and lipid oxidation with those regulating insulin signaling.  
Clearly, a detailed understanding of the metabolic basis of insulin 
resistance will be crucial for the identification of potential drug targets 
and in the treatment of type 2 diabetes.   
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1.5 The search for type 2 diabetes candidate genes  
 
From the discussions above (see 1.2 – 1.4), it is clear that defects in 
one or many proteins involved in skeletal muscle glucose uptake, 
glycogen synthesis or substrate oxidation may lead to severe defects in 
glucose homeostasis.  Evidence that genes play an important role in the 
development of type 2 diabetes originally came from studies performed 
on twins.  Studies in the USA and Denmark showed a high 
concordance rate (i.e. the presence of a given trait in both members of 
a pair of twins) for type 2 diabetes among monozygotic twins, reaching 
41% and 55%, respectively (Newman et al., 1987; Harvald and Hauge, 
1963).  In dizygotic twins, the values were significantly lower (10% and 
15%, respectively).  Moreover, it is well known that some populations in 
the world have extremely high prevalence of type 2 diabetes, which 
cannot be attributed to environmental factors alone.  An excellent 
example of this is the Pima Indian population; by the 1990s about 8% of 
young men and women aged 20-24 had the disease, and 3% of those 
aged 15-19 years were also affected in this population (Bennett, 1999; 
see also Knowler et al., 1978).  
 
1.5.1 Simple and complex forms of type 2 diabetes 
 
Based on the role of genetic factors, type 2 diabetes may be divided 
into two broad groups – those that are monogenic and those that are 
polygenic in nature.  Monogenic forms, constituting only a small 
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proportion of type 2 diabetes cases (10%), are simpler in nature and 
are frequently characterised by rare mutations in a single gene that 
have significant detrimental effects on the protein function.  Monogenic 
forms are characterised by early age of diagnosis and usually a more 
severe clinical picture with the known forms commonly occurring as a 
result of a defect in insulin secretion and/or severe insulin resistance.  
Genetic background is far more important with the environment only 
slightly modifying the clinical outcome (Malecki, 2005, Malecki and 
Klupa, 2005). 
 
Polygenic type 2 diabetes occurs far more frequently and accounts for ~ 
90% of all cases.  Polygenic forms of type 2 diabetes are thought to be 
the result of an interaction between environmental and genetic factors, 
which may actually constitute several genes.  The variations associated 
with polygenic disorders are usually very common and often result in 
amino acid substitutions that modify a particular protein.  Importantly, 
the causal alleles (alternative forms of a genetic locus) of the 
polymorphisms are often present in both healthy and type 2 diabetic 
patients with different frequencies and therefore the genes associated 
with polygenic diabetes can be considered “susceptibility loci” (Malecki, 
2005, Malecki and Klupa, 2005).   
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1.5.2 Strategies used in the search for type 2 diabetes genes 
 
Generally the strategies used to search for diabetes genes can be 
divided into two groups: (1) the genome scan and (2) the candidate 
gene approach.  Whilst it is beyond the scope of this thesis to describe 
in detail the processes involved in each method, a brief outline of each 
will be provided as it has very significant relevance when discussing 
calpain-10. 
 
1.5.2.1 The genome scan  
 
By far the more complicated and laborious of the two techniques is the 
genome scan.  This method is based on searching, using specific 
laboratory and analytical techniques, for a statistical signal that 
indicates the probability of co-segregation of a disease with a specific 
chromosomal locus.  Any presence of a signal is then defined as a 
linkage between a trait under investigation and a chromosomal location 
(i.e. there is an association of that given disease with a specific area 
within a chromosome).  The challenge is then to find which gene and, 
specifically, which mutations within that gene are responsible – 
regardless of its proposed biological role.  This step is called positional 
cloning was the method used to identify calpain-10 as a type 2 diabetes 
candidate gene (see 1.5 and 1.6).    
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1.5.2.2 The candidate gene approach 
 
This method is much simpler than the genome scan and essentially 
involves selecting a gene based on its biological function (e.g., for a 
type 2 diabetes gene, one may look at genes known to be important for 
insulin action and/or insulin release) and then looking for mutations 
within its sequence using direct sequencing methodology.  These 
approaches have been successfully applied to simple monogenic forms 
of type 2 diabetes (e.g., MODY3 gene and NEUROD1 gene for the 
genome scan and candidate gene approach, respectively).   
 
For the study of polygenic diseases, investigators need to search for 
common variants that are present in a diseased group and a healthy 
control group, and look for the susceptibility alleles that are more 
prevalent in the diseased group.  Importantly, in polygenic forms of type 
2 diabetes, individual genetic susceptibility variants may have very 
minimal consequences at the individual level (e.g. small increases on 
individual risk for the disease), however for the whole population, the 
effects can be profound.   
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1.6 Positional cloning of type 2 diabetes genes 
 
The number of chromosomal locations that harbour type 2 diabetes 
genes has been investigated using genome scans in hundreds of 
families of various ethnic and racial groups.  The first of these studies 
conducted a genome scan on 170 Mexican-American families and 
found an association near 2q37 (Hanis et al., 1996).  This susceptibility 
locus was termed NIDDM1 and was narrowed down to a target region 
of approximately 7 cM.  Its effect was later to be shown to depend on 
the genotype at an unlinked locus and on its interaction with an area 
encompassing the CYP19 gene on chromosome 15 (Cox et al., 1999).  
 
1.7 Calpain-10 as a type 2 diabetes gene 
 
Continuing the work on the NIDDM1 locus described above, Horikawa 
et al. (2000) constructed a genomic contig (a group of clones 
representing overlapping regions of the genome) encompassing most of 
the 7 cM region that was most likely to include a type 2 diabetes gene.  
They identified 214 polymorphic sites across this region and tested for 
their association with type 2 diabetes.  Five single nucleotide 
polymorphisms (SNPs) showed a difference in allelic frequencies 
between cases and controls and sequencing this region revealed two 
genes: calpain-10 (CAPN10) and G protein coupled receptor 35 
(GPR35).  None of the SNPs that were in the coding region of CAPN10 
or GPR35 were associated with the disease.  However, one of the 
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polymorphisms, designated SNP-43, a common G->A transition within 
intron 3 of CAPN10, was associated with the evidence for linkage in the 
NIDDM1 region in Mexican-American sib-pairs concordant with the at-
risk genotype (G/G).  Importantly, an increase in the frequency of the G 
allele was observed in patients when compared to controls.  However, 
type 2 diabetes was only associated with a particular haplotype 
combination of two SNPs, SNP-43 and SNP-63 and the number of 
times a 32 nucleotide sequence (Indel-19) was repeated within the 
calpain-10 gene (Horikawa et al., 2000).   
 
1.7.1 Replication of the association of calpain-10 with diabetes 
 
For many genetic association studies, the importance of replication of 
the original findings cannot be overemphasised.  For calpain-10 and 
diabetes in particular, replication studies have produced very 
contrasting results.  Firstly, a number studies have confirmed the initial 
finding.  In middle aged participants of the Atherosclerosis Risk in 
Communities study (269 prevalent diabetes cases and 1,159 non-
diabetic control subjects), those with the G/G genotype at SNP-43 were 
more likely to have diabetes than those with either the G/A or A/A 
genotype (Garrant et al., 2002).  Over the nine year follow up however, 
166 of the control subjects developed incident diabetes, but the 
incidence of diabetes for those with the G/G genotype did not differ 
significantly from those with at least one copy of the A allele.  The 
authors estimate that because of the high frequency of the G allele, 
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approximately 25% of the susceptibility of type 2 diabetes in African 
Americans may be associated with the G/G genotype at SNP-43.  In a 
Mexican population, another SNP, SNP-44 was associated with type 2 
diabetes, but the haplotype combination was not (del Bosque-Plata et 
al., 2004).  Malecki et al. (2002) genotyped 229 type 2 diabetic and 148 
control Polish subjects at SNP-43, -19 and -63 and found an 
association with a novel haplotype combination but not with the 
previously identified haplotype or the SNPs individually.  Similarly in the 
Korean population, a novel diplotype in the calpain-10 gene was 
associated with type 2 diabetes (Kang et al., 2006).  In the British 
population, Lynn et al. (2002) demonstrated that subjects with the G/G 
genotype at SNP-43 had higher 2 h plasma glucose levels during an 
oral glucose tolerance test (OGTT) compared to those with the G/A and 
A/A genotypes.  Similarly those with previously described risk haplotype 
had higher fasting and 2 h plasma glucose compared to the rest of the 
study population (Lynn et al., 2002).     
 
Additional studies have also investigated the association of calpain-10 
SNPs and type 2 diabetes related physiological traits.  For example, the 
A allele at SNP-43 was associated with intra-abdominal fat area and 
high insulin levels during an OGTT (Pihlajamaki et al., 2006).  
Comparing 395 diabetic and 298 control subjects, Orho-Merlander et al. 
(2003) not only showed an association with calpain-10 SNPs and type 2 
diabetes but also suggested an association between variation in the 
calpain-10 gene and elevated plasma FFA and serum insulin 
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concentrations.  In common with these findings, Carlsson et al. (2004) 
found that carriers of the G allele at SNP-43 had significantly elevated 
triglyceride levels compared to carriers of the G/A alleles, whereas 
Goodarzi et al. (2005) provided evidence for a role of calpain-10 
variants in atherosclerosis in a population enriched for both 
atherosclerosis and insulin resistance.  They also showed that calpain-
10 affected insulin secretion and insulin sensitivity (Goodarzi et al., 
2005).  Other studies have also investigated the association between 
calpain-10 variation and insulin mediated glucose disposal and insulin 
secretion.  In a comprehensive analysis Tripathy et al. (2004) showed 
that subjects with the SNP-44 (T/T) and SNP-43 (G/G) genotypes had 
lower levels of insulin stimulated glucose disposal.                
  
However, a large number of studies that have investigated a link 
between calpain-10 variants and type 2 diabetes have not found one 
and this is particularly the case in many European populations.  In a 
study of 1,603 Finnish subjects, Fingerlin et al. (2002) found no 
association between SNP-43, -19 and -63 and an increased risk of type 
2 diabetes.  In a large number (n = 6018) of Danish whites, Jensen et 
al. (2006) recently found no association between SNP-43 or -44 and 
type 2 diabetes.  Nor was there any association between these SNPs 
and type 2 diabetes related traits such as obesity (Jensen et al., 2006).  
Daimon et al. (2002) reached a similar conclusion when they studied a 
Japanese cohort of 81 diabetic subjects and 81 non-diabetics. Similarly, 
in a Scandinavian population, Rasmussen et al. (2002) failed to find an 
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association with the three locus haplotype combination and type 2 
diabetes or related traits (insulin resistance and insulin release).  In a 
British group of subjects, Evans et al. (2001) did not find any 
association of type 2 diabetes with calpain-10 variants, either 
individually or as part of the haplotype combination.  However, in 
keeping with previous studies (del Bosque-Plata et al., 2004) there was 
an association with the rare SNP-44 C allele in the British population 
(Evans et al., 2001).  A variety of other studies have similarly found no 
association between calpain-10 variants and type 2 diabetes (Baier et 
al., 2000; Hegele et al., 2001; Tsai et al., 2001; Sun et al., 2002; 
Horikawa et al., 2003; Iwasaki et al., 2005; Einarsdottir et al., 2006).   
 
1.7.2 Meta-analyses and the association of calpain-10 and diabetes 
 
As a result of the inconsistencies surrounding the confirmation of an 
association between calpain-10 variants and type 2 diabetes, there 
have been a number of meta analyses published in an attempt to clarify 
the association between calpain-10 and diabetes.  The first meta-
analysis focused on the association between the SNP-44 genotype and 
type 2 diabetes (Weedon et al., 2003).  The authors identified 10 
case/control studies consisting of 3,303 subjects spread across a 
number of ethnic groups.  The frequency of the rare risk C allele at 
SNP-44 varied from 6% in Mexican Americans to 25% in Botnians (a 
population from the Botnia region in Western Finland).  Combining the 
data from these studies together with a new study performed as part of 
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the meta analysis confirmed the association of SNP-44 with type 2 
diabetes (Weedon et al., 2003).  Interestingly, SNP-44 is in perfect 
linkage disequilibrium with the missense mutation Thr504Ala and two 
additional SNPs in the 5’-UTR of calpain-10 and therefore may not be 
the causal variant but rather a marker for it (Weedon et al., 2003).   
 
A more comprehensive meta-analysis combined 21 published studies, 
one third of which involved white Europeans, one third Americans 
(including Pima and Mexican Americans) and the remaining third  
involved Asians (Song et al., 2004).  This study analysed the effect of 
all of the major calpain-10 SNPs for an association with type 2 diabetes.  
There were significant differences in the allele frequencies of SNP-43, -
44, Indel-19 and SNP-63.  Most notably there was a large variation in 
the frequency of the risk G allele at SNP-43, which varied from 0.62 in 
Pima Indians to 0.96 in Japanese.  However, the allele frequencies 
were not different between cases and controls.  Analysis of the 
population based studies using a recessive model revealed that 
individuals homozygous for the G allele at SNP-43 had a 19% 
increased risk for type 2 diabetes, but using a dominant effect model 
there was no association.  In the family based studies (e.g. Evans et al., 
2001) the authors found no evidence for overtransmission of the G 
alleles at SNP-43 from the heterozygous parents to diabetic offspring.  
There were also considerable differences in the frequencies of 
haplotype combinations across different populations.  When 
investigating calpain-10 variants and diabetes related quantitative traits, 
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individuals homozygous for the G allele at SNP-43 had higher systolic 
blood pressure, but this was based on data from only three trials.  Other 
metabolic traits, including fasting and 2 h blood glucose and serum 
insulin concentrations (during an OGTT), were not different between 
carriers of the G/G genotype and carriers of the A allele.  The authors 
calculated that to detect the modest association between calpain-10 
and type 2 diabetes using a population based approach, studies 
required 2,188 cases and an equal number of controls, which none of 
the studies to date has used.  A similar problem was found to exist 
amongst family based studies.  
 
The most recent meta-analysis attempted to resolve the inconsistent 
association between calpain-10 variants and type 2 diabetes in 
Europeans (Tsuchiya et al., 2006).  For this analysis, all case/control 
studies that genotyped individuals at SNP-43, Indel-19 and SNP-63 
were considered in addition to an additional study of 2,514 subjects 
performed for the purpose of the meta-analysis.  The final study group 
consisted of 3,237 cases and 2,935 controls (therefore matching the 
above criteria).  The results from the meta-analysis indicated a trend 
towards a significant association of the SNP-43 G allele with type 2 
diabetes (P=0.09).  Analysis of the haplotype combinations indicated 
that there was some limited evidence for an association with three 
separate haplotypes.   
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In summary therefore, these meta-analyses indicate that variants in the 
calpain-10 gene are associated with type 2 diabetes, although it is clear 
from numerous studies that the impact of these variants is considerably 
variable across populations.  Nevertheless, the finding of an association 
between calpain-10 and type 2 diabetes was remarkable for a number 
of reasons, but not least because calpain-10 was an unknown gene 
with no previous links to disease, including type 2 diabetes.  Moreover, 
whilst the calpain superfamily was well known and well studied (1.7), it 
was difficult to hypothesise exactly how calpain-10 might effect insulin 
action and/or insulin release based on what was known about the 
actions and the regulation of the calpain system.  
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1.8 The calpain superfamily    
 
Calpains are a family of intracellular calcium activated cysteine 
proteases that are involved in the partial proteolysis of specific protein 
substrates.  The first documentation of calpain in mammalian cells was 
reported 40 years ago (Guroff et al., 1964) and calpain was first purified 
from porcine skeletal muscle (Dayton et al., 1976a; Dayton et al., 
1976b) and has since been found in most organisms studied ranging 
from insects to humans.  Most tissues that are known to contain calpain 
also contain a specific inhibitor of their activity known as calpastatin, 
which was also purified from porcine skeletal muscle shortly after the 
first documentation of calpain in the same tissue (e.g. Murachi et al., 
1980).   
 
The calpain family currently consists of 14 members (Fig 1.1), but by far 
the most studied of these is the so-called ubiquitous calpains, µ- and m-
calpain (or calpain 1 and 2).  The nomenclature of the two ubiquitous 
calpains is governed by their calcium requirements for half-maximal 
activity – micromolar (3-50 µM) and millimolar (0.4-0.8 mM) calcium 
concentrations for µ- and m-calpain respectively (Cong et al., 1989). 
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1.8.1 Properties of µ- and m-calpain – the ubiquitous calpains 
 
cDNAs encoding  µ- and m-calpain have been cloned and sequenced 
for human (Ohno et al, 1986), monkey, mouse, rat (DeLuca et al., 
1993), bovine, porcine (Smith et al., 2001), rabbit (Emori et al., 1986a; 
Emori et al., 1986b) and chicken (Ohno et al., 1984) calpains, and much 
is known about the structure of these two proteins as a result.  A brief 
discussion of the structure of theses ubiquitous calpains is essential 
when considering the domain structure and possible actions of calpain-
10.  
 
1.8.1.1 Domain structure 
 
In their native form, the ubiquitous calpains exist as heterodimers with a 
common small regulatory subunit of 28 kDa, and a large 80 kDa 
catalytic subunit (Fig 1.2) (Aoki et al., 1986).  Based on their amino acid 
structure, the ubiquitous calpains have been divided into six domains; 
domains I-IV form the larger 80 kDa subunit and domains V-VI 
constitute the smaller 28 kDa subunit (Fig 1.1 and 1.2).  Recent 
crystallographic studies of rat (Hosfield et al., 1999) and human (Strobl 
et al., 2000) m-calpain, however, have shown that the 80 kDa subunit 
consists of six ‘domains’ – including a linker domain between domains 
III and IV and an 18 amino acid NH2 terminal domain (Fig 1.1 and 1.2).   
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Figure 1.1 The domain structure of the calpain superfamily 
 
The domain structure of both the ubiquitous calpains (µ- and m-calpain) is shown in 
addition to that of the atypical calpains (e.g. calpain-10).  Generally, calpains are 
divided into as many as six domains (I – VI), each with distinct functions.  The “T” 
domain has been found in the atypical calpains and replaces the calcium binding 
domain IV. Adapted from Suzuki et al. (2004). 
 
 43 
1.8.1.2 Large 80 kDa subunit 
 
The catalytic domain II of the 80 kDa subunit is made up of an amino 
acid triad consisting of a Cys residue at position 115 (µ-calpain) or 105 
(m-calpain), a His residue at position 272 (µ-calpain) or 262 (m-calpain) 
and an Asn residue at position 296 (µ-calpain) or 286 (m-calpain) (Goll 
et al., 2003).  This catalytic triad is characteristic of other cysteine 
proteases such as papains or cathepsins, although the remainder of 
domain II shares little sequence homology with these other proteases 
(Goll et al., 2003).  Domain II is, however, highly conserved amongst 
species (Goll et al., 2003).  The crystallographic studies of m-calpain 
have shown that domain II consists of two sub-domains, domains IIa 
and IIb (Fig 1.1 and 1.2) (Moldeveanu et al., 2002).  Importantly for 
studies of calpain activation, the active site Cys is in domain IIa, 
whereas the His and Asn residues are in domain IIb.     
 
Domain III has yet to be assigned a definitive function, although it is 
commonly referred to as an ‘electrostatic switch’ (Ma et al., 2001), 
whereby it may play a role in the activation of calpain through a number 
of interactions with the other calpain domains, most notably with the 
catalytic domain II.  The C2 like fold revealed by crystallographic 
studies of m-calpain suggest a role for domain III in membrane 
association processes (Hosfield et al., 1999), which may also be an 
important step in calpain activation.  Domain III also contains a putative 
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EF-hand calcium binding site at the boundary with domain II 
(Andressen et al., 1991). 
 
Domain IV displays some homology to calmodulin and, based on the 
amino acid structure, contains four sets of sequences that predict EF-
hand calcium binding sites (Goll et al., 2003).  The crystal structure of 
m-calpain shows that domain IV may actually begin at amino acid 
residue 530, and include the EF-hand sequence at 541-552 (Fig 1.2) 
(Strobl et al., 2000).  This EF-hand sequence may be important in the 
dimerisation of the 28 and 80 kDa subunit (Goll et al., 2003).   
 
1.8.1.3 Small 28 kDa subunit 
 
Domain V contains a Gly rich region at the NH2 terminus, and is 
therefore thought to be to a hydrophobic domain that may bind 
phospholipid (Imajoh et al., 1986).  Domain VI, like domain IV of the 
larger subunit is often referred to as a calmodulin-like domain, and 
amino acid structure predicts four EF-hand calcium binding sites (Ohno 
et al., 1986).  Like domain IV however, the crystal structure has 
revealed an additional calcium binding site at positions 108-119 (Fig 
1.2) (Blanchard et al., 1997; Lin et al., 1997). 
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Figure 1.2  Domain structure of µ- and m-calpain.   
 
Shown is the domain structure of µ- and m-calpain and also the structure of m-calpain 
after studies of its crystallographic structure, as outlined in the text. The solid black 
bars in domain IV represent EF hand calcium binding sites. Adapted from Goll et al. 
(2003). 
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1.8.1.4 Activation of calpain 
 
The exact mechanisms of calpain activation are currently not well 
understood, although significant advances are now being made 
following the publication of the crystal structure of m-calpain.  It has 
been established that calcium is essential for µ- and m-calpain activity, 
within specific ranges (3-50 µM and 400-800 µM for µ- and m-calpain 
respectively) (Goll et al., 2003).  However, free calcium concentrations 
inside cells (0.3 – ȝ0DUHFRQVLGHUDEO\ORZHUWKDQWKRVHQHHGHGE\
both calpains, and some mechanism must therefore exist to lower the 
calcium requirements of the calpains. A number of possible 
mechanisms have been suggested, including autolysis (Suzuki et al., 
1981; Dayton et al., 1982), membrane association (Cong et al., 1989) 
and the involvement of so-called activator proteins (Pontremoli et al., 
1987a; Pontremoli et al., 1987b). 
 
1.8.1.5 Regulation of calpain activity by calpastatin    
 
Whilst it is beyond the scope of this thesis to discuss in full the 
proposed mechanisms that regulate calpain activity, one aspect of 
calpain regulation i.e. calpastatin inhibition, requires consideration.  
During the initial purification of m-calpain, it was discovered that muscle 
extracts with calpain activity also contained an inhibitor of this activity.  
The name calpastatin was proposed for this inhibitor by Takashi 
Murachi in 1979 (see Murachi et al., 1980).  Historically, it has been 
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difficult to characterise calpastatin for a number of reasons, most 
notably because it is highly susceptible to proteolytic degradation and 
because a number of isoforms exist from a single gene.  At least 8 
different isoforms have been identified in tissues thus far, and frequently 
more than one isoform exists in a single tissue (e.g. Geesink et al., 
1998).  The use of at least four alternative promoters and the ability to 
alter domain L by alternative splicing means that it is possible to 
produce a number of calpastatin polypeptides from a single gene (e.g. 
Takano et al., 2000; Parr et al., 2004).  The physiological significance of 
the various isoforms remains unknown.  Calpastatin is the only known 
inhibitor specific for the calpains, and does not inhibit any other 
proteases for which it has been tested (e.g. papain, cathepsin) (Goll et 
al., 2003).  Exactly how calpastatin regulates calpain activity in vivo, 
however, is not fully understood.  What is known is that calcium is 
required for calpastatin to bind to and inhibit the calpains (Kapprell and 
Goll, 1989), that calpastatin inhibition is reversible and calpastatin can 
be released from calpain by chelating calcium with EDTA.  In most 
cases, the concentration of calcium required for binding of calpastatin to 
calpain is much lower than that required to initiate proteolytic activity of 
the calpains (Kapprell and Goll, 1989), although it is much higher than 
free calcium concentration inside cells.  There is currently no evidence 
that calpastatin actually binds calcium itself.   
 
 
 48 
Calpastatin has been shown to bind to both domains IV and VI of the 
calpain molecule (Nishimura and Goll, 1991), and it might be the case 
that by doing so calpastatin is poised to prevent any calpain activity in 
the absence of calcium (Melloni et al., 2006).  This is supported by 
studies showing that calpastatin and calpain colocalise inside cells 
(Kumamoto et al., 1992).  Because of the differences in the calcium 
concentrations required for calpastatin binding and calpain activity, 
under certain circumstances calpains must be active when calpastatin 
is bound to calpain.   
 
Importantly for the study of calpain-10, it appears that calpastatin does 
not inhibit the atypical, homodimeric forms of calpains as it must bind to 
three sites on the calpain molecule to be effective, and this includes 
calcium dependent binding to domain VI in the small 28 kDa subunit.  
For example, calpastatin does not inhibit the weak proteolytic activity of 
expressed domains IIa/IIb (Moldovenveanu et al., 2002) and only 
slightly inhibits the activity of lens specific calpain-3 (LP82), which does 
not possess a small subunit (Nakamura et al., 1999).  Therefore in 
these and perhaps other atypical calpains (e.g. calpain-10), one of the 
three critical calpastatin binding domains is absent.  
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1.8.2 Physiological functions of calpain 
 
The ubiquitous calpains cleave polypeptides at a limited number of sites 
to leave large, mostly catalytically active fragments, and therefore, it is 
accurate to describe calpains as being regulatory enzymes.  They do 
not appear to have a broad digestive function like the proteasome or the 
enzymes contained within the lysosome.   
 
1.8.2.1 In vitro and in vivo substrates 
 
A large number of proteins (>100) are known to be cleaved by calpain 
in in vitro assays.  Generally, these proteins fall into one of four 
categories: 1) cytoskeletal proteins, 2) kinases and phosphatases, 3) 
membrane associated proteins and 4) transcription factors.  Many of the 
cytoskeletal proteins involved in linking the cytoskeleton to the plasma 
membrane are cleaved rapidly by the calpains and include talin, 
vinculin, spectrin, filamin, band 4.1a, band 4.1b and ezrin.  Similarly, 
most of the intermediate filament proteins such as desmin and vimentin 
are cleaved rapidly by the calpains.  Calpain cleavage of the 
cytoskeletal proteins severs their cross-linking abilities in most cases.  
Identification of in vivo substrates of calpain, however, has been difficult 
due to the non-specific nature of synthetic calpain inhibitors and in most 
cases it remains to be seen whether the same specific substrates exist 
under in vivo conditions.    
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1.8.2.2 Calpain and cytoskeletal remodelling 
 
The proteolytic activity of the calpain system on skeletal muscle was 
originally identified by Busch et al. (1972) who established that isolated 
myofibrils treated with calpains exhibited rapid and extensive Z-disk 
degradation.  Muscle tissue contains three classes of proteins: 1) the 
sarcoplasmic or cytoplasmic proteins that constitute ~ 30% of total 
muscle protein; 2) the myofibrillar or contractile proteins that make up ~ 
55% of muscle protein; and  3) the stroma proteins (including the 
plasma membrane) that constitute the remaining ~ 10%.  
 
Of the myofibrillar proteins, the calpains rapidly cleave titin (Suzuki et 
al., 1996; Taylor et al., 1995) and nebulin (Taylor et al., 1995) at sites 
near the Z-disk.  In addition, the calpains cleave the intermediate 
filament protein desmin that attaches the Z-disk to the sarcolemma 
(Nelson and Traub, 1983).  As a result, the proteins constituting the Z-
disk, including Į-actinin, are released and the Z-disk disappears, 
leaving a space in the myofibril.  The released Į-actinin can rebind to 
actin, indicating that it has been released from the Z-disk in a largely 
undegraded form (Goll et al., 1991).  Close examination of muscle 
tissue in conditions of muscle wasting shows that the muscle often has 
abnormal Z-disks, and in some severe cases, the Z-disks are missing 
altogether (Goll et al., 2003).  Moreover, the calpains also rapidly cleave 
troponins T (Goll et al., 2003) and I (Ho et al., 1994) and tropomyosin 
(Goll et al., 2003), and C-protein (Goll et al., 2003), which contribute to 
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stability of the thin and thick filaments, respectively.  Thus the net result 
of calpains on skeletal muscle is the progressive disruption of the Z-disk 
leading eventually to its complete loss, the subsequent release of actin 
and myosin filaments and production of fragments of titin, nebulin, 
desmin and other proteins.  Further degradation of these proteins likely 
involves the recruitment of other proteases (e.g. proteasome).    
 
1.8.2.3 Calpains and skeletal muscle differentiation 
 
One of the classical functions of the calpain system is the degradation 
of cytoskeletal/plasma membrane attachments.  The proteins involved 
in cytoskeletal/plasma membrane interactions, such as talin (Muguruma 
et al., 1995), dystrophin (Yoshida et al., 1992) and spectrin (Yoshida et 
al., 1995) are rapidly cleaved in in vitro assays.  Moreover, many 
studies have shown that calpains are located near the plasma 
membrane under certain conditions (Kumamoto et al., 1992). 
 
A well studied example of cell fusion is fusion of skeletal muscle 
myoblasts during differentiation to form myotubes (Schollmeyer, 1986a, 
1986b).  During muscle development, myoblasts withdraw from the 
mitotic cycle, align, and then fuse to form multinucleated myotubes that 
accumulate skeletal muscle proteins such as actin, myosin and titin to 
form skeletal muscle fibres.  The fusion of myoblasts involves extensive 
remodelling of the cytoskeletal/plasma membrane attachments.  Kaur 
and Sanwai. (1981) first reported that calpain activity increased 
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significantly as L6 or L8 rat myoblast cell lines fused to form myotubes.  
Further evidence comes from studies that have injected the specific 
calpain inhibitor calpastatin directly into myoblasts just before fusion, 
which resulted in the complete abolition of fusion without killing the 
myoblast (Temm-Grove et al., 1999), and from studies employing 
antisense oligodeoxyribonucleotide strategies (e.g. Balcerzak et al., 
1995).  Specific inhibition of m-calpain synthesis by approximately 50% 
in rat myoblasts led to a corresponding reduction in myogenesis by 
approximately 70% (e.g. Balcerzak et al., 1995).  Whilst the levels of 
calpain expression do not change during myoblast differentiation, the 
expression of calpastatin is significantly reduced prior to myoblast 
fusion and recovers following fusion (Barnoy et al., 1996).  More recent 
experiments have shown that overexpression of calpastatin inhibits 
myoblast fusion and fusion-associated protein degradation, including 
talin and fodrin, which is also known as spectrin (Barnoy et al., 2005).  It 
has also been reported that desmin, vimetin and fibronectin are also 
good substrates for calpains during myogenesis (Dourdin et al., 1999) 
and that the two calpains may have different roles in myogenesis 
(Cottin et al., 1994).  Calpastatin overexpression also reduced the 
expression of myogenin which is one of the muscle specific 
transcription factors that determine the initiation and maintenance of the 
myogenic program (Barnoy et al., 2005).  
 
Similarly, calpains have also been implicated in cell spreading and 
motility (Huttenlocher et al., 1997; Palecek et al., 1998).  Early 
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experiments used cell permeable calpain inhibitors to show that integrin 
mediated cell migration was dependent on calpain activity (Huttenlocher 
et al., 1997).  Reduced levels of µ-calpain in a Chinese hamster ovarian 
cell line also showed reduced migration rates with similar morphological 
changes (Huttenlocher et al., 1997).  Inhibition of calpain activity via the 
overexpression of calpastatin was later found to inhibit the turnover of 
vinculin and zyxin-containing adhesive contact sites (Bhatt et al., 2002).  
Stable overexpression of calpastatin in C2C12 myoblasts similarly led 
to a complete abolition of multinucleated myotube formation confirming 
the critical role of calpains in skeletal muscle myogenesis (Dedieu et al., 
2004).   
 
1.8.2.4 Calpain and skeletal muscle growth (moved) 
 
As mentioned above (see 1.8.2.1 and 1.8.2.2), calpains cleave a 
number of myofibrillar proteins and play an important role in cytoskeletal 
remodelling and myoblast differentiation in vitro.  These findings led to 
the hypothesis that changes in skeletal muscle mass would be 
correlated with alterations in the expression of calpain and calpastatin.  
A number of lines of evidence now exist to support such a hypothesis.      
 
Firslty, specific calpain inhibition by calpastatin overexpression in mice 
in vivo leads to marked skeletal muscle hypertrophy (Otani et al., 2004; 
Tidball and Spencer, 2002).  Calpastatin overexpression has also been 
associated with elevated calcium calmodulin-dependent protein kinase 
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II (CaMKII) levels in muscle (Otani et al., 2004) and it is possible this 
may link calpain to skeletal muscle hypertrophy indirectly as CaMKII 
has been linked to the activation of additional proteolytic systems 
(Menconi et al., 2004).       
 
Secondly, tKHDGPLQLVWUDWLRQRIȕ-adrenergic agonists to animals results 
in large increases in the rate of accumulation of muscle mass and this 
treatment has been shown to affect the activity and expression of the 
calpain system.  In particular, skeletal muscle calpastatin activity was 
significantly increased, the activity of µ-calpain was decreased and m-
calpain was increased ZLWK WKHDGPLQLVWUDWLRQRIȕ-agonists in skeletal 
muscle (Bardsley et al., 1992; Parr et al., 1992; Forsberg et al., 1989).  
These data suggest that reductions in µ-calpain activity may, in part, 
mediate the increase in muscle mass, which is consistent with the 
findings from calpastatin overexpressing mice.  A bovine calpastatin 
promoter has been isolated and been shown to be functional in cell 
transfection studies and inducible by dibutyryl cAMP (Cong et al., 1998; 
Sensky et al., 2006) highlighting a possible mechanistic link between ȕ-
adrenergic stimuli and changes in the calpain system.     
 
Jones et al. (2004) measured calpain expression following two weeks of 
limb immobilisation in humans.  Following the immobilisation period 
there was an approximate 5% reduction in quadriceps lean skeletal 
muscle mass and the mRNA levels of the muscle specific calpain-3, but 
not µ- and m-calpain or calpastatin, were decreased with immobilisation 
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(Jones et al., 2004).  Rehabilitation exercise following immobilisation led 
to an increase in muscle mass and an increase in the expression of µ- 
and m-calpain and calpastatin 24 h after the first bout of exercise.  
Calpastatin and m-calpain mRNA levels returned to basal levels after 
six weeks of rehabilitation, whilst µ-calpain continued to rise until at six 
weeks post rehabilitation they were higher than basal values.  An early 
increase in µ-FDOSDLQ ZLWK H[HUFLVH LV FRQVLVWHQW ZLWK WKH ȕ-agonist 
studies showing an initial increase in µ-calpain with an increase in 
muscle mass.  These studies suggest that calpain may play a role in the 
initial remodelling of skeletal muscle that is necessary for hypertrophy.  
In addition a reduction in calpain-3 would be expected during atrophy as 
LGMD2A is due to a loss of calpain-3 substrate processing ability, not 
an increase.  This may be related to a role of calpain-3 in the NF-țB 
pathway, which has consistently been linked to the regulation of skeletal 
muscle mass (Hasselgren et al., 2005).  Additionally, these studies 
indicate that of the ubiquitous calpain members, µ-calpain is the one 
most strongly associated most with skeletal muscle hypertrophy. 
 
Finally, a possible role for calpain in skeletal muscle atrophy is further 
supported by the finding that calpain cleaves the transcription factor 
&(%3ȕVHH 1.8.2.5).  Recent evidence suggests that this transcription 
factor is upregulated in states of skeletal muscle atrophy, including 
sepsis-induced muscle atrophy (Penner et al., 2002; Yang et al., 2005).  
Muscle atrophy during sepsis is associated with an increase in the DNA 
ELQGLQJDFWLYLW\RI&(%3ȕLQDGGLWLRQWRDQLQFUHDVHLQ the accumulation 
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RI &(%3ȕ SUotein in the nucleus (Penner et al., 2002).  Interestingly, 
&(%3ȕELQGLQJVLWHVDUHSUHYDOHQWLQWKHSURPRWHUVRIYDULRXVJHQHVRI
the ubiquitin-proteasome system (Penner et al., 2002) although specific 
evidence for a direct OLQNEHWZHHQ&(%3ȕDFWLYDWLRQDQGDQLQFUHDVHLQ
proteasome expression and activity is currently not available.  These 
data may provide a potential link between muscle atrophy and the 
calpain and ubiquitin-proteasome protease pathways.      
 
In summary, therefore, numerous lines of evidence suggest that 
calpains participate in the disassembly of the Z-disk and therefore play 
an important role in skeletal muscle protein turnover.  Clearly, the 
calpain system does work alone in this task and it is probably the case 
that the role of the calpain system is to target substrates for further 
degradation by other proteolytic systems.  The ubiquitin-proteasome 
proteolytic pathway is essential for the development of muscle atrophy 
(Hasselgren et al., 2005) and it is likely that it acts alongside calpain 
activation, digesting released proteins into smaller peptide residues 
(Goll et al., 2003).      
 
1.8.2.5 Calpain and signal transduction pathways 
 
Calpains have been shown to cleave many of the kinases, 
phosphatases and cytoskeletal proteins involved in signal transduction 
pathways in in vitro assays, but it has been difficult to identify specific 
calpain cleavages in vivo that are specific to particular transduction 
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pathways.  One of the first classical signalling proteins to be identified 
as a calpain substrate in vitro and one which is relevant to the 
development of insulin resistance was protein kinase C (PKC) 
(Kishimoto et al., 1983, 1989) (see 1.2.1.5 and 1.3.1.4).  The authors 
used in vitro calpain cleavage assays to demonstrate that a number of 
purified PKC isoforms were cleaved by both µ- and m-calpain to 
produce a catalytically active fragment originally described as protein 
kinase M (PKM) (Kishimoto et al., 1983, 1989).  Interestingly, this 
process of PKC cleavage was enhanced by the simultaneous presence 
of phospholipid and diacylglycerol.  Part of the role of calpains in signal 
transduction may be related to their role in cytoskeletal/membrane 
interactions.  Indeed, Liang et al. (2006) have recently linked the role of 
calpains in myogenesis to their cleavage of PKC and have shown, 
using µ- and m-calpain antisense oligonucleotides, that downregulation 
of µ- and m-calpain expression inhibited myoblast differentiation and 
altered the expression of various PKC isoforms inclXGLQJ 3.&Į DQG
3.&į   
 
Recent data from transgenic mice overexpressing calpastatin 
highlighted a possible role for calpain in insulin signalling and GLUT4 
translocation (Otani et al., 2004).  It was shown that calpastatin 
overexpression does not affect glucose tolerance, but does lead to a 
reduction in AKT/PKB protein content and an upregulation in GLUT4 
protein.  Levels of GLUT4 mRNA were downregulated whilst other 
insulin signalling proteins were not affected (IR, IRS-1, PI3K).  It is 
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suggested by the authors that the lack of an increase in glucose uptake 
that would be expected with the changes in GLUT4 protein can possibly 
be explained by the observed reduction in AKT/PKB.  It is thought that 
the changes in GLUT4 were indeed a result of calpain inhibition 
because: 1) GLUT4 mRNA was reduced as was the expression of two 
transcription factors – MEF2A and MEF2D and 2) GLUT4 was shown to 
be cleaved by µ-calpain in vitro as part of their study.   
 
In part two of these studies (Otani et al., 2006) it was reported that 
AMPK and CAMKII were increased 3-fold and it was hypothesised that 
these changes in the calpastatin overexpressing mice would lead to an 
increase in contraction mediated glucose uptake.  AMPK is activated by 
increases in the AMP:ATP ratio and decreases in phosphocreatine, and 
thus is activated during muscle contractions, whereas CaMKII may be 
activated by calcium during muscle contraction.  There is currently no 
evidence to support the idea that the calpain system is involved in the 
activation of AMPK or CaMKII.  However, despite the increases in 
GLUT4, AMPK and CAMKII, there was no increase in contraction 
mediated glucose uptake when compared to wild type mice suggesting 
that inhibition of calpain results in impairment of a step in the GLUT4 
translocation process downstream of the insulin- and contraction-
signalling pathways.  It is possible that calpain is involved in the very 
late stages of GLUT4 vesicle translocation and fusion and this has been 
suggested from studies of calpain-10 and glucose stimulated insulin 
release from the pancreas (see 1.9.2.4).     
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1.8.2.6 Calpain and transcription factors 
 
The concept that calpains are involved in gene regulation comes largely 
from early studies showing that calpain cleaved transcription factors 
such as c-Jun (Hirai et al., 1991) c-Fos (Pariat et al., 2000), IkappaB  
and p53 (Gonen et al., 1997; Kubbatat and Vousdon, 1997; Pariat et al., 
1997).  Many of these studies have used non-specific calpain inhibitors 
and therefore the results have been questioned and it has been 
suggested that the proteasome and not the calpain system is 
responsible for the observed degradation of transcription factors (Goll et 
al., 2003).  More recent studies, however, have used the more specific 
calpain inhibitor calpastatin to demonstrate a role for calpain in the 
cleavage of transcription factors.  For example, calpastatin 
overexpression in L6 myoblasts led to significant increases in the 
protein levels of CCAAT/enhancer-ELQGLQJSURWHLQȕ &(%3ȕ) (Wei et 
al., 2006).  Employing the use of mobility shift assays (EMSA) and 
luciferase reporter constructs, the authors showed that in myotubes 
WUHDWHGZLWKFDOSHSWLQWKH'1$ELQGLQJDFWLYLW\DQG&(%3ȕGHSHQGHQW
gene activation was increased (Wei et al., 2006).  More specific 
overexpression of µ- and m-calpain conversely reduced levels of 
&(%3ȕ LQ P\REODVWV H[SUHVVLQJ -calpain predominantly (Wei et al., 
2006).  Finally, co-immunoprecipitation revealed that calpains and 
&(%3ȕ LQWHUDFW DW WKH SURWHLQ OHYHO  7DNHQ WRJHWKHU WKHVH UHVXOWV
strongly suggest that calpain may play a role in the degradation and 
UHJXODWLRQRI&(%3ȕ  These findings may be relevant in discussion of 
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the role of calpains in skeletal muscle atrophy given the proposed role 
of C/EBP in skeletal muscle wasting (Penner et al., 2002; Yang et al., 
2005) (see 1.8.2.4).    
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1.9 Structure and function of calpain-10 
 
1.9.1 Domain structure of calpain-10 
 
An understanding of how calpain-10 differs structurally from the other 
calpain family members is critical for the understanding of calpain-10 
function.  Calpain-10 has been placed into the calpain family based 
entirely on sequence homology to the ubiquitous calpains.  The gene 
encoding calpain-10 consists of 15 exons spanning approximately 31 kb 
(Fig 1.3).  Analysis of human cDNA revealed a complex pattern of 
alternative splicing which leads to the generation of up to 8 different 
protein isoforms of approximately 672, 544, 517, 513, 444, 274, 139 
and 138 amino acids (Fig 1.4) (Horikawa et al., 2000). 
 
Calpain-10 is an atypical calpain in that domain IV has been replaced 
by a domain III like structure.  Therefore it appears that its protease 
domain is followed by a tandem repeat of two domains that are similar 
to domain III.  In the early calpain-10 literature (e.g. Horikawa et al., 
2000), the last domain was originally described as a T domain, but it is 
now thought of as a III-like domain (Fig 1.4).  In terms of domain 
structure, calpain-10 can be regarded as a close relative of other 
atypical calpain members, calpain-5 and -6 (Suzuki et al., 2004).  Whilst 
the sequences around the active site triad (Cys-105, His-262 and Asn-
286 for m-calpain and Cys-73, His-238, Asn-263 for calpain-10) are 
highly conserved among calpain family members, calpain-10 is different 
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from calpain-5 and -6 and other calpains in its amino acid sequence.  
Most importantly, residues in domain II that are thought important for 
calcium binding and which are common among the typical calpains are 
not conserved and, second, acidic and basic loops in domain III 
important for calcium and phospholipid binding are not present in the 
two domain III-like domains in calpain-10 (Suzuki et al., 2004).  The 
result of this is that calpain-10 probably has none of the calcium binding 
sites normally found in the typical calpain family members (Suzuki et al., 
2004).  The regulation of calpain-10 activity by calcium, if indeed it is 
regulated by calcium, would therefore be expected to be different from 
the other typical calpain members (Suzuki et al., 2004).  To date there 
has been no description of any protease activity of calpain-10 and 
detailed investigations into the structure and function of calpain-10 have 
been difficult due to problems of purifying the protein.  
 
The mRNA of calpain-10 is expressed ubiquitously in all adult and fetal 
human tissues examined (Horikawa et al., 2000), and similar ubiquitous  
mRNA and protein expression has been confirmed in rats (Ma et al., 
2001).  The mRNA level of calpain-10 varies between tissues but 
appears to be highest in the heart, followed by the brain, liver, kidney, 
and pancreas in humans (Horikawa et al., 2000).  Three of eight splice 
variants identified for calpain-10 completely lack an intact domain II and 
thus probably have no protease activity (Fig 1.4) (Horikawa et al., 
2000).  The expression of calpain-10a and -10f appear to represent the 
majority of calpain-10 transcript in skeletal muscle tissue (Yang et al., 
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2001).  Some calpain-10 is detectable in the soluble fraction by Western 
blotting using an antibody raised against a synthetic rat peptide, but it is 
preferentially found in the insoluble fraction in rat tissues including 
skeletal muscle (Ma et al., 2001).  In skeletal muscle fibres from young 
mice, calpain-10 is detected predominantly at the sarcolemma and 
nucleus and an increase in intracellular calcium concentration leads to 
an increase in the nuclear localisation of calpain-10 in rat cultured lens 
epithelial cells (Ma et al., 2001). 
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Figure 1.3  Exon structure and splicing pattern for human calpain-10 
transcripts.  
 
The calpain-10 gene expands through 15 exons and a complex pattern of alternative 
splicing generates up to eight isoforms, designated a – h.  Each shaded box indicates 
the domain for which that exon, or part of the exon, encodes (see Fig 1.4). Adapted 
from Horikawa et al. (2000). 
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Figure 1.4  Domain structure of human calpain-10 
 
Calpain-10 is made up of domain I, domain II and a repeat domain III. Alternative 
splicing (Fig 1.3) is thought to generate a number of proteins ranging in size from 672 
(10a) to 138 (10f) amino acids. The numbers indicate the amino acid residue at the 
boundaries between the domains. Also shown is the predicted molecular weight of 
each calpain-10 isoform. Adapted from Horikawa et al. (2000).  
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1.9.2 Physiological functions of Calpain-10 
 
Determining the function of calpain-10 has been and still is a 
tremendous challenge.  Unfortunately, very little progress has been 
made in elucidating exactly what it is that calpain-10 does and this is 
particularly the case for some of the most important tissues for glucose 
homeostasis in humans, including the pancreas and skeletal muscle.  
The task has been complicated further by the apparent complex nature 
of the expression of calpain-10 isoforms and the potentially modifying 
influence of the identified risk SNPs.  Perhaps the first question that 
arose in response to the initial findings that genetic variation in the 
calpain-10 gene influenced risk for type 2 diabetes concerned what 
influence these polymorphisms had, if any, on calpain-10 expression 
and subsequent function.  
 
1.9.2.1 Single nucleotide polymorphisms and calpain-10 function 
 
The SNP associated with an increased risk for type 2 diabetes (SNP-
43) is located in intron-3 of calpain-10 (a region of DNA that is spliced 
out after transcription).  Whilst this at risk allele has been linked to a 
wide variety of physiological phenotypes (see section 1.6), it is not clear 
how an SNP located in a non-coding region can influence the 
expression and/or function of a protein.  The idea that polymorphisms 
located within introns can affect gene expression is not without 
precedent however.  For example, a polymorphism in intron 1 of 
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COL1A1, encoding the binding site for the transcription factor Sp1, 
affects expression of this gene and is associated with reduced bone 
density and osteoporosis (Uitterlinden et al., 1998).        
 
Experiments in vitro indicated that the intronic region surrounding SNP-
43 occurred as a cis-acting element that was able to influence calpain-
10 gene transcription (Horikawa et al., 2000).  Using gel shift (EMSA) 
experiments, the authors were able to show that nuclear extracts could 
bind to the region around SNP-43 but that the G/A mutation had no 
effect on this binding.  In follow up studies, Baier et al. (2000) inserted a 
46 bp fragment of the SNP-43 region into a luciferase reporter construct 
and showed that the G allele had greater promoter activity than the A 
allele.  Analysis of human skeletal muscle biopsy samples has added 
strength to the idea that SNP-43 affects gene transcription by showing 
that the at risk G/G genotype is associated with reduced calpain-10 
mRNA expression when compared to the G/A and A/A group (Baier et 
al., 2000, Carlsson et al., 2005).  It is interesting to note that the rare 
allele at SNP-44 is in perfect linkage disequilibrium with the missense 
mutation T504A and this mutation affects gene transcription (Evans et 
al., 2001).  
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1.9.2.2 Calpain-10 and glucose uptake 
 
As mentioned above, the G/G genotype at SNP-43 was associated with 
reduced skeletal muscle calpain-10 mRNA expression in the skeletal 
muscle of Pima Indians (Baier et al., 2000).  The level of skeletal 
muscle calpain-10 mRNA was also correlated with whole body glucose 
oxidative capacity suggesting the possibility that calpain-10 expression 
is associated with muscle glucose utilisation.  More recent work has 
strengthened the finding that SNP-43 influences calpain-10 mRNA 
expression in skeletal muscle and also indicates that muscle calpain-10 
mRNA expression is upregulated by insulin infusion following 24 h of 
lipid infusion in human subjects with impaired glucose tolerance 
(Carlsson et al., 2005).   
 
Paul et al. (2003) showed that specific inhibition of calpain-10 using an 
inducible antisense oligonucleotide system decreased insulin stimulated 
glucose uptake in 3T3-L1 adipocytes by approximately 50%, whilst not 
affecting basal glucose uptake.  Inhibition of calpain-10 expression also 
reduced insulin stimulated translocation of the specific glucose 
transporter GLUT4 to the plasma membrane of 3T3-L1 adipocytes, and 
reduced insulin stimulated actin reorganisation.  Importantly, calpain 
was not shown to be required for the phosphorylation of critical 
signalling molecules involved in GLUT4 translocation, including insulin 
UHFHSWRUȕ,5ȕLQsulin receptor substrate 2 (IRS2) and Akt/PKB (Paul 
et al., 2003). 
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The idea that calpains in general are involved in glucose transport in 
skeletal muscle has also been examined in vitro.  In isolated muscle 
strips, non-specific calpain inhibition has also been shown to reduce 
insulin mediated glucose transport (Sreenan et al., 2001).  Insulin 
stimulated 2-deoxyglucose uptake in the presence of the calpain 
inhibitors ALLM and E-64-d was considerably reduced (Sreenan et al., 
2001).  Attempting to control for the potential non-specific nature of 
these inhibitors, the authors showed that cathepsin inhibitor had no 
effect on insulin stimulated glucose transport.  The reduction in glucose 
transport with calpain inhibition was matched by similar reductions in 
glycogen synthesis in isolated muscle strips (Sreenan et al., 2001).  
Again, this study, whilst informative does not provide direct evidence for 
a role of calpain-10 in insulin mediated glucose transport in skeletal 
muscle.    
 
In mice overexpressing the specific calpain inhibitor calpastatin in vivo, 
skeletal muscle glucose uptake remained unchanged despite elevated 
levels of the glucose transporter GLUT4 protein, indicating insulin 
resistance relative to GLUT4 content (Otani et al., 2004).  GLUT4 
protein was also cleaved by m-calpain in vitro (Otani et al., 2004) 
suggesting that calpastatin overexpression inhibits calpain mediated 
GLUT4 turnover.  Interestingly in the muscles of the calpastatin 
transgenic animals, the relative insulin resistance was associated with 
reduced expression of the critical insulin signalling protein Akt/PKB 
(Otani et al., 2004).  Whilst these studies provide evidence that calpains 
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in general are involved in GLUT4 mediated glucose transport, it is not 
clear which specific calpain isoform is responsible for these effects.  As 
mentioned previously calpastatin probably does not have any inhibitory 
action on calpain-10 but calpain-10 may participate in these pathways 
indirectly via interactions with other members of the calpain family.       
 
1.9.2.3 Calpain-10 and skeletal muscle differentiation 
 
Examination of the role of calpain-10 in muscle cell differentiation in 
vitro showed that as isolated human myoblasts differentiated to form 
multinucleated myotubes in culture, the expression of a 60 kDa 
immunoreactive band thought to represent a calpain-10 isoform or 
cleavage product increased (Logie et al., 2005).  This finding is 
consistent with a role for calpain in the degradation of 
cytoskeletal/plasma membrane attachments during myogenesis (see 
1.8.2.3).  The potential mechanisms and protein substrates involved in 
calpain-10 mediated muscle differentiation are yet to be elucidated.  
 
1.9.2.4 Calpain-10 and insulin release 
 
Assessment of the role of calpain in insulin secretion from the pancreas 
has shown that long-term 48 h exposure to non-specific calpain 
inhibitors reversibly suppresses glucose-induced insulin secretion by 
40-80% in mouse islets (Zhou et al., 2003).  In contrast, short-term 4 h 
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exposure to non-specific calpain inhibitors increases the insulin 
secretory response to glucose as a result of accelerated exocytosis of 
insulin containing granules (Sreenan et al., 2001).  Using an approach 
more specific to calpain-10 – stable overexpression of calpain-10 in a 
human pancreatic cell line (INS1), glucose responsive insulin secretion 
was enhanced in a calcium dependent manner (Marshall et al., 2005).  
Direct binding of a putative 54 kDa calpain-10 isoform to proteins 
important for the fusion of insulin containing granules with the plasma 
membrane was also reported (Marshall et al., 2005).  One of these 
proteins (SNAP-25) undergoes calcium mediated proteolysis during the 
exocytosis of insulin containing granules and this was inhibited with the 
use of non-specific calpain inhibitors providing a possible link between 
calpain-10 and insulin secretion in INS1 cells (Marshall et al., 2005).  
 
In pancreatic islets, it has also been shown that calpain-10 mediates 
ryanodine-induced apoptosis and may also be required for apoptosis 
induced by fatty acid palmitate and by hyperglycaemia (Johnson et al., 
2004).  Intracellular calcium stores play an important role in the 
regulation of apoptosis in many cell types.  Ryanodine receptor calcium 
channels transmit calcium to the closely associated mitochondria and 
regulate mitochondrial ATP production and thus may be critical in 
FDOFLXP LQGXFHG DSRSWRVLV LQ WKHȕ-cell.  DNA laddering reflecting the 
organised cleavage of DNA and a marker of apoptosis were detected 
within 36 h of exposure of islets to a blocking concentration of 
ryanodine indicating that inhibition of calcium flux through ryanodine 
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UHFHSWRUVDFWLYDWHVȕ-cell apoptosis (Johnson et al., 2004).  Ryanodine 
was found to increase calpain activity and the calpain inhibitor ALLM 
EORFNHGERWKU\DQRGLQHDQGSDOPLWDWH LQGXFHGȕ-cell apoptosis.  Using 
the same transgenic mice as described above, the authors also showed 
that calpastatin overexpression reduced ryanodine and palmitate 
induced apoptosis.  In mice, ryanodine increased calpain-10 mRNA in 
islets by 2.5 fold but did not affect µ- or m-calpain (Johnson et al., 
2004).  In islets from calpain-10 knock-out mice ryanodine failed to 
increase calpain activity and ryanodine and palmitate induced apoptosis 
was reduced (Johnson et al., 2004).  Finally, hypoglycaemia, but not 
hyperglycaemia induced apoptosis was completely inhibited in calpain-
10 knock-out mice, whereas it was increased in islets overexpressing 
calpain-10 (Johnson et al., 2004).  These data suggest a role for 
calpain- LQ ȕ-cell apoptosis pathways and indicate a possible link 
between glucose concentrations, apoptosis and calpain-10.           
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1.10 Calpain-3 as a type 2 diabetes gene 
 
Recent evidence suggests that calpain-3 may influence the risk for type 
2 diabetes.  The NIDDM1 locus has been shown to interact with a gene 
on chromosome 15 (near CYP19) to further increase susceptibility to 
diabetes in Mexican Americans (Cox et al., 1999).  The association of 
this region with type 2 diabetes has been confirmed in a Japanese 
population (Mori et al., 2002).  This locus on chromosome 15 includes 
the calpain-3 gene, and given that calpain-3 is highly expressed in 
skeletal muscle which is a major site for insulin action, it is possible that 
an interaction between calpain-10 and calpain-3 in skeletal muscle may 
further increase the risk for type 2 diabetes. 
 
1.11 Structure and function of calpain-3 
 
1.11.1 Domain structure of calpain-3 
 
The human calpain-3 gene is located on chromosome 15q15.1-q21.1 
and covers a region of approximately 140 kb.  The major product of the 
gene is encoded by 24 exons corresponding to a 3316 bp mRNA which 
is predominantly expressed in adult skeletal muscle (Sorimachi et al., 
1989).  Multiple alternative transcripts have been detected in human, 
mouse, rat and rabbit tissues, but usually with an expression level 100- 
to 1000-fold lower (Herasse et al., 1999; Kawabata et al., 2003).  Some 
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of these transcripts are expressed from an additional alternative 
ubiquitous promoter known to be present in human and mouse 
genomes or from a lens-specific promoter detected in mouse, rat and 
rabbit genomes but absent from the human genome (Duguez et al., 
2006). 
 
Translation of the calpain-3 gene product leads to the production of a 
94 kDa protein consisting of a short N-terminal region (domain I), a 
papain-like proteolytic domain (domains IIa and IIb), a C2-like domain 
(domain III) and a calcium-binding domain composed of five EF-hands 
(domain IV) as found in the ubiquitous calpains (Fig 1.5).  Uniquely, 
calpain-3 possesses three sequences which are not found in any other 
calpains.  These have been termed NS (N-terminal sequence), IS1 and 
IS2 (inserted sequences 1 and 2) (Fig 1.5) (Duguez et al., 2006).  The 
NS sequence is a 20–30 amino acid N-terminal domain which is found 
in domain I and which corresponds to a regulatory propeptide found in 
other cysteine proteinases (Duguez., 2006).  The IS1 sequence is a 
polypeptide of about 50 amino acids which is embedded in the 
proteolytic domain.  This sequence contains three autolytic sites and, as 
a consequence, deleting this region renders calpain-3 inactive (Herasee 
et al., 1999).  The IS2 sequence has also been demonstrated to be 
important for the control of the activity of calpain-3 (Herasse et al., 
1999; Ono et al., 1998).    
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Figure 1.5  Calpain-3 protein domain structure.  
 
The four domains including the specific calpain-3 insertion sequences (NS, IS1 and 
IS2) are shown.  These insertion sequences are thought to control the stability of the 
calpain-3 protein.  
 
 
1.11.2 Physiological functions of calpain-3 
 
1.11.2.1 Calpain-3 autolysis and activation 
 
Calpain 3 autolysis occurs rapidly in cells or poorly extracted muscle 
samples and possibly after physiological activation in living muscle 
(Sorimachi et al., 1993).  It generates a small fragment of 30 kDa and a 
large C-terminal fragment, the size of which ranges from 60 to 55 kDa 
depending on the extent of autolysis (Kinbara et al., 1998).  IS2 is a 
peptide of about 80 amino acids encoded by exons 15–16 and located 
between domain II and domain III.  A basic sequence encoded by exon 
15 seems to act as a nuclear translocation signal at least in human and 
NS IS1 IS2 IIa IIb III IV IIa
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COS-7 cells (Sorimachi et al., 1993).  IS2 has been demonstrated to be 
important in the control of the activity of calpain 3, as exon 16 deletion 
leads to loss of substrate proteolysis (Herasse et al., 1999). 
 
Because of the rapid autolysis of calpain-3, it has so far been 
impossible to obtain crystals of the full molecule.  However, a three 
dimensional model of calpain-3 based on the known structure of m-
calpain shows that the proteolytic domain can be subdivided into two 
globular subdomains (domain IIa and IIb), forming a catalytic cleft at 
their interface (Jia et al., 2001).   As in ubiquitous calpains, domain III of 
calpain-3 fits a C2 motif.  In this model, IS1 and IS2 have been 
structured as loops protruding out of the globular core structure (Jia et 
al., 2001).  
 
1.11.2.2 Calpain-3 and muscle growth 
 
Calpain-3 in skeletal muscle is bound to titin/connectin at the N2A and 
M-line regions, as shown with the use of the yeast two hybrid system 
(Sorimachi et al., 1995).  Experiments in vitro have shown that calpain-3 
is capable of cleaving numerous myofibrillar proteins including titin 
itself, filamin C, vinexin, exrin and talin (Taveau et al., 2003; Guyon et 
al., 2003; Kramerova et al., 2004).  It is currently not clear whether 
calpain-3 is able to cleave these proteins in vivo but the close proximity 
of these proteins to calpain-3 would indicate such an interaction.  
Evidence that calpain-3 is critical for muscle function, however, comes 
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from the finding that loss-of-function mutations within the calpain-3 gene 
cause limb girdle muscular dystrophy type 2A (LGMD2A) (Richard et 
al., 1995).  It is thought that it is the loss of substrate processing ability 
of calpain-3 that causes LGMD2A (Ono et al., 1998), although the exact 
physiological substrates are not known.  It is clear that calpain-3 is not 
essential for the initial building of functional skeletal muscle as patients 
with LGMD2A develop normally and the mean age of onset of the 
disease is in the second decade of life (Duguez et al., 2006).  It has 
also been demonstrated convincingly that calpain-3 is not critical for 
myoblast proliferation and fusion as the expression of full length 
calpain-3 occurs after muscle innervation and fusion in vivo 
(Fougerousse et al., 1998).  Denervation of healthy adult mouse muscle 
leads initially to the disuse of the muscle and, later, atrophy and this is 
associated with reduced calpain-3 mRNA (Stockholm et al., 2001).  In 
humans, disuse atrophy is similarly associated with reductions in 
muscle mass and calpain-3 mRNA levels (Jones et al., 2004).  Together 
these results indicate that the function of calpain-3, which is directed 
towards the proteolysis of specific substrates, seems to be important in 
fully differentiated fibres and its absence leads to degeneration and 
death of the fibre, most likely as a result of the deregulation of 
sarcomere remodelling (e.g. Kramerova et al., 2005).   
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1.11.2.3 Calpain-3 and signal transduction pathways in muscle 
 
The idea that calpain-3 participates in signalling pathways in skeletal 
muscle came from the observation that in LGMD2A patients, 
myonuclear apoptosis in the deltoid muscle was correlated with altered 
subcellular distribution of Inhibitor ț B-alpha (Iț%Į) and Nuclear Factor ț 
B (NF-țB) (Baghdiguian et al., 1999).  More specifically, calpain-3 
deficiency was associated with accumulation and nuclear translocation 
of Iț%ĮDQGincreased sarcoplasmic localisation of NF-țB (Baghdiguian 
et al., 1999).  Degradation of Iț%Į XQPDVNV WKH QXFOHDU ORFDOLVDWLRQ
signal on the p65 subunit of NF-țB allowing it to move to the nucleus 
and activate the expression of genes involved in cell survival.  Purified 
recombinant Iț%Į ZDV FRPSOHWHO\ GHJUDGHG LQ D FDOFLXP GHSHQGHQW
manner by the ubiquitous calpains in vitro (Baghdiguian et al., 1999).  In 
a cell expression system, co-expression of calpain-3 and Iț%ĮOHGWRD
significant reduction in the levels of Iț%Į %DJKGLJXLDQ HW DO     
These results indicate that reduced cleavage of Iț%Į DV D UHVXOW RI
reduced calpain-3 activity, leads to increased NF-țB sequestration in 
the cytoplasm and increased apoptosis in the skeletal muscle of 
LGMD2A patients.  Interestingly, this pathway may also provide a 
possible link between calpain-3 and insulin resistance as NF-țB has 
been linked to serine phosphorylation of IRS1 and a downregulation of 
insulin mediated glucose uptake (see 1.3.1.2).      
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1.11.2.4 Calpain-3, insulin resistance and type 2 diabetes  
 
Calpain-3 plays an important role in the structure and function of 
skeletal muscle, as outlined above.    Interestingly it was recently shown 
that the calpain-3 gene overlaps that of the gene encoding Į-
glucosidase C, a gene which is important for glycogen breakdown 
(Kawabata et al., 2003).  These data suggest the possibility that both 
genes affect one another’s transcription (Kawabata et al., 2003).  Only 
one study has investigated calpain-3 expression in relation to type 2 
diabetes related traits.  Walder et al. (2003) reported that reduced 
calpain-3 mRNA expression was associated with phenotypes related to 
obesity and insulin resistance (e.g., increased abdominal fat mass and 
circulating blood glucose) in both humans and Psammomys obesus, a 
polygenic animal model of obesity and type 2 diabetes.  Moreover, 
skeletal muscle calpain-3 expression has been shown to be affected in 
states of insulin resistance; for example, fasting in lambs (Illian et al., 
2001) and chicks (Nakashima et al., 2005) leads to an increase in 
calpain-3 expression.    
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1.12 Summary and aims 
 
Early studies on calpain-10 provided strong evidence to suggest that 
calpain-10 was associated with an increased risk for type 2 diabetes in 
a number of populations.  Since these findings, some studies have 
attempted to identify possible mechanisms whereby calpain-10 may 
influence carbohydrate metabolism.  These studies have provided only 
limited evidence in vitro to suggest that calpain-10 is directly involved in 
glucose utilisation.  Moreover, in humans, there is currently no evidence 
to suggest that calpain-10 plays a direct role in glucose utilisation in 
human skeletal muscle in vivo.  
 
The aim of this thesis was to examine the effect of altering skeletal 
muscle insulin sensitivity in healthy humans on the expression of 
calpain-10 and -3.  A number of physiological interventions were 
performed in humans in vivo to manipulate insulin sensitivity in both a 
positive and a negative fashion and the expression of calpain-10 and -3 
mRNA and protein was determined in skeletal muscle biopsies.  In the 
first such study, healthy human subjects underwent short-term 48 h 
fasting and it was hypothesised that this intervention would induce 
transient insulin resistance, which could be restored by 24 h of high 
carbohydrate refeeding.  It was envisaged that this fasting induced 
insulin resistance would be accompanied by a reduction in calpain-10 
mRNA and protein expression in skeletal muscle and would therefore 
 81 
provide evidence that calpain-10 was functionally linked to, rather than 
associated with, states of insulin resistance.       
 
In the second and third studies, subjects underwent a one week high fat 
diet and an Intralipid infusion, respectively and it was hypothesised that 
an increase in fat availability in both studies would induce skeletal 
muscle insulin resistance.  It has been shown previously that calpain-10 
is regulated by lipid infusion in humans and therefore these studies had 
the joint aim of assessing the role of elevated FFA and insulin 
resistance on calpain-10 expression in skeletal muscle.  It was also 
hypothesised that calpain-3 expression levels would be reduced in 
these interventions as calpain-3 expression has previously been 
negatively correlated with FFA and insulin resistance.  
 
In the following chapter, a single bout of moderate intensity cycling 
exercise was employed as an intervention with the aim of increasing 
insulin sensitivity in an insulin independent manner.  Previous studies 
have suggested a link between exercise, albeit accompanied with 
muscular damage, and calpain activation in vivo.  It was hypothesised 
that calpain-10 expression would be induced in these states, possibly 
as a result of the increased calcium release that is seen during 
exercise.  It was also hypothesised that calpain-3 expression would be 
activated during exercise and that this may be seen as a characteristic 
pattern of autolysis on Western blots of calpain-3 protein in skeletal 
muscle.   
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In the final chapter of this thesis, the expression of calpain-10 was 
investigated in the skeletal muscle of insulin resistant type 2 diabetic 
patients.  Again, it was hypothesised that calpain-10 expression would 
be downregulated in the skeletal muscle of these patients.  This finding 
would provide conclusive evidence of an association between calpain-
10 and type 2 diabetes.  Also in the final chapter, the role of variation in 
the calpain-10 gene on carbohydrate oxidation and glucose disposal 
was investigated by combining results from all of the previous studies.  
It was expected that the at-risk variation in the calpain-10 gene would 
be linked to reduced insulin stimulated glucose disposal and 
carbohydrate oxidation.  
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2 General Methods 
 
2.1 Chemical reagents and equipment  
 
All general laboratory chemicals were obtained from the following 
suppliers, unless otherwise stated: Fisher Scientific (Loughborough, 
Leicestershire, UK), Sigma Aldrich Chemicals (Poole, Dorset, UK), 
Promega (Southampton, UK) or GE healthcare (Little Chalfont, UK).  
Laboratory buffers were made up with distilled water or ultra-pure Milli-
Q Elix water (Millipore Corporation, Watford, UK) where required.  
Water used for nucleic acid work was always DNase and RNase free, 
and was purchased from Sigma Aldrich.  The majority of molecular 
biology reagents and enzymes were purchased from Promega and/or 
New England Biolabs (Hitchin, Hertfordshire, UK).  Real-time PCR 
consumables were purchased mostly from Applied Biosystems 
(Warrington, UK) with additional materials purchased from Invitrogen 
(Paisley, UK) or ABgene (Epsom, Surrey, UK) where required.   
 
Equipment which was used but is not specified in the text was as 
follows. Centrifuges used were the Biofuge 13 (Heraeus 
Instruments/Kendro, Hertfordshire, UK), the Hawk 15/05 (MSE, London, 
UK) and the Centraur swinging bucket centrifuge (MSE, London, UK).  
Instruments used for protein quantification were the Spectra Max 190 
(Molecular Devices Ltd., Wokingham, UK), the Ultraspec Plus (Biochom 
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Ltd, Cambridge, UK) and the 680 XR microplate reader (Bio-Rad, 
Hemel Hemstead, UK).  For DNA quantification either the GeneQuant 
Pro (Biocom Ltd., Cambridge, UK) or the NanoDrop ND-1000 
(Wilmington, USA) was used.  The machines used for PCR were the 
Peltier Thermal Cycler-200 (MJ Research Inc, Massachusetts, USA) 
and the Mastercycler (Eppendorf, Cambridge, UK).  For real-time PCR 
the same ABI Prism 7700 (Applied Biosystems, Warrington, UK) system 
was always used.  
 
For running large (200 mm x 100 mm) sodium dodecyl sulphate 
polyacrylamide gel electrophoresis gels (SDS-PAGE), a dual plate unit 
was used (Fisher or GE healthcare).  Western blotting of large protein 
gels was performed using a Trans-blot fitted with plate electrodes (Bio-
Rad).  For small mini protein gels (80 mm x 50 mm), the Mini-Protean II 
system (Bio-Rad) was used for gel running and Western blotting.  
Horizontal DNA agarose electrophoresis was carried out using the Sub-
Cell system (Bio-Rad).    
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2.2 Human studies  
 
Each individual chapter described in this thesis represent a distinct 
study or group of studies.  Inevitably each study involved a distinct set 
of techniques, whilst a number of techniques were common to each 
study.  The protocols common to all chapters are described in this 
chapter and those that are more specific to individual chapters are 
described in the relevant chapter.    
 
2.2.1 Human Volunteers 
 
All subjects were recruited from the students and staff of the University 
of Nottingham or from the local population.  Posters were used to 
advertise the studies and these were usually placed in and around the 
university campus.  Prospective studies were also advertised on the 
website of the Centre of Integrated Systems Biology and Medicine 
(http://www.nottingham.ac.uk/cisbm/).  The experimental protocol was 
described to potential subjects in detail and time was allocated to allow 
for the individual to ask any questions that they may have had regarding 
any aspect of the study.  Following this meeting, subjects were then 
asked to give written informed consent and complete a basic medical 
screening involving a general health questionnaire and measurements 
of height and weight using a stadiometer and an electronic balance, 
respectively.  Blood pressure and ECG readings were taken and a 
blood sample was collected from an antecubital vein for analysis of full 
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blood count and markers of renal and hepatoligical function (QMC).  All 
studies were approved by the University of Nottingham Medical School 
Ethical Committee. 
 
2.2.2 Blood sampling and analysis  
 
On study visits, arterialised-venous (a-v) blood samples were obtained 
from the dorsal surface of a superficial vein in the non-dominant hand.  
The hand was placed in a small chamber which was heated to 
approximately 55°C to arterialise the venous drainage of the hand.  
After heating the hand for approximately 15 min, local anaesthetic was 
applied to the skin (1% lignocaine hydrochloride, Antigen 
Pharmaceuticals Ltd., Roscrea, Ireland) and a 21 gauge cannula was 
inserted retrogradally into a vein.  The hand was then returned to the 
chamber where it remained for the duration of the study.  In cases 
where exercise was in progress (chapter 6), subjects were asked to 
place their hand into the heated chamber approximately 5 min before 
sampling began.  An isotonic saline drip (0.9% sodium chloride BP, 
Baxter Healthcare Ltd., Thetford, UK) was used to keep the cannula 
clear an accessible at all times.  Blood samples were withdrawn via a 
three-way tap with the first 2 ml being discarded to avoid dilution with 
saline.     
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2.2.2.1 Determination of blood glucose 
 
Following blood sampling an aliquot of approximately 25 µl of whole 
blood was aspirated into an automated glucose analyser (YSI 2300 
STAT plus, Yellow Springs, OH, USA) for determination of whole blood 
glucose concentration.  The YSI STAT 2300 uses a steady state 
measurement methodology, where membrane based glucose oxidase 
catalyses the oxidation of glucose to gluconic acid and hydrogen 
peroxide (H2O2) (Twomey et al., 2004; Astles et al., 1996).  The glucose 
analyser was calibrated prior to each experiment and at regular 
intervals during the experiment, as described by the manufacturer.  
 
2.2.2.2 Determination of serum insulin concentrations 
 
For collection of serum, an aliquot of whole blood was collected into 5 
ml tubes (BD Vacutainer, SSTII advance) and allowed to clot for at least 
20 min, following which the serum was collected by centrifugation at 
3,000 g for 15 min and stored at -80°C.  Serum insulin was determined 
at a later date using a solid phase (coat-a-count) radioimmunoassay 
(Diagnostic Products Corporation, California, USA) according to the 
manufacturers instructions (appendix 1).   
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2.2.2.3 Determination of plasma free fatty acids (FFA) 
 
For collection of plasma, an aliquot of whole blood was also collected 
into 6 ml tubes (BD vacuatiner, LH 102 I.U) containing 30 µl of 200 mM 
EGTA (to inhibit lipolysis) and lithium heparin, and plasma was 
collected by centrifugation at 3,000 g for 10 min and stored at -80°C.  
Plasma FFA concentrations were determined using the NEFA C Kit 
(WAKO Chemicals, Germany) according to the manufacturers 
instructions (appendix 1).   
 
2.2.2.4 Determination of ketones 
 
Whole blood ȕ-hydroxybutyrate was measured in perchloric acid (10%) 
treated whole blood samples, according to the method of Williamson et 
al. (1962) (appendix 1).  This assay was performed by Sally Cordon at 
the School of Biomedical Sciences, University of Nottingham.      
            
2.2.2.5 Determination of glucagon concentrations 
 
Plasma samples from whole blood were prepared as described above 
and plasma glucagons was analysed using a double-antibody glucagon 
test kit (Diagnostic Products Corporation, California, USA) according to 
the manufacturers instructions (appendix 1).  This assay was 
 89 
performed by Dr. K. Chokkalingam at the Queens Medical Centre, 
Nottingham.     
 
2.2.2.6 Genomic DNA extraction 
 
In all studies undertaken, a baseline blood sample was collected during 
the first experimental visit for the extraction of genomic DNA and for the 
determination of each individuals genotype at various calpain-10 SNPs 
(chapter 1, 1.6).  The DNA was extracted from 300 µl of whole blood 
using the Wizard Genomic DNA purification kit (Promega).  Three 
hundred microliters of blood was added to 900 µl of cell lysis solution 
and inverted 5-6 times to mix the contents well before being incubated 
at room temperature for 10 min to lyse the cells.  The sample was then 
centrifuged at 13,000 g for 20 seconds at room temperature, the 
supernatant removed and the remaining white blood cells were 
resuspended in approximately 20 µl of residual liquid from the 
supernatant.  Three hundred microliters of nuclei lysis solution was 
added to the cells and pipetted gently to lyse the white blood cells.  
Protein was precipitated with 300 µl of protein precipitation solution and 
collected by centrifugation at 13,000 g for 3 min.  The supernatant was 
transferred to a clean eppendorf containing 300 µl of isopropanol and 
the tube was inverted repeatedly until white DNA strands became 
visible (usually 5-10 inverts).  At this point the DNA was collected by 
centrifugation at 13,000 g for 1 min, washed with 75% ethanol and 
resuspended in 100 µl of H2O.  DNA was quantified and the 
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determination of each subjects genotype at a number of loci is 
described below (see 2.5). 
 
2.2.3 Urine sampling and analysis 
 
Urine samples were collected during each study visit in chapter 4 and 
chapter 5 and stored in 5 ml aliquots at –20°C in 10% thymol until 
analysis.  For determination of protein oxidation in chapter 4, urine 
nitrogen was determined using the Kjeldahl method and was performed 
at the University of Surrey, UK.  In chapter 5, protein oxidation was 
estimated from urea excretion as most urinary nitrogen (>80%) is in the 
form of urea.  Urea concentrations were determined using a 
commercially available kit (Randox Laboratories, UK) according to the 
manufacturer’s instructions (appendix 1) and this assay was performed 
by Dr. K. Chokkalingam, Queens Medical Centre, Nottingham.  It was 
assumed that for each gram of nitrogen excreted in the urine, 6.04 litres 
of O2 were consumed and 4.89 litres of CO2 were produced and results 
were normalised for protein content according to equations (1) and (2) 
below.  
 
2.2.4 Indirect calorimetry 
 
Resting metabolic rate (RMR) and substrate oxidation rates were 
determined in vivo from gaseous exchange data obtained using a 
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ventilated hood system.  RMR was measured by using an open-circuit 
indirect calorimeter (Gas Exchange Measurement (GEM) system, 
Nutren Technology Ltd, Manchester, United Kingdom).  After a warm-up 
period of 30 min, a reference gas (5% CO2 and 95% O2) was used to 
calibrate the oxygen and carbon dioxide analysers.  Ingoing and 
outgoing air were analysed for oxygen and carbon dioxide composition 
every minute during each period of measurement, which was 20 
minutes.  Readings from the metabolic monitor were collected every 
minute with a personal computer, and this allowed for minute by minute 
calculations of the respiratory exchange ratio (RER) and of metabolic 
rate using the Weir equation (Weir, 1949).  Substrate oxidation rates 
were estimated from V
.
O2 and 
 
V
.
CO2 values using stoichiometric 
equations as described in detail by Frayn (1983).  The calculations used 
for the determination of carbohydrate (COX) and fat oxidation (FOX) 
based on O2 consumed and CO2 produced are summarised in 
equations 1 and 2, where n grams of urinary nitrogen are being 
excreted per minute.    
COX = 4.55 V
.
CO2 – 3.21 
FOX = 1.67 
V
.
O2 – 2.87 n   (1) 
V
.
O2 – 1.67 
 
V
.
CO2 – 1.92 n   (2) 
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2.2.5 Peak oxygen uptake test (V.
 
O2 max) 
In chapter 6 each subject was asked to complete an incremental 
exercise test on a bicycle ergometer prior to the study to establish their 
maximal oxygen uptake, or V
.
O2 peak.  The subjects warmed up for a 
few minutes at low intensity before the workload was increased to 100 
W and then subsequently by 25 – 50 W every 3 min depending on their 
estimated fitness status.  During the cycling, subjects breathed trough a 
mouthpiece and valve and V
.
O2 and the rate of carbon dioxide 
production (V. CO2) were measured by indirect calorimetry (Vmax, 
Sensor Medics, Yorba Linda, CA).  Subjects were asked to maintain a 
constant speed throughout the test (~ 80 rpm) and were deemed to 
have reached their V
.
O2 peak when they were no longer able to 
maintain this speed as the workload increased.  Heart rate (Polar A1, 
Polar Electro Oy, Kempele, Finland) and perceived exertion (Borg and 
Linderholm, 1970) were monitored throughout to confirm that the 
subjects had reached their peak value.  Linear regression was used to 
estimate the work load required for a given percentage of the V
.
O2 peak.  
During studies in which bicycling exercise was a component (chapter 6 
only), measurements of V. O2 and V
.
CO2 were taken using the same 
equipment at regular intervals during the exercise period for 
determination of oxygen uptake and for calculations of substrate 
oxidation rates as described above.      
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2.2.6 The hyperinsulinaemic-euglycaemic clamp technique 
 
In all experiments (except chapter 3), to quantify insulin sensitivity 
subjects underwent a hyperinsulinaemic-euglycaemic clamp essentially 
as described by DeFronzo et al. (1979).  The clamps varied in duration, 
ranging from 4 h (chapter 4 and chapter 6) to 6 h (chapter 5), but in all 
cases involved the simultaneous intravenous infusion of a 
predetermined fixed dosage of insulin and a variable rate glucose 
infusion.  The insulin infusion rate was aimed at achieving a 
physiologically high serum insulin concentrations of approximately 80 
mU/L, whilst the blood glucose concentration was ‘clamped’ at 
approximately 4.5 mmol/L to represent normal fasting values.   
 
After the subjects reported to the laboratory, their weight was recorded 
and they were allowed a short rest period before a cannula was 
inserted into the non-dominant hand for the sampling of arterialised 
blood (see 2.2.2), and an additional cannula was inserted for the 
infusion of insulin and glucose.  The insulin infusion rate (ml/hr) was 
calculated by multiplying the F value [(body surface area/insulin syringe 
conc.)*(desired insulin clamp conc. (mU/m2)/40)] by the rate constant 
(DeFronzo et al., 1979).  At 0-2 min, a bolus of insulin was given, which 
was gradually reduced every 2 min until 10 min into the clamp, where it 
was kept constant throughout the remainder of the clamp.  The glucose 
infusion (2 mg/kg/min) was started at 4 min, and increased to 2.5 
mg/kg/min at 10 min.  During the remainder of the clamp procedure, 
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arterialised blood samples were taken every 5 min for the immediate 
determination of blood glucose concentrations.  If the blood glucose 
concentration deviated from 4.5 mmol/l, then the glucose infusion rate 
was adjusted accordingly.  At the end of the clamp period, the infusion 
of insulin was stopped and the subject was immediately fed a large 
carbohydrate rich meal.  During this period, the infusion of glucose was 
maintained but was reduced slowly to allow the subjects blood 
concentrations to return to normal postabsorptive values, at which point 
the infusion of glucose was stopped, all catheters were removed, and 
the subject was allowed to leave the laboratory.   
 
2.2.7 Muscle Sampling and analysis 
 
Muscle samples were obtained from the vastus lateralis muscle by an 
experienced clinician using the needle muscle biopsy technique 
(Bergström, 1962).  Briefly, subjects rested in a supine position and the 
skin overlaying the area to be sampled was shaved, if required, and 
thoroughly cleaned with iodine solution and then anaesthetised (1% 
lignocaine hydrochloride, Braun Ltd., Melsungen, Germany).  After 
allowing a short time for the anaesthetic to take affect, a small scalpel 
blade was used to make a 0.5 cm incision through the skin.  A biopsy 
needle was then inserted through the incision and a small sample of 
muscle (~ 50-100 mg) was removed.  Muscle biopsy samples were 
snap frozen and stored in liquid nitrogen until further use.  
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2.2.7.1 Skeletal muscle total RNA extraction  
 
Total RNA was extracted from ~10-30 mg of skeletal muscle biopsy 
tissue using Trizol reagent (Invitrogen, Paisley, UK) which is an 
adaptation of the guanidine isothiocyanate method developed by 
Chomczynski and Sacchi. (1987).  Each piece of frozen muscle was 
homogenised on ice with a power homogeniser (PowerGen 700, 
Fisherbrand, Fisher Scientific) in 800 µl of Trizol reagent and 20 µl of 
glycogen (10 µg/µl) for 2 x 15 seconds with the sample being placed on 
ice for 30 seconds in between.  The sample was allowed to stand at RT 
for 5 minutes before the addition of 160 µl of chloroform:isoamyl alcohol 
(49:1).  The sample was then mixed by inversion for 20 seconds and 
then vortexed briefly and allowed to stand at RT for 2 min before 
centrifugation at 12,000 g for 15 min at 4°C.  The aqueous phase was 
then transferred to a fresh tube and 400 µl of ice cold isopropanol was 
added and the samples were placed at -20°C overnight to precipitate 
the RNA.  The next day, the RNA was pelleted by centrifugation at 
12,000 g for 15 min at 4°C.  The supernatant was removed and the 
pellet was washed with 800 µl of ice cold 75% ethanol and the samples 
were centrifuged again at 10,000 g for 10 min at 4°C.  The supernatant 
was decanted and samples were placed over tissue paper for 
approximately 5 min to drain off any remaining ethanol.  Following a 
brief pulse in the centrifuge, any last remaining ethanol was removed 
using a pipette, and the RNA pellet was dissolved in 30 µl of RNase 
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free H2O on ice and the RNA solution was stored at -80°C.   Integrity of 
extracted RNA was always checked on agarose gels (see 2.3.4). 
 
2.2.7.2 RNA quantification         
 
The concentration of extracted total RNA was quantified using the 
Ribogreen RNA quantification kit (Molecular Probes, Invitrogen, Paisley, 
UK).  Two microliters of the RNA was diluted 10-fold in RNase free H2O 
and 10 µl of this was added to 490 µl of 1 x TE buffer and 500 µl of 
ribogreen solution diluted 1:200 in 1 x TE.  The fluorescence (excite at 
480 nm, emit at 520 nm) of each sample was measured with a F-2000 
fluorescence spec (Hitachi instruments Inc., Naperville, USA).  For the 
standard curve, the supplied ribosomal RNA stock solution was diluted 
1:50 in 1 x TE and increasing volumes of the diluted standard was 
added to 1 x TE to a final volume of 500 µl to give a standard curve 
ranging from 0-50 ng.  Five-hundred microliters of the ribogreen solution 
was then added to each standard and measured as described above.      
 
2.2.7.3 First strand cDNA synthesis 
 
Reverse transcription was carried out on 0.5 µg total RNA essentially as 
described in Parr et al. (2001).  Each RNA sample was diluted to 0.05 
µg/µl and 10 µl of this was added to 1 µl random hexamer primers 
(Promega) and 4 µl H2O and incubated at 70°C for 5 min  in a 
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Mastercycler thermocycler (Eppendorf, Hamburg, Germany).  The 
samples were immediately placed in ice before the addition of 10 mM 
dNTPs, 0.5 µl RNase inhibitor, 5 µl MMLV reverse transcriptase buffer 
and 1 µl of MMLV reverse transcriptase (all Promega) in a final volume 
of 25 µl.  In the same thermocycler, the samples were incubated at RT 
for 10 min followed by 42°C for 1  h and 70°C for 1 5 min.  
 
2.2.7.4 Quantitative real-time polymerase chain reaction (qRT-PCR) 
 
Following reverse transcription, the first strand cDNA was always 
diluted fourfold (i.e. 75 µl of RNase free H2O was added to 25 µl first 
strand cDNA solution).  Quantification of reverse transcribed cDNA was 
performed in real time using an ABI 7700 Sequence Detection System 
as described above.  Human cDNA sequences were obtained from 
GenBank and primers and dual-labelled fluorescent oligonucleotide 
probes (5’FAM and 3’TAMRA) were designed (appendix 2) using 
Primer Express version 2.0 software (Perkin-Elmer, Norwalk, CT).  
Real-time PCR was performed using PCR Universal Master Mix 
(Applied Biosystems, Warrington, UK).  Each reaction contained 5 µl 
cDNA template, 12.5 µl PCR Universal Master Mix, 300 nM primers and 
125 nM dual labelled fluorescence probe in a reaction volume of 25 µl.  
Each RT-PCR reaction was performed in triplicate and all results were 
QRUPDOLVHG WR Į-actin mRNA expression using the standard curve 
method.  In chapter 7, results were normalised to HMBS mRNA 
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expression using the standard curve method.  The primers and probes 
used in this thesis for qRT-PCR are listed in appendix 2.  
 
2.2.7.5 Skeletal muscle protein extraction 
 
Approximately 10-30 mg of tissue was homogenised for 30 s in 10 
volumes of extraction buffer A containing 20 mM Tris-HCL, 5 mM 
EDTA, 2 mM DTT (pH 7.5) containing a cocktail of protease inhibitors 
(P8340, Sigma, Dorset, UK) (chapters 3 and 4).  In later chapters 
(chapters 5 and 7), muscle tissue was homogenised in 10 volumes of 
extraction buffer B containing (50 mM HEPES, 10 % glycerol, 1 mM 
EDTA, 10 mM NaF, 1 mM Na3VO4, 150 mM NaCl and 1% Triton X-100, 
pH 7.5) to improve the solubility of calpain-10 in particular (2.2.7.6).  
Whole muscle lysates were centrifuged at 13,000 g for 20 min at 4oC to 
pellet insoluble material and equal volumes of 2 x Laemmli sample 
buffer (20% glycerol, 125 mM Tris-HCl (pH 6.8), 4% SDS (w/v), 100 mM 
DTT (or 100 mM ȕ–mercaptoethanol), 0.02% (w/v) bromophenol blue) 
was added to the supernatant fraction.  Protein pellets that remained 
from extractions with buffer A and B were resuspended in 
approximately 400 µl of 2 x Laemmli sample buffer supplemented with 8 
M urea and 2 M thiourea and incubated overnight at room temperature 
with gentle shaking in order to fully dissolve the protein pellet.  
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2.2.7.6 Comparison of protein extraction buffers 
 
To compare the extractability of calpain-10 with buffer A and buffer B, a 
small pilot experiment was performed.  Briefly, baseline muscle biopsy 
protein was extracted from 5 random subjects with buffer A and the 
buffer B using identical procedures as described above.  Samples for 
analysis were taken at each stage of the extraction process: i.e. after 
homogenisation (designated whole homogenate), and after 
centrifugation (supernantant and insoluble pellet).  Protein samples 
were quantified and equal quantities of protein were run on SDS-PAGE 
gels, transferred to nitrocellulose membranes and immunoprobed for 
calpain-10 exactly as described below.  As shown in Fig 2.1, replacing 
the extraction buffer to one that included a non-ionic detergent resulted 
in significant improvements in the solubility of calpain-10 protein.  The 
quantity of calpain-10 protein in the supernatant fraction using buffer A 
was very low and was almost undetectable, whereas with buffer B 
quantification of calpain-10 in the supernatant fraction was clearly more 
viable.   
 
When using buffer A, it is clear from the Western blot images that the 
majority of the total calpain-10 pool is being measured as very little 
immunoreactive calpain-10 is detected in the supernatant fraction 
following centrifugation, leaving the remainder in the insoluble fraction.  
In the case of buffer B, Fig 1 shows that most of the calpain-10 detected 
in the whole homogenate fraction is also detected in the supernatant 
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following centrifugation, again indicating that the majority of calpain-10 
protein is indeed being detected.  As an index of the biological and 
analytical variation, the coefficient of variation (CV) for the Western blot 
determination of calpain-10 was calculated for the relevant fractions in 
the above experiment.  In the pellet remaining from buffer A and in the 
supernatant from buffer B, the CV for calpain-10 determination was 
6.9% and 12.1%, respectively.      
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Figure 2.1  The effect of different extraction buffers on calpain-10 protein 
solubility in skeletal muscle (n = 5).   
 
Shown is a representative Western blot for calpain-10 (75 kDa) following extraction 
with either buffer A or buffer B. *P<0.001 vs. buffer A. 
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2.2.7.7 Protein quantification 
 
The Lowry (Lowry et al., 1951) or BCA (Smith et al., 1985) method was 
used to quantify protein concentration following extraction with 
extraction buffer A or B, respectively.  The Lowry method involves two 
reactions; the first reaction is a biuret reaction which reduces Cu+2 to 
Cu+1 and the second uses this Cu+1 to reduce the Folin-Ciocalteau 
reagent.  This reaction is detectable in the range of 500 – 750 nm.  A 
number of solutions were made up for the assay and mixed to form a 
reagent A and a reagent B.  Reagent A contained 2% Na2CO3 in 0.1 M 
NaOH, 2% KNa tartrate and the copper reagent 1% CuSO4 in a 10:1:1 
ratio.  Reagent B contained 0.1 M NaOH and Folin-Ciocalteau reagent 
in a ratio of 10:1.  Samples for analysis were diluted ten fold in water 
and 5 µl of this was added to a well in a 96 well plate in duplicate.  For 
the standard curve, BSA standard solutions were made ranging from 0 
µg/5 µl to 1µg/ 5 µl and 5 µl of each standard was added to wells in 
duplicate giving a standard curve range of 0 – 1 µg.  Following this, 195 
µl of 0.1 M NaOH was added to all sample and standard wells to give a 
final volume of 200 µl in each well.  Fifty microliters of reagent A was 
added to each well and the plate was incubated at room temperature for 
5 min.  Fifty microliters of reagent B was then added to each well and 
the plate was incubated at room temperature for a further 15 min before 
it was read at 620 nm in a spectrophotometer plate reader. 
 
 
 103 
When buffer B was used, the BCA (bicinchoninic acid) method of 
protein quantification (BCA protein assay kit, Pierce, Cramlington, UK) 
was employed to allow for any interfering substances that might have 
been present in the new buffer (e.g. Triton X-100).  Standards were first 
prepared using BSA to give a range of 2000 – 25 µg/ml and 10 µl of 
each standard and sample were pipetted into a microplate well in 
duplicate.  A working reagent was prepared from reagent A and reagent 
B (supplied in the kit) in a ratio of 50:1, and 200 µl of this was added to 
each well.  The plate mixed briefly for 30 s and incubated at 37°C for 30 
min before being read at 562 nm.       
           
Protein pellets remaining from the extraction procedures were 
quantified using the 2D-Quant Kit (GE healthcare, Little Chalfont, UK) 
according to the manufacturers instructions.  Again, a BSA standard 
curve of 0 – 50 µg/ml was prepared from the stock solution of 2 mg/ml 
by the addition of 0 – 25 µl to 1.5 ml eppendorf tubes in duplicate.  
Three microliters of each sample in 2 x laemmli buffer was added to 1.5 
ml eppendorf tubes before 500 µl of precipitant was added to all sample 
and standard tubes; tubes were then briefly vortexed and incubated at 
room temperature for 2-3 min.  Five-hundred microliters of co-
precipitant was then added to each tube and tubes were again mixed 
briefly before being centrifuged at  10 000 g for 10 min.  Supernatants 
were carefully removed and proteins were dissolved in 100 µl of copper 
solution and 400 µl of water.  To each tube was added 1 ml of working 
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colour reagent before samples were incubated at room temperature for 
15-20 min and finally read at 480 nm.      
 
2.2.7.8 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
 
SDS-PAGE was carried out essentially as described by Laemmli 
(1970).  Protein samples were diluted in an equal volume of 2 x 
Laemmli sample buffer and each sample was then mixed and boiled for 
5 min to ensure protein denaturation before being centrifuged briefly at 
maximum speed to collect any cell debris.  Equal quantities of each 
sample, based on results from the quantification, were then loaded onto 
polyacrylamide gels consisting of a 5% (v/v) stacking gel and a main gel 
which ranged in concentration from 8-12% (v/v) depending on the 
application.  Gels were run in SDS running buffer (25 mM Tris, 192 mM 
glycine and 1% (w/v) SDS at a constant voltage of 200 V for 
approximately 40 min.  Prestained protein markers (Precision Plus 
Protein Standards, Bio-Rad, UK) were loaded onto each gel to 
accurately and consistently determine the size of each migrated band.   
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2.2.7.9 Western blotting    
  
Western blotting was performed according to Towbin et al. (1979) and 
Burnette, (1981).  The Western blot buffer used in this thesis contained 
400 mM glycine, 25 mM Tris and 10% methanol.  Whilst SDS-PAGE 
gels were running, nitrocellulose or polyvinylidene difluoride (PVDF) 
membranes (GE healthcare, Little Chalfont, UK) were cut to size, as 
were four pieces of 3MM paper.  Blotting membranes, 3MM paper and 
western blot sponges were soaked in the western blot buffer for at least 
20 min whilst the gel was running.  In the case of PVDF membranes, 
these were hydrated for 15 sec in methanol and washed for 5 min in 
water before being soaked in western blot buffer.  When the gel had 
finished running, it was soaked very briefly in western blot buffer (<5 
min).  Following this, the western blot sandwich was assembled; a 
sponge was laid onto one side of a blotting cassette, and placed on top 
of this was two sheets of 3MM paper, then the gel, followed by the 
membrane, the final two pieces of 3MM paper, and finally the remaining 
sponge.  Care was taken not to introduce air bubbles into the sandwich.  
The cassette was clamped together and placed into a western blotting 
tank, taking care to ensure that the gel side of the assembly was 
orientated adjacent to the cathode.  Western blotting was carried out for 
approximately 2 h at 150 – 350 mA depending on the size of the 
transfer tank used.  Buffer was always kept cold during Western blotting 
with the use of cold packs or a super cooling coil contacted to the mains 
water supply.  
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2.2.7.10 Immunoprobing with calpain antisera 
 
For the determination of calpain-10 protein expression, equal quantities 
(30 µg) of insoluble skeletal muscle protein extracts (chapter 3 and 4) 
or supernatant protein (chapter 5 and 7) were loaded onto 10% 
polacrylamide gels and transferred to PVDF membranes as described 
above (see 2.2.7.9).  The PVDF membrane was removed from the 
Western blot apparatus following transfer and briefly washed in 
methanol before being placed in Ponceau S stain (0.5% (w/v) Ponceau 
S in 5% (w/v) trichloroacetic acid) for approximately 1 min and 
membranes were visualised by destaining in methanol.  This was to 
ensure 1) equal transfer efficiency across the gel and 2) that equal 
quantities of protein were loaded into each well.  Ponceau S stain was 
removed by washing briefly in TBS-T (50 mM NaCl, 100 mM Tris, 1% 
(v/v) Tween 20).  Non-specific binding was then blocked in 5% (w/v) 
non-fat dried milk (Marvel) in TBS-T for 1 h at room temperature before 
incubating overnight at 4ºC with the primary antibody, diluted 1:1000 in 
5% (w/v) Marvel TBS-T.  The next morning, any unbound antibody was 
removed by washing with 1% (w/v) Marvel TBS-T for 12 x 5 min with 
fresh changes of solution each time.  The membrane was then 
incubated for 1 h with the secondary antibody, which was anti-rabbit 
IgG linked to horseradish peroxidase (HRP) (GE healthcare, Little 
Chalfont, UK).   
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The membrane was developed with ECL Plus Western Blotting 
Detection Reagents (GE healthcare, Little Chalfont, UK).  For this, a 
40:1 ratio of reagent A to reagent B was mixed together, pipetted on to 
the membrane (0.1ml/cm2) and incubated for 5 min at room 
temperature.  The membrane was blotted using 3MM Whatman 
chromatography paper to remove the detection reagents and wrapped 
in cling film before being taped into an autoradiograph cassette.  In the 
dark room, the membrane was exposed to autoradiography film 
(Hyperfilm ECL, GE healthcare) before being developed in 1 x Kodak X-
ray developer solution (Calumet Photographic Company, Nottingham, 
UK) briefly washed in water and fixed in 1 x Ilford Hypam rapid fixing 
solution (Calumet Photographic Company).  Western blot signals were 
quantified by scanning densitometry and analysed with Quantity-One 
Multi-Analyst software (Bio-Rad, Hertfordshire, UK).   
 
For calpain-3, equal quantities (30 µg) of insoluble skeletal muscle 
protein extracts were run on 10% SDS-PAGE gels and transferred to 
nitrocellulose membranes as described above (see 2.2.7.9).  These 
membranes were stained with Ponceau S in the same way, except that 
water replaced methanol.  The same detection procedure was used as 
described above for calpain-10 except that membranes were blocked 
overnight at 4°C  before being incubated with a polyclonal antibody 
raised against a recombinant protein corresponding to domain-III of 
porcine calpain-3 (2.4), diluted 1:500 for 1 h.  For the quantification of 
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calpain-3 autolysis products, the densities of the 60 and 58 kDa bands 
were added to the density of the 55 kDa band.   
 
All results for calpain were normalised to the levels of desmin protein, 
which was quantified on each blot using a polyclonal anti-desmin 
antibody, diluted 1:500 (D-8281, Sigma, Dorset, UK).  Briefly, 
membranes were stripped of detection reagents and primary and 
secondary antibodies using Restore Western Blot Stripping Buffer 
(Pierce, Rockford, USA) according to the manufacturers instructions 
and incubated overnight with the desmin antibody.  The same detection 
procedure was used as described above for calpain-10.   
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2.3 Calpain-10 antisera 
 
The generation of calpain-10 antisera was attempted in this thesis via 
the expression and purification of a small peptide corresponding to 
domain III of human calpain-10a.  This was absolutely necessary as at 
the commencement of this project no calpain-10 antibodies were 
commercially available.  
 
2.3.1 Human calpain-10 cDNA synthesis 
 
An Expressed Sequence Tag (EST) containing a partial human calpain-
10 cDNA sequence was used as a template for the generation of a 528 
bp fragment of the human calpain-10 gene.  A search of all available 
ESTs was carried out using the Genbank 
(http://www.ncbi.nih.gov/Genbank/) Express Sequence Tags database 
(dbEST).  EST matches were aligned and the best match for the 
desired sequence was purchased from the I.M.A.G.E consortium 
(Integrated Molecular Analysis of Genomes and their Expression; 
http://www.image.llnl.gov) using MRC geneservice 
(http://www.hgmp.mrc.ac.uk/geneservice/index.shtml).  
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2.3.2 Amplification of human calpain-10 cDNA  
 
Forward and reverse primers were designed to amplify a 528 bp region 
from within the EST based on sequences selected from domain III of 
human calpain-10a (see chapter 1, Fig 1.4).  The forward primer was 
5’-GGGGAGTTCTGGGTGGAGGAG-3’ and corresponded to amino 
acids 299 – 305 of human calpain-10a and the reverse primer was 5’-
GTCCCCAGCACCTTCCTG-3’ and this corresponded to the non coding 
strand complimentary to amino acids 469 – 474 of human calpain-10a.  
Additional nucleotides were incorporated during synthesis at the 5’ ends 
of the forward and reverse primer to facilitate cloning into the EcoRI 
(GGATCC) and BamHI (GAATCC) site of the pGEX-4T-1 fusion vector 
(GE healthcare, Little Chalfont, UK), respectively. 
  
PCR reactions were performed in 50 µl final volumes containing the 
following reagents; 1 x Taq polymerase buffer (10 x stock: 200 mM Tris-
HCl pH 8.4, 500 mM KCl, 50 mM MgCl2), 10 µM each dNTP, 10 pmol 
forward and reverse primer, 2.5 U Ampli Taq Gold (Applied Biosystems) 
and approximately 30 ng plasmid DNA.  PCR cycling conditions were 
95°C for 5 min followed by 40 cycles of 95°C for 30 sec, 65°C for 1 min 
and 72°C for 1 min, and a final extension step of 72°C for 10 min.  
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2.3.3 DNA precipitation 
 
DNA was concentrated and purified using an ethanol (EtOH)/sodium 
acetate (NaAc) method.  Briefly, 2 volumes of 100% ethanol and 1/10 
volume of 3M NaAc, pH 5.5, was added to the DNA sample and was 
left at -20qC for at least 30 min.  The DNA was collected by 
centrifugation at 15,000 g for 20 minutes at 4qC.  The pellet was 
washed in cold 75% EtOH and collected by centrifugation at 15,000 g 
for 10 min.  The supernatant was decanted and the DNA was allowed to 
air dry briefly before being re-suspended in H2O.   
 
2.3.4 Horizontal agarose gel electrophoresis 
 
DNA products were verified on 1% (w/v) agarose gels.  Agarose was 
dissolved in a 1 x concentrated TAE buffer (2 M Tris, 50 mM EDTA, 5.7 
% acetic acid), and boiled briefly to dissolve.  After the mixture had 
cooled, it was poured into a casting module and a suitable comb was 
placed at one end for sample loading.  Gels were run at 100 V for 
approximately one hour and removed from the casting module and 
stained in 0.5 µg/ml ethidium bromide (EtBr) for half an hour and briefly 
de-stained in H2O.  DNA bands were visualised using Bio-Rad’s Gel 
Doc 2000 and Multianalyst program (Bio-Rad).   
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2.3.5 Restriction endonuclease digestion 
 
Typically for analytical use, restriction digests were performed in 20 µl 
volumes containing 2 µl of substrate DNA (QJ, 15.5 µl H2O, 2 µl 
10 x buffer and 0.5 µl of enzyme (~ 5 units).  For cloning experiments, 
larger amounts of DNA (vector and insert) were used and this meant 
scaling up the reactions volume considerably. 
 
The purified calpain-10 cDNA was inserted into the pGEX-4T-1 vector 
using the BamHI/EcoRI restriction sites.  First, 400 ng of the human 
calpain-10 cDNA was digested with BamHI and EcoRI in the same 
reaction, using 5 U of each enzyme in a 1 x mulitcore buffer (Promega) 
for 2 h at 37°C.  After 1 h, an additional aliquo t (5 U) of each enzyme 
was added.  The PGEX-4T-1 vector was digested in two separate 
reactions; the vector was first linearised with EcoRI and then digested a 
second time with BamHI.  In between digests, DNA was purified using 
the ethanol/sodium acetate method as described above (see 2.3.3) to 
remove non-compatible buffers.  Reactions were performed in a final 
volume of 150 µl containing 500 ng DNA and 50 U of either enzyme in a 
1 x buffer (buffer E and H for BamHI and EcoRI, respectively).  Again, 
the contents were mixed and placed at 37°C for 2 h, and an additional 
aliquot (50 U) of enzyme was added after 1 h.  Following restriction 
digests, agarose gel electrophoresis (see 2.3.4) was used to estimate 
the quantity of both calpain-10 and PGEX-4T-1 DNA using molecular 
weight standards with known concentrations.   
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2.3.6 Ligation  
 
In order to obtain the best efficiency for ligation, two vector:insert ratios 
of 1:1 and 1:3 were generally used.  The following equation was used to 
calculate the quantity of insert DNA that was required for a given 
concentration of the vector DNA.  
 
 
       ng of vector x kb size of insert        x     molar ratio of insert  
                   kb size of vector          vector 
 
 
To ligate calpain-10 into the pGEX-4T-1 vector using a 1:1 ratio, 
approximately 4.2 ng of the insert DNA was added to a reaction mix 
containing 2 x ligation buffer (60 mM Tris-HCl, 20 mM MgCl2, 20 mM 
DTT, 2 mM ATP, 10% polyethylene glycol), 40 ng digested pGEX-4T-1 
vector and 3 Weiss units of T4 DNA ligase.  For a 1:3 vector:insert ratio, 
the amount of insert required was approximately 12.7 ng and the 
reaction mixture was adjusted accordingly.  All ligation reactions were 
left overnight at 4°C.   
 
2.3.7 Transformation 
 
A 5 ml overnight culture of Escherichia Coli (E.coli) was back diluted 
into 20 ml of Lauria-Bertani-Miller (LB) media (10 g tryptone, 5 g yeast 
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extract and 10 g NaCl2/l), and the culture was grown to the log phase 
(OD600 = 0.4-0.5).  Cells were then collected by centrifugation (3,000 g, 
10 min) and resuspended in ice cold 0.1 M CaCl2 using chilled, blunt 
ended pipette tips and left on ice for 1 h until competent.  Approximately 
10 ng of ligation mix was then added to 200 µl of cells and left on ice for 
a further 30 min.  The cells were then heated to 42°C for exactly 2 mi n 
and placed back on ice for 20 min.  Approximately 800 µl of LB media 
was then added to the cells and cells were allowed to grow at 37°C with 
shaking (200 rpm) for a minimum of 45 min.  Cells were collected and 
50-100 µl of resuspended cells were streaked onto LB-agar (15 g/l of 
LB media) plates containing ampicillin (50 µg/ml).  
 
2.3.8 Plasmid purification and confirmation of positive transformants 
 
Plasmid DNA was isolated using the GenElute plasmid miniprep kit 
(Sigma).  Five millilitres of LB media (+ 100 µg/ml ampicillin) was 
inoculated with a single colony from an LB-agar plate and left shaking 
overnight at 37°C.  The next day, cells were collected by centrifugation 
at 13,000 g for 1 min, the supernatant removed and cells resuspended 
in 200 µl of resuspension solution and lysed with the addition of 200 µl 
of lysis solution.  The lysis solution was thoroughly mixed with the 
resuspended cells and left at room temperature for 5 min to ensure 
adequate lysis.  Cell debris was precipitated with the addition of 350 µl 
of neutralisation/binding solution and collected by centrifugation at 
13,000 g for 10 min.  A GenElute miniprep column was then inserted 
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into a 2 ml eppendorf tube and the lysate was transferred to the column 
before it was centrifuged at 13,000 g for 1 min.  The column flow-
through was discarded and 750 µl of wash solution was added to the 
column and the column was again centrifuged at 13,000 g for 3 min to 
ensure removal of ethanol from the column.  One-hundred microliters of 
H2O was then added to the column and the DNA was collected by 
centrifugation at 13,000 g 2 min.  Positive transformants were identified 
by digesting out the ligated DNA fragment using the same restriction 
enzymes that were used to clone it into the vector (see 2.3.5).  
Restriction digest reactions were then run on agarose gels (see 2.3.4) 
to confirm the presence of insert DNA. 
 
2.3.9 Glycerol stocks 
 
Confirmed positive clones were stored permanently by adding 500 µl of 
80% glycerol to 1 ml of an overnight culture, mixing them together and 
then snap freezing the culture in liquid nitrogen and storing it at -80°C.  
 
2.3.10 Fusion protein expression  
 
A scrape from a glycerol stock of positive transformants was streaked 
onto an LB-agar plate containing ampicillin (50 µg/ml) and allowed to 
grow overnight at 37°C.  Colonies were then picked and grown 
overnight in 2YTA media (16 g tryptone, 10 g yeast extract and 5 g 
 116 
NaCl2/L) containing ampicillin (50 µg/ml) at 37°C with shaking (200  
rpm).  The following morning, cultures were back diluted 1:100 in 2YTA 
media, and allowed to grow to the log phase (OD600 0.4-0.5), at which 
point IPTG was added to a final concentration of 0.1 mM.  Cells were 
allowed to grow at 37°C with shaking for a further 2 h, and were then 
collected by centrifugation and frozen at -20°C until further use.    
 
2.3.11 Fusion protein preparation 
 
Fusion proteins were extracted from induced E.coli following the 
methods described by Frangioni and Neel (1993).  Briefly, cell pellets 
were resuspended and lysed in a 2% N-laurylsarcosine (sarkosyl) 
solution containing 5 mM DTT and 5 mM EDTA.  Cell debris was then 
collected by centrifugation at 10,000 rpm for 15 min and Triton-X was 
added to the supernatant to a final concentration of 1% (v/v).  The 
supernatant containing the fusion proteins was then incubated with 
glutathione-agarose beads (Sigma) for a minimum of 20 min at 4°C.  
Agarose beads were collected by centrifugation at 3,000 rpm for 5 min 
and washed three times with ice cold phosphate buffered saline (PBS) 
(137 mM NaCl, 10 mM phosphate, 2.7 mM KCl, pH 7.4).  Fusion 
proteins were eluted from the agarose beads with an elution buffer 
containing 5 mM reduced glutathione, 50mM tris-HCl and 5mM EDTA 
(pH 9.5) and mixed with equal volumes of 1 x Laemmli sample buffer 
and subjected to SDS-PAGE. 
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2.3.12 Gel purification of fusion proteins 
 
12% SDS-PAGE gels were prepared as described (see 2.2.7.8) and 
approximately 250 µl of the fusion protein/bead solution was loaded and 
run at 200 V for 40 min.  Bands corresponding to the correct size were 
excised from the gel using a reference lane which had been stained in 
coomassie blue and destained in 10% acetic acid as a reference.  
Fusion proteins were eluted from gel slices using Bio-Rad’s Electro-
Eluter Model 422 according to the manufacturer’s instructions.  Aliquots 
of purified fusion proteins were run on SDS-PAGE gels to verify the 
presence of the correct fusion protein.      
 
2.3.13 Immunisations 
 
Two rabbits (New Zealand white) were injected subcutaneously with 
approximately 30 µg of the purified GST-calpain-10 fusion protein.  For 
the primary injection, an emulsion was made with 1 ml of the antigen 
and 1 ml of Freunds complete adjuvant, and was injected over four sites 
(0.25 ml/site) on each animal.  Booster injections were given at 3, 5 and 
7 weeks following the primary injection until maximum titre was 
reached.  For the booster injections, the antigen was prepared in the 
same way, except that the emulsion was made with Freunds incomplete 
adjuvant.  Bleeds were taken prior to the primary injection and before 
each booster injection to test for the presence of any non-specific cross 
reacting antibodies.  Approximately 3-5 mls of blood was taken from the 
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ear of each rabbit.  Blood was “ringed” to loosen the clot from the tube 
and was left overnight at 4°C.  Serum containing the IgG fraction was 
collected the next day and stored at -20°C until used.   
 
2.3.14 Calpain-10 antisera from the University of Chicago 
 
Calpain-10 antisera was also obtained as a gift from Prof. G.I.Bell at the 
University of Chicago, USA for comparison with the internally produced 
one.  This was also a rabbit polyclonal antibody but was raised against 
a small peptide sequence corresponding to amino acids 35-50 of 
human calpain-10a (domain I-II, chapter 1, Fig 1.4) conjugated to 
keyhole limpet hemocyanin (KLH) and was designated N7.  When 
obtained, this antibody had not been tested for use in human skeletal 
muscle extracts and therefore required verification for specificity, as did 
the calpain-10 antisera raised in-house. 
 
2.3.15 Verification of calpain-10 antisera   
 
2.3.15.1 Dot-blot tests 
 
Dot-blot tests were initially used to test for the presence of cross 
reacting antibodies at each stage in the immunisation schedule.  Serial 
10-fold dilutions of the antigen (see 2.3.12) were dotted onto strips of 
nitrocellulose, which were then blocked with 5% (w/v) Marvel TBS-T for 
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at least 1 h, and then incubated with serum which was diluted to 1:50, 
1:500 and 1:5000 concentrations in 5% (w/v) Marvel TBS-T.  The strips 
were then washed for 30 min with 1% (w/v) Marvel TBS-T and 
incubated with anti-rabbit IgG alkaline phosphatase secondary antibody 
for 20 minutes.  Strips were again washed for 30 min with 1% (w/v) 
Marvel TBS-T and the colour reaction was initiated with the addition of 
the enzyme substrate (Sigma Fast™ 5-Bromo-4-Chloro-3-Indolyl 
Phosphate/Nitro Blue Tetrazolium tablets). 
 
2.3.15.2 Western blot analysis 
 
Each antibody was tested in the first instance on Western blots 
containing human skeletal muscle protein extracts and also on Western 
blots containing whole brain lysates from wild type and calpain-10 
knock-out mice, which were produced in the laboratory of Prof. G.I.Bell, 
University of Chicago.  In the case of the internally produced antibody, 
the Western blot included a lane which contained the fusion protein that 
was used to immunise the animals to confirm the presence of specific 
cross-reacting antibodies.  In addition, for the internally produced 
antibody, the final bleed serum was compared to the pre-immune serum 
in terms of specific cross reactivity.   
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2.3.15.3 In vitro transcription and translation of human calpain-10 
 
To investigate the specificity of the N7 antibody to the full length human 
calpain-10 protein, the full length protein was produced in vitro in a 
relatively pure form.  The entire calpain-10 coding sequence, or open 
reading frame (ORF) in the pcDNA-3.1-HisA vector (Invitrogen) was  
first obtained from Prof. G.I.Bell and this was subcloned into the TNT 
vector (Promega).  To achieve this, the calpain-10 ORF was amplified 
from the pcDNA-3.1-HisA vector using the forward primer 5’-
AAAGAATTCGAGGCAACCGGCTGCAGATG-3’ and the reverse 
primer 5’-AAAGCGGCCGCTGCAAATCATCAGCGCTCAT-3’ in a 20 µl 
final volume containing 10 pmol each primer, 1.5 mM MgCl2, 10 µM 
each dNTP, 1 x reaction buffer, 0.25 U Taq Gold and ~ 30 ng template 
DNA.  PCR cycling conditions were 94°C for 5 minutes followed by 35 
cycles of 94°C for 30 seconds, 55°C for 30 seconds and 72°C for 2 
minutes and a final extension step of 72°C for 10 minutes.  The PC R 
fragment and TNT vector (Promega) were digested with EcoRI and NotI 
and run on an agarose gel using the standard techniques described 
above (2.3.5 and 2.3.4).  Both products were then purified with an 
ethanol precipitation (see 2.3.3) and the calpain-10 ORF was then 
ligated into the TNT vector using the EcoRI and NotI sites in the vector 
(see 2.3.6).     
 
The pcDNA-3.1-HisA-calpain-10 DNA vector was then transcribed and 
translated in a 25 µl reaction using the rabbit TNT Coupled Reticulocyte 
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Lysate Transcription/Translation System (Promega) according to the 
manufacturers instructions.  Briefly, 0.5 µg of the DNA was mixed with 
12.5 µl reticulocyte lysates, 1 µl TNT buffer, 0.5 µl amino acid mix (-
methionine), 1 µl [35S] methionine (>1000 Ci/mM), 0.5 µl T7 RNA 
polymerase, 0.5 µl RNasin and 8 µl of H2O.  Reactions were run in 
duplicate in the presence or absence of [35S] methionine and were run 
on 10% (w/v) SDS-PAGE gels and transferred to PVDF membranes as 
described above (2.2.7.9).  Confirmation of the expression of the full 
length protein was initially determined by the detection of the [35S] 
labelled protein.  For this the PVDF membrane was dried and placed 
into a western blot cassette and a phosphoscreen (Kodak, Rochester, 
USA) was then placed on top of the membrane and left in place 
overnight, after which the phosphoscreen was scanned in a 
phosphorimager (Bio-Rad).  Specificity of the N7 antibody to the in vitro 
produced protein was then investigated by immunoprobing the other 
PVDF membrane containing the unlabelled protein with each antibody 
(see 2.2.7.10). 
 
2.4 Calpain-3 antisera 
 
The calpain-3 antisera used throughout this thesis was produced 
internally by Dr. T. Parr of the Department of Nutritional Sciences, 
University of Nottingham and has been described in detail previously 
(Parr et al., 1999).    
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2.5 Determination of calpain-10 SNPs 
 
Each individual’s genotype at SNP-43, Indel-19 and SNP-63 were 
determined essentially as described by Carlsson et al (2004) for SNP-
43 and by Evans et al. (2001) for Indel-19 and -63, with minor 
modifications.   
 
SNP-43 was amplified using the forward primer 5’-
GCTGGCTGGTGACATCAGTGC-3’ and reverse primer 5’-
ACCAAGTCAAGGCTTAGCCTCACCTTCATA-3’ in 20 µl volumes 
containing 10 pmol each primer, 1.5 mM MgCl2, 10 µM each dNTP, 1 x 
reaction buffer, 0.25 U Ampli Taq Gold and ~ 25 ng human genomic 
DNA.  PCR cycling conditions were 94°C for 5 minutes followed by 32 
cycles of 94°C for 30 seconds, 60°C for 30 seconds and 72°C for 30 
seconds, followed by a final extension step of 72°C for 10 m inutes.  
PCR products were digested for 16 h at 37°C with 10 U Nde I in 40 µl 
reactions and run on 4% agarose gels.  If the individual was 
homozygous for the G allele (allele 1) then a single band of 254 bp was 
visualised on the gel and if they were homozygous for the A allele 
(allele 2), then two bands of 223 and 31 bp were seen.  A G/A 
heterozygote was identified by the presence of all three bands.   
 
Indel-19 was amplified using forward primer 5’- 
GTTTGGTTCTCTTCAGCGTGGAG-3’ and reverse primer 5’-
CATGAACCCTGGCAGGGTCTAAG-3’ using the same reaction 
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conditions as above except that the annealing temperature was 60°C.  
PCR products were run on 3% (w/v) agarose gels; allele 1 (two repeats) 
was visualised as 155 bp and allele 2 (three repeats) as a band of 187 
bp.  
 
SNP-63 was amplified using the forward primer 5’- 
AAGGGGGGCCAGGGCCTGACGGGGGTGGCG-3’ and reverse 
primer 5’- AGCACTCCCAGCTCCTGATC-3’.  The PCR conditions were 
the same as those for Indel-19, except that the annealing temperature 
was 62°C.  PCR products were digested with 2 U of HhaI in 1 × NE4 
buffer at 37°C for  2 h. The digested products were separated on 3% 
(w/v) agarose gels.  Alleles 1 (C) and 2 (T) were seen as 162 and 192 bp 
products, respectively. 
 
2.6 Statistics 
  
Data in all chapters were analysed using a general linear model (GLM) 
for repeated measures (SPSS, Version 13.0).  In chapter 3 this was a 
one-way analysis (time) and in chapters 4, 5 and 6 this was a two way 
analysis (treatment and time).  Student’s t test (two-tailed) was used to 
compare paired data where appropriate, with Bonferroni corrections if 
required (i.e. for multiple t-tests) to avoid type 1 error.  When missing 
data was evident, and when indicated, a linear mixed model with 
repeated measures was used to eliminate the effects of loss of data and 
power.  In a standard GLM repeated measures analysis, when data is 
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missing at any time point for a subject, all data for that subject is 
automatically removed (a so-called “listwise deletion”) and in some 
cases this can result in significant loss of statistical power leading to an 
increased risk of type 2 error.  This was a particular problem for the 
analysis of mRNA and protein expression in chapter 4 and chapter 5, 
where occasionally protein and/or total RNA was not extracted in some 
subjects due to small muscle biopsy samples at certain time points 
leading to random missing data points.  A linear mixed model is able to 
analyse data with missing values and is therefore an improvement on 
the GLM, particularly in cases where a small number of missing values 
are present in a repeated experimental design.  The effects of SNPs in 
chapter 7 was analysed using paired t tests for independent samples.  
A P value less than 0.05 was considered significant.  All data are 
expressed as mean (± SEM) throughout this thesis and this includes 
applies to all text, figures and tables.  
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3 Short-term fasting and skeletal muscle calpain 
expression in healthy humans 
 
3.1 Introduction 
 
The adaptive response to fasting involves a series of metabolic 
alterations, characterised initially by increased release of free fatty acid 
(FFA) from endogenous stores and reduced production and oxidation of 
glucose.  Whilst the exact mechanisms underlying these adaptations 
are not fully understood, the physiological responses to starvation are 
commonly accompanied by a significant reduction in whole body insulin 
sensitivity (Mansell and Macdonald, 1990) and alterations in the 
expression of many genes that are important for glucose oxidation and 
transport.  The reduction in glucose uptake with fasting may be 
mediated by changes in the expression of the glucose transporter 
GLUT4 (see 1.2.1.4).  In fasted rats, levels of GLUT4 mRNA in adipose 
tissue are reduced with fasting and refeeding the rats leads to a 
complete recovery of the GLUT4 mRNA (Sivitz et al., 1989; Berger et 
al., 1989; Camps et al., 1992).  In skeletal muscle the response of 
GLUT4 to starvation is not as clear with some studies demonstrating an 
increase (Woloshak et al., 1993; Neufer et al., 1993) and others no 
change (Kraegen et al., 1993) in GLUT4 content following fasting in 
rodents.  Therefore, the role of GLUT4 in fasting mediated insulin 
resistance in humans remains unclear.  This is especially true given that 
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GLUT4 mRNA and protein levels are not different in the skeletal muscle 
of type 2 diabetic patients or insulin resistant obese subjects (Pederson 
et al., 1990; Shepherd and Kahn, 1999).  In these cases, it is likely that 
changes in GLUT4 translocation and not expression mediate, in part, 
the insulin resistance seen in these subjects.  
 
Calpain-10 has been linked to GLUT4 mediated glucose uptake in 
adipocytes in vitro (see 1.9.2.2).  In rat adipocytes, specific inhibition of 
calpain-10 using antisense technology reduced insulin mediated 
glucose transport by 50% and significantly reduced GLUT4 
translocation to the plasma membrane via effects on actin reorginisation 
(Paul et al., 2003).  However, as outlined in chapter 1, there is currently 
no direct evidence linking calpain-10 and GLUT4 mediated pathways of 
glucose uptake in skeletal muscle.  The muscle specific calpain-3 has 
previously been shown to be affected by fasting treatment in lambs 
(Ilian et al., 2001).  In this study, skeletal muscle calpain-3 protein 
expression was significantly elevated after only one day of fasting but 
after seven days was lower than pre-fast values (Ilian et al., 2001).  
Moreover, fasting and refeeding chicks led to marked increases and 
decreases in skeletal muscle calpain-3 mRNA, respectively (Nakashima 
et al., 2005).       
 
Experiments primarily carried out in rodents suggest that transcriptional 
regulation of a number of key genes involved in lipid and CHO 
metabolism may also be responsible for the metabolic adaptations to 
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starvation and refeeding.  Short-term fasting in rats and mice has been 
previously shown to increase the expression of genes involved in fatty 
acid transport and beta oxidation such as lipoprotein lipase (LPL), 
carnitine palmitoyltransferase I (CPT1), long chain acyl CoA 
dehydrogenase (LCAD), the fatty acid transporter CD36 and uncoupling 
protein 3 (UCP3) (Holst et al. 2003; de Lange et al. 2004), indicating 
that increased fatty acid influx into muscle during starvation is 
accompanied by an adaptive increase in gene expression.  Regulation 
of oxidative glucose disposal appears to be controlled at the 
transcriptional and post-transcriptional level. Suppression of skeletal 
muscle pyruvate PDC activity plays a major role in the downregulation 
of CHO oxidation in response to starvation (Sugden et al. 1993).  In 
humans, starvation was shown to increase PDK4 transcription 
(Pilegaard et al. 2003a) and mRNA content in skeletal muscle 
(Pilegaard et al. 2003a; Spriet et al. 2004). 
 
The aim of the present study was to investigate the effects of fasting 
induced insulin resistance on the mRNA and protein expression of 
calpain-10, -3 and GLUT4 in human skeletal muscle.  It has been 
shown that a reduction in calpain-10 is associated with insulin 
resistance in humans and it was hypothesised that fasting induced 
insulin resistance would be linked to a similar reduction in calpain-10 
mRNA and protein expression.  Based on the limited available 
evidence, this reduction in calpain-10 would be expected to lead to a 
reduction in GLUT4 translocation and, if GLUT4 is a substrate for 
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calpain-10, possibly an accumulation of GLUT4 content.  It was 
hypothesised that a restoration of insulin sensitivity with high 
carbohydrate refeeding would reverse these changes in calpain-10 and 
GLUT4 levels.  On the other hand, calpain-3 was expected to increase 
with fasting as has been previously described in animal models.       
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3.2 Subjects and Methods 
 
3.2.1 Subjects and experimental design 
 
Ten healthy male volunteers (age 26 ± 1 yr, body mass 81 r 4 kg, BMI 
26 ± 1 kg.m2) participated in this study, which was approved by the 
University of Nottingham Medical School Ethics Committee.  All 
subjects underwent a 48 h period of fasting followed by a 24 h period of 
refeeding with a high carbohydrate diet (total energy 3086 r 19 kcal of 
which 75% energy as CHO, 10% fat and 15% protein).  During fasting, 
subjects refrained absolutely from food but were allowed water, 
electrolytes, non-sugared carbonated drinks and, except on study days, 
black non-sugared decaffeinated coffee and tea.  Subjects consumed 
80 mmol of sodium and 40 mmol of potassium daily as slow release 
tablets to minimize the potentially confounding effects of fluid 
deprivation and intravascular volume depletion on cardiovascular 
reflexes and sympathetic nervous system activity. Subjects were 
required to continue with their normal daily activities but to refrain from 
formal heavy exercise sessions during the period of starvation.  The 
high CHO diet was designed after analysing the subjects diet with 
Microdiet software (Downlee Systems Limited, UK) using dietary figures 
produced by the subjects who were requested to weigh and record their 
normal food intake for three days prior to the trial.  On three occasions, 
before and after 48 h of starvation and after 24 h of refeeding, subjects 
underwent a 16 min insulin tolerance test (ITT) to quantify insulin 
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sensitivity (3.2.2).  On day 1 of the study, prior to the commencement of 
fasting and on day 4 following refeeding, subjects consumed a 
standardized breakfast (providing 1g CHO/kg body mass) 4 h before 
they arrived at the laboratory, at which point baseline measurements 
were taken.  Muscle biopsy samples were obtained from the vastus 
lateralis before and after 24 h and 48 h of starvation, and after 24 h of 
refeeding and snap frozen in liquid nitrogen until further use.   
 
3.2.2 Insulin tolerance test (ITT) 
 
In this chapter, whole body insulin sensitivity was estimated using an 
insulin tolerance test (ITT) (Bonora et al., 1989).  Briefly, at 0 min of the 
ITT, an intravenous bolus of human Actrapid insulin (0.1 U per kg body 
mass) was administered and blood samples for glucose determination 
were then taken every 2 min.  The test was terminated at 16 min and a 
25 ml bolus of 20% glucose was infused to prevent symptoms of 
hypoglycaemia.  Following this, a high CHO meal was provided.  Blood 
glucose concentrations were checked for stability before the subject 
was allowed to leave the laboratory.  Data from this test were 
expressed as the percentage decline in blood glucose (mM) per min 
from 4 to 16 min after the insulin injection, since no changes in blood 
glucose concentration were observed within the first 4 min of the ITT 
test (Bonora et al., 1989).  The ITT has been used widely as an index of 
insulin sensitivity and the results from this test have been shown in 
direct comparison studies to correlate closely (r between 0.81-0.86) with 
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results from the hyperinsulinaemic-euglycaemic clamp technique 
(Akinmokun et al., 1992; Bonora et al., 1989).   
  
3.2.3 Blood analysis 
 
Blood glucose, serum insulin and plasma FFA were analysed as 
described (general methods, 2.2.2). 
 
3.2.4 RNA extraction and Real Time PCR 
 
Total RNA was extracted from skeletal muscle biopsy samples and 
qRT-PCR was performed on reverse transcribed cDNA as described 
(general methods, 2.2.7.4).  The effects of fasting and refeeding on the 
levels of calpain-10 and -3 and GLUT4 mRNA were assessed.  The 
real-time PCR primers and probes used are listed in appendix 2.  
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Figure 3.1  Schematic diagram of the starvation study protocol.   
 
Subjects reported to the lab following a standardised breakfast and began 48 h of 
fasting.  Following fasting, subjects then underwent 24 h of high CHO refeeding.  
Insulin tolerance tests were performed before and after 48 h of fasting and after 24 h 
of refeeding.  Blood samples and muscle biopsies were taken before, during and after 
fasting and after refeeding for the measurement of blood metabolites and mRNA and 
protein expression, respectively. 
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3.2.5 Calpain antisera 
 
Calpain-10 and -3 antisera were produced and obtained as described in 
the general methods (2.3 and 2.4).  
 
3.2.6 Western blot analysis of Skeletal Muscle Protein Extracts  
 
Calpain-10 and -3 protein levels were quantified in the skeletal muscle 
protein pellets as described in the general methods (2.2.7.10).  For the 
quantification of calpain-3 autolysis products in this chapter, 
autoradiograph films were exposed for longer to allow for more accurate 
quantification and were then normalised to the same desmin values.  
Protein levels of GLUT4 were determined for two subjects only due to 
limited tissue.  For this, 30 µg of soluble muscle protein extract on 
nitrocellulose membrane was probes with an anti-GLUT4 antibody, 
diluted 1:500 (Santa Cruz Biotechnology, USA) using the same 
procedure as for calpain-3 (general methods, 2.2.7.10).   
 
3.2.7 Statistical analysis 
 
Statistical analysis was performed as described in the general 
methods (2.6).   
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3.3 Results 
 
3.3.1 Calpain-10 antisera 
 
In this chapter, the determination of calpain-10 protein expression was 
performed for the first time in this thesis and therefore the 
characterisation of each calpain-10 antibody is presented here.  
Determining the specificity of the antibodies was important for the future 
quantification of calpain-10 protein levels in this and in the subsequent 
chapters of this thesis.  
 
3.3.1.1 Recombinant calpain-10 purification 
 
In Fig 1A, it is shown that the GST-calpain-10 fusion protein was 
expressed at high levels in E.Coli and contributed to a significant 
proportion of the total protein content of the induced E.Coli.  It is also 
shown that the expression of the fusion protein was much higher in the 
induced E.Coli when compared to the non-induced cells (Fig 1A).   This 
expressed fusion protein was purified successfully (Fig 3.2B) and 
rabbits were immunised with the purified protein as described in the 
general methods (2.3.13) section.     
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3.3.1.2 Antisera verification 
 
Initial investigations into the internally produced antisera showed that 
one of the antibodies (designated 690) cross reacted strongly with the 
antigen on dot-blot tests and Western blots (Fig 3.3A and 3.3B) and 
was able to detect a band of approximately 73 kDa on Western blots of 
human skeletal muscle extracts (Fig 3.3C).  However, the pre-immune 
serum was also able to detect a very light band at approximately the 
same size suggesting that this band may be non-specific (Fig 3.3C).  
Further studies showed that this antibody was not able to distinguish 
between wild type and calpain-10 KO mice on Western blots of whole 
brain lysates (Fig 3.3D).  
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Figure 3.2  Production (A) and purification (B) of a recombinant GST-
calpain-10 fusion protein.   
 
In the upper panel (A), lane 1 on the SDS-PAGE gel contains the molecular weight 
marker, lanes 2 and 4 the uninduced E.coli lysates and lanes 3 and 6 contain lysates 
from E.Coli that were induced to express the recombinant GST-calpain-10 fusion 
protein, indicated by the arrow.  The gel purified protein, shown on a separate SDS-
PAGE gel (B) was used for subsequent immunisations.    
50 kDa 
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 1   2    3    4     5 
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Figure 3.3  Characterisation of the polyclonal antibody (609) raised 
against a recombinant GST-calpain-10 protein.   
Testing of the 609 antibody on dot-blot tests containing the purified antigen (A) and 
against recombinant E.Coli induced to express the same antigen (B) revealed 
specificity for the 46 kDa GST-calpain-10 protein. Subsequent testing on Western 
blots, however, revealed that the 73 kDa band recognised by the 609 serum in human 
skeletal muscle was also detected by the pre-immune serum from the same animal, 
indicated by the arrow (C). Finally, the antibody did not differentiate between calpain-
10 WT and KO mice on Western blots of whole brain lysates (D).      
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In contrast, Western blot analysis of insoluble human skeletal muscle 
protein with the antibody obtained from the University of Chicago 
(designated N7) revealed a major band for calpain-10 at 75 kDa, but 
also demonstrated the presence of smaller bands at 60 kDa and 32 kDa 
(Fig 3.4A).  The N7 antibody also clearly recognised a 75 kDa in vitro 
translated protein, corresponding to full length human calpain-10 
(isoform a) (Fig 3.4B) and detected 32 and 25 kDa proteins in whole 
brain lysates from wild type, but not calpain-10 knock-out mice (Fig 
3.4C), 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 139 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4  Characterisation of the N-terminal antibody (N7) obtained 
from the University of Chicago.   
Western blot analysis of insoluble human skeletal muscle protein with the N7 antibody 
revealed major bands for calpain-10 at 75, 60 and 32 kDa, as shown by the arrows 
(A).  The N7 antibody also clearly recognised a 75 kDa in vitro translated protein (B) 
and detected 32 and 25 kDa proteins on Western blots of whole brain lysates from 
wild type, but not calpain-10 knock-out mice (C),  The solid black bars represent the 
molecular weight markers. 
B 
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3.3.2 Insulin sensitivity and blood measurements 
 
The ITT used in the present study measures the decrease in blood 
glucose concentration in response to an intravenous administration of 
insulin and thus provides an index of whole body insulin sensitivity.  As 
expected, 48 h fasting significantly reduced the percentage decline in 
blood glucose per minute during the ITT by ~45% when compared to 
pre fast values (PRE FAST 5.16 ± 0.44 vs. 48 h FAST 2.94 ± 0.31 
%/min, p<0.01) and this partially recovered to basal values following 
refeeding (PRE FAST 5.16 ± 0.44 vs. REFED 4.02 ± 0.34 %/min, 
P<0.05) (Fig 3.5A).  This reduction in the fall in blood glucose 
concentration during the ITT at 48 h post fasting coincided with a 
decrease in fasting blood glucose concentrations (PRE FAST 4.3 ± 0.1 
vs. 48 h FAST 3.5 ± 0.1 mmol/L, P<0.001) and a reduction in fasting 
serum insulin concentrations (PRE FAST 29.5 ± 3.5 vs. 48 h FAST 16.4 
± 1.2 pmol/L, P<0.01) with both fully recovering to basal values 
following refeeding (Table 3.1).  In contrast, plasma FFA markedly 
increased with fasting more than 2-fold from its baseline value 
(P<0.001) (Table 3.1). 
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Table 3.1  Blood glucose, serum insulin and plasma FFA before and after 
fasting and refeeding (n = 10). 
 
 
 
 
**P<0.01, ***P<0.001 vs. pre fast values 
 
 
 
 
 
 
 
 
  
Pre fast 
 
24 h fast 
 
48 h fast 
 
24 h refed 
 
Blood Glucose 
(mmol/l) 
 
4.3 ± 0.1 
 
4.09 ± 0.1 
 
3.51 ± 0.1*** 
 
4.44 ± 0.1 
Serum Insulin 
(mU/l) 
4.9 ± 0.6 4.4 ± 0.5 2.7 ± 0.2** 5.3 ± 0.9 
Plasma FFA 
(mmol/l) 
0.46 ± 0.07 0.76 ± 0.12 0.97 ± 0.10*** 0.45 ± 0.08 
 142 
0.0
1.0
2.0
3.0
4.0
5.0
6.0
Pre fast 48 h fast 24 h refed
%
 
de
c
lin
e
 
in
 
bl
o
o
d 
gl
u
c
o
s
e
 
(m
M
)/m
in
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5  The effect of fasting and refeeding on whole body insulin 
sensitivity (n = 10) (A) and on skeletal muscle GLUT4 protein (n = 2) (B) 
and mRNA (n = 10) (C) expression.  
Insulin sensitivity is expressed as the percentage decline in blood glucose (mM) per 
min and was determined using an ITT. Also shown is Western blots for GLUT4 protein 
performed on two subjects (B).  *P<0.05, **P<0.01 vs. pre fast values. 
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3.3.3 Calpain-10 and GLUT4 expression 
 
Basal GLUT4 mRNA levels were gradually reduced following 24 h and 
48 h of fasting and failed to recover fully to basal values with refeeding 
(PRE FAST 4.7 ± 0.5 vs. 24 h FAST 3.3 ± 0.4 vs. 48 h FAST 2.8 ± 0.2 
vs. REFED 3.5 ± 0.7, P<0.05) (fig 3.5C).  Post-hoc analysis revealed 
that GLUT4 mRNA was reduced significantly after 48 h fasting 
(P=0.013), but not 24 h, and was not significantly different to pre fast 
following refeeding (Fig 3.5C).  Due to limited tissue, the determination 
of GLUT4 protein content was only possible in two subjects in the 
present study; GLUT4 protein levels in these two individuals appeared 
to match the changes in GLUT4 mRNA and were also reduced with 
fasting (Fig 3.5B).       
 
Total calpain-10 mRNA expression remained unchanged by fasting and 
refeeding (PRE FAST 3.9 ± 0.5 vs. 48 h FAST 3.2 ± 0.3 vs. REFED 4.2 
± 0.9, Fig 3.6A).  As the probe and primers hybridized to an area 
common to multiple isoforms of calpain-10 mRNA, these data represent 
the summative expression of five potential calpain-10 mRNA transcripts 
(10a to 10e).  It is likely that isoform 10a represents the majority of the 
mRNA in skeletal muscle as has been previously demonstrated (Yang 
et al., 2001).  The expression of the 75 kDa protein band was 
unchanged by fasting and refeeding relative to desmin (Fig 3.6B), as 
was the expression of the smaller 60 and 32 kDa bands, which may 
represent various isoforms of calpain-10.  
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Figure 3.6  Effects of fasting and refeeding on calpain-10 mRNA (A) (n = 
10) and full length protein expression (B) (n = 9). 
Representative Western blots for calpain-10 (75 kDa) and desmin (55 kDa) are shown 
(B). Calpain-10 and desmin were measured on the same Western blot.   
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3.3.4 Calpain-3 expression 
 
Calpain-3 (PRE FAST 2.4 ± 0.2 vs. 48 h FAST 2.3 ± 0.1 vs. REFED 2.5 
± 0.3, Fig 3.7A) mRNA expression was unaffected by fasting and/or 
refeeding.  Western blot analysis of calpain-3 revealed a major band at 
~94kDa corresponding to the full length protein, and some smaller well 
documented autolysis products at ~60, 58 and 55 kDa (Kinbara et al., 
1998) (Fig 3.7B).  There was no significant effect of fasting and 
refeeding on the expression of the full length calpain-3 protein or on the 
accumulation of these calpain-3 autolysis products (Fig 3.7B). 
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Autolysis products 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7  Effects of fasting and refeeding on calpain-3 mRNA (n = 10) 
(A) and protein expression (n = 9) (B). 
 
A representative Western blot of calpain-3 (94 kDa) is shown (B). The quantification of 
autolysis products (55 – 60 kDa) was performed on different autoradiograph films and 
it is not intended that the absolute quantity of the autolysis products is compared 
directly to the quantity of the full length protein, as described in the text (3.2.6).  
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3.4 Discussion 
 
Previous studies on humans using insulin clamps and stable isotopes 
have demonstrated a reduction in insulin sensitivity and a shift in basal 
and insulin-stimulated substrate utilisation from CHO to fat with fasting 
(Mansell & Macdonald, 1990; Webber et al. 1994).  In the basal state 
after a 48 h fast, forearm muscle demonstrated a reduced glucose 
uptake and markedly increased glycerol output, indicating increased fat 
utilisation (Mansell & Macdonald, 1990).  During insulin infusion there 
was marked reduction in glucose uptake by the forearm muscle, 
indicating skeletal muscle insulin resistance (Mansell & Macdonald, 
1990).  However, the molecular mechanisms underlying the effects of 
starvation on insulin resistance were not examined and remain unclear.  
In the present study, it was hypothesised that the adaptive changes to 
fasting in skeletal muscle were associated with a reduction in calpain-10 
and -3 mRNA and protein expression and possibly an accumulation of 
GLUT4 content.  
 
The detection of calpain-10 protein in human skeletal muscle is 
characterised in this chapter for the first time.  It was necessary to 
attempt to produce a human calpain-10 antibody as at the time of 
production, there were no commercially available antibodies for 
purchase and the only antibodies used in the literature were designed 
to cross react with rat calpain-10.  The first antibody was produced 
internally (designated 609) and the other antibody (designated N7) was 
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obtained as a gift from Prof. G.I.Bell from the University of Chicago, 
USA.  Initial testing of 609 showed that this antibody reacted very 
strongly with the antigen that was used for immunisations (i.e. the 
recombinant GST-calpain-10 protein), both on dot-blot tests and on 
western blots of E.coli that were induced to synthesise the recombinant 
protein in large quantities.  However, more detailed analysis showed 
that this antibody detected a band of approximately 73 kDa in human 
skeletal muscle.  Not only was this band smaller than the predicted size 
of full length calpain-10 (75 kDa) but it was also visible when probing 
with the pre-immune serum which was obtained prior to immunization 
with the recombinant protein.  Moreover, 609 failed to distinguish 
between calpain-10 WT and KO mice on western blots and detected a 
band of 73 kDa in both WT and KO tissue.  In contrast, the N7 antibody 
detected 32 and 25 kDa bands in WT but not calpain-10 KO mice and 
also recognised a number of bands on Western blots of human skeletal 
muscle extracts, one of which corresponded to the predicted size of full 
length human calpain-10.  Finally it was shown that this antibody was 
able to detect a 75 kDa in vitro produced human calpain-10 protein.  
Based on this evidence, the N7 antibody was deemed the more suitable 
for use in this chapter and for the remainder of this thesis.           
 
In the present study, fasting reduced insulin sensitivity (as estimated 
using an ITT) by ~45% and this coincided with a reduction in GLUT4 
mRNA and protein levels.  GLUT4 mRNA has been shown to be 
reduced in insulin sensitive tissues following fasting in rats (Sivitz et al., 
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1989), and similarly the present study shows for the first time in humans 
that GLUT4 mRNA is reduced in skeletal muscle following 48 h of 
fasting and only partly recovers following high carbohydrate refeeding.  
The changes in GLUT4 expression closely mirrored the alterations in 
insulin sensitivity with fasting and refeeding, and may account, at least 
in part, for the failure of insulin sensitivity to fully recover following 
refeeding.  These data are in contrast to studies in humans 
demonstrating that GLUT4 expression is not correlated with rates of 
glucose uptake and is not different in the skeletal muscle of insulin 
resistant and type 2 diabetic patients (Pedersen et al., 1990).  Further 
studies have provided evidence to suggest that GLUT4 translocation to 
the plasma membrane is limiting glucose uptake in insulin resistant 
states (Garvey et al., 1998) and, whilst this was not measured in the 
present study, it seems likely that GLUT4 translocation would also be 
impaired following fasting.      
 
The changes in GLUT4 expression occurred in the absence of any 
change in the mRNA and protein expression of calpain-10.  A number 
of studies have focused on a possible link between calpain-10 and 
GLUT4 trafficking as a mechanism whereby calpain-10 may influence 
glucose uptake into insulin sensitive tissues as outlined in chapter 1 
(see 1.9.2.2).  Specific inhibition of calpain-10 in adipocytes inhibited 
insulin stimulated GLUT4 translocation via reduced actin reorganisation 
(Paul et al., 2003).  A reduction in calpain-10 with fasting may lead to 
insulin resistance via a similar reduction in GLUT4 translocation and 
 150 
possibly an accumulation of GLUT4 protein.  Importantly, however, 
such a specific interaction between GLUT4 and calpain-10 has not 
been demonstrated in skeletal muscle in vitro or in vivo, although some 
indirect evidence does exist to support this idea.  Otani et al. (2004) 
demonstrated that overexpression of the highly specific calpain inhibitor 
calpastatin resulted in a 3-fold increase in GLUT4 protein in the skeletal 
muscle of transgenic mice and that GLUT4 was a calpain substrate in 
vitro.  In contrast to the hypothesis, calpain-10 was unchanged with 
fasting and refeeding whilst GLUT4 expression was downregulated, 
suggesting that calpain-10 expression is not important for skeletal 
muscle GLUT4 expression in insulin resistant states.  One limitation of 
the present study is that measurements of calpain-10 activity were not 
obtained and cannot be measured at present.  This is an important 
point because it is possible that changes in the expression of the 
ubiquitous calpains may not be necessary for their activity.  If this is true 
for calpain-10, then perhaps a change in expression may not be 
expected during fasting and, instead, a reduction in calpain-10 activity 
may be limiting GLUT4 translocation, which unfortunately was not 
measured in this study.  This model may not be consistent with the idea 
that GLUT4 is a calpain-10 substrate or with the observed reduction in 
GLUT4 content however, as a reduction in calpain-10 activity would be 
expected to lead to an increase in GLUT4 protein.  Clearly, more 
detailed in vitro work using specific inhibition of calpain-10 in skeletal 
muscle is needed to clarify the role of calpain-10 in GLUT4 mediated 
pathways.      
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The primers and probe set used to assess calpain-10 mRNA hybridised 
to a region common to many of the calpain-10 mRNA isoforms and 
therefore the data represent the summative expression of five calpain-
10 isoforms (a-e).  It is technically very difficult to measure the 
expression of individual calpain-10 isoforms and it has been shown in 
any case that calpain-10a represents the majority of the calpain-10 
message in skeletal muscle (Yang et al, 2001).  Consideration of the 
expression of calpain-10 isoforms is important because some studies 
have indicated that smaller calpain-10 isoforms may be more 
physiologically relevant (Logie et al., 2005, Marshall et al., 2005).  In 
SDQFUHDWLFȕ-cells for example, it has been suggested that a smaller 54 
kDa calpain-10 isoform is a regulator of insulin exocytosis (Marshall et 
al., 2005) and in human primary muscle cell cultures a 60 kDa calpain-
10 band is increased with muscle cell differentiation (Logie et al., 2005).  
It is important to note that the antibodies used in these studies have not 
been fully characterised in human tissues and are designed to cross 
react with rat and not human calpain-10 (Ma et al., 2001), as is the 
focus of this thesis.  Moreover, the immunoreactive bands were not 
sequenced in these studies making it impossible to rule out non-specific 
binding of the antibody.  All of the bands recognised by the N7 antibody 
in this chapter similarly have not been sequenced and non-specific 
binding also cannot be ruled out, although the tests performed in this 
chapter go some way to provide evidence that this antibody is specific 
to human calpain-10.   
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What the observed calpain-10 bands represent is currently unknown.  In 
calpain-10 knock-out mice, it was clear that there was at least one other 
band at 25 kDa, in addition to the full length protein, that cross reacted 
with the antibody.  In human skeletal muscle, there was a similar sized 
band at approximately 30 kDa.  This band may represent calpain-10f as 
this isoforms has been shown to contribute to the total calpain-10 
expressed in skeletal muscle (Yang et al., 2001).  The 60 kDa band 
observed on Western blots in this chapter similarly may represent 
isoforms 10b, 10c or 10d as their estimated molecular weights are close 
to 60 kDa.  Alternatively these bands may represent post-translational 
proteolytic cleavage and/or autolysis of the full length 75 kDa protein, a 
common feature that occurs throughout the calpain system.  It is also 
plausible that these bands indicate activation of calpain-10 in vivo in a 
similar manner to that described for calpain-3 autolysis (Kinbara et al., 
1998).  Based on the present study however, alternative protein 
isoforms of calpain-10 do not appear to play a significant role in the 
adaptive response to fasting and refeeding as they were not affected by 
fasting and refeeding.  
 
There are a number of potential explanations as to why skeletal muscle 
calpain-10 expression was not affected by fasting and refeeding in the 
present study.  Firstly, it could be argued that the magnitude of the 
physiological insult at the level of the skeletal muscle was not sufficient 
to observe a change in calpain-10 expression in this tissue.  This is 
possible given that the ITT only provides a rough estimate of overall 
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tissue responsiveness to insulin and does not allow for a quantitative 
measurement of insulin mediated glucose metabolism, although it has 
been used successfully to screen for the presence of insulin resistance.  
The relative contribution of peripheral (skeletal muscle) and hepatic 
tissues to the reduction in insulin sensitivity seen with fasting is 
therefore not known and, as a result, the magnitude of insulin 
resistance in skeletal muscle could have been overestimated in the 
present study.  However evidence against this suggestion comes from a 
previous study which used an almost identical fasting protocol and 
demonstrated that during a hyperinsulinaemic-euglycaemic clamp that 
there was a marked reduction in glucose uptake by the forearm muscle, 
indicating skeletal muscle insulin resistance (Mansell & Macdonald, 
1990).  Furthermore, it is possible that fasting induced insulin resistance 
is primarily a result of changes in genes important for glucose and fat 
oxidation and, in the short-term, may not necessarily be a result of a 
downregulation of insulin signaling pathways.    Indeed fasting has been 
associated with an increase in the transcription and/or mRNA content of 
several genes important for lipid metabolism, including lipoprotein lipase 
(LPL) and CPT1 (Ladu et al., 1991; Hildebrandt and Neufer, 2000; 
Pilegaard et al., 2003a).  The regulation of the pyruvate dehydrogenase 
complex (PDC) has also been studied in response to starvation in both 
rodents and humans.  Fasting causes a significant increase in PDK4 
mRNA and protein content in rats, a response which is reversed by 
refeeding (Sugden et al., 2000; Wu et al., 1999; Wu et al., 1998).  In 
humans, similar responses have been seen (Pilegaard et al., 2003a; 
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Spriet et al., 2004).  In contrast, initial steps in the insulin signaling 
pathway have previously been shown to be unchanged by fasting in 
rats (Saad et al., 1992).  The phosphorylation of AKT/PKB is 
unchanged by fasting in the skeletal muscle of chicks (Nakashima et al., 
2006) and a two-day very low energy diet in obese subjects was not 
associated with changes in the expression of the insulin receptor or 
IRS1, or on PI3K activity (Jazet et al., 2005).  Given the proposed role 
of calpain-10 in insulin signaling pathways, under these circumstances, 
one may not expect to observe a change in calpain-10 expression with 
fasting and refeeding.  A further explanation could be related to 
circumstances under which measurements of skeletal muscle calpain-
10 mRNA and protein expression were made.  Muscle biopsies were 
obtained ubder basal (fasted) conditions during the 48 h fasting protocol 
and under postprandial conditions following refeeding.  It would have 
been interesting to determine calpain-10 expression under 
hyperinsulinaemic conditions following fasting and refeeding and it is 
possible that insulin stimulated calpain-10 mRNA and protein 
expression would have been different following fasting and refeeding.  
This point is also relevant when considering the interaction of calpain-
10 and GLUT4 mentioned above; calpain-10 inhibition has only been 
demonstrated to reduce GLUT4 translocation under insulin stimulated 
conditions in adipocytes.  It is possible that a reduction in calpain-10 
expression may have been seen if insulin clamps were performed 
following fasting.      
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To date only a single study has described an association between 
insulin resistance and calpain-3 expression (Walder et al., 2001).  In 
this study, skeletal muscle calpain-3 mRNA was negatively correlated 
with fat mass and fasting glucose in non-obese human subjects, and 
with circulating insulin and glucose levels in Psammomys obesus.  
There was no effect of fasting-induced insulin resistance and its 
reversal on calpain-3 mRNA or protein levels.  This observation further 
highlights the difference between the presence of a nutrient-gene 
association, which might not necessarily imply a cause and effect 
relationship, and a functional nutrient-gene interaction under conditions 
of altered nutrient supply.   
 
As with calpain-10, measurement of calpain-3 protein revealed multiple 
bands representing the full length protein and a number of autolysis 
products.  Interestingly, Western blot analysis revealed no significant 
increase in the appearance of calpain-3 autolysis products throughout 
the intervention.  Given that there is strong evidence supporting the 
notion that calpain-3 autolysis products are indeed markers of activity, 
significant accumulation of these products was expected if calpain-3 
activation was evident.  Kinbara et al. (1998) documented the 
appearance of autolysis products at 60, 58 and 55 kDa, which were 
shown to originate from a unique insertion sequence (IS1) region of 
calpain-3, which is thought to be responsible for calpain-3 instability 
(Kinbara et al., 1998).  More recent analysis in skeletal muscle 
myoblasts has shown that this autolysis is critical for the activity of 
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calpain-3 (Taveau et al., 2003).  Expression of wild-type active calpain-
3 in myoblasts led to profound morphological changes as a result of a 
disorganisation of the actin cytoskeleton and of focal adhesions 
(Taveau et al., 2003).  Removal of the IS1 encoding region (exon 6) 
completely prevented the degradation and disorganisation of the actin 
cytoskeleton and focal adhesions indicating that calpain-3 autolysis is 
required for calpain-3 function (Taveau et al., 2003).  In porcine skeletal 
muscle in situ, it has previously been shown that the presence of full 
length calpain-3 is reduced 24 h postmortem (Parr et al., 1999).  In 
human (Murphy et al., 2006) and toad (Verburg et al., 2005) skeletal 
muscle, addition of calcium leads to the accumulation of autolysis 
products.  Collectively, these data suggest that calpain-3 autolysis is 
linked to its activation as is common with other members of the calpain 
family.  In the present study, however, a lack of accumulation of 
calpain-3 autolysis products on Western blots indicates that calpain-3 
was not significantly activated.  This finding is consistent with recent 
evidence from exercise studies supporting the idea that calpain-3 may 
not be important for glucose uptake into skeletal muscle (Murphy et al., 
2006). 
 
The failure to observe a change in calpain-3 in response to fasting may 
be related to its proposed role in proteolysis.  It is not known in the 
current study whether significant proteolysis was observed in skeletal 
muscle and an absence of proteolysis may partially explain the lack of 
effect of fasting on calpain-3 mRNA and protein expression.  Fasting 
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chicks (Nakashima et al., 2005) and lambs (Ilian et al., 2001) did lead to 
marked increases in skeletal muscle calpain-3 mRNA.  In each of these 
studies, quantification of myofibrillar degradation revealed significant 
skeletal muscle proteolysis and this may explain the increased calpain-
3 expression.   
 
3.5 Conclusions 
 
In the present study, fasting was associated with a reduction in whole 
body insulin sensitivity, as estimated using an ITT, and this was most 
likely associated with some degree of skeletal muscle insulin 
resistance; refeeding with a high carbohydrate diet restored whole body 
insulin sensitivity.  It was hypothesised that fasting would lead to a 
reduction in calpain-10 mRNA and protein expression as reduced 
calpain-10 mRNA has previously been associated with insulin 
resistance in humans.  However, fasting did not affect calpain-10 mRNA 
or protein levels, which were characterised in this study for the first time 
using a novel antibody.  The mRNA and protein (in two subjects only) of 
the proposed calpain-10 substrate, GLUT4 was reduced with fasting 
despite no change in calpain-10 protein.  More detailed studies are 
needed to investigate the effect of more pronounced skeletal muscle 
insulin resistance on calpain-10 expression.  Furthermore, fasting may 
not be the ideal intervention to investigate the potential role of calpain-
10 in insulin signaling pathways and studies that significantly affect the 
components of this pathway need to be performed.  It is also not known 
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from the present study whether a change in the calpain-10 activity was 
responsible for the fall in GLUT4 and this is an interesting area for 
investigation.  Calpain-3 mRNA and protein expression was similarly 
unchanged by fasting and refeeding and it is suggested that previous 
reports of an upregulation of calpain-3 with fasting may be related to 
changes in skeletal muscle proteolysis in those studies.   
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4 The effect of a one week high fat diet on insulin 
resistance and skeletal muscle calpain expression 
 
4.1 Introduction 
 
In chapter 3 it was shown that short term fasting was associated with a 
reduction in whole body insulin sensitivity, alterations in serum insulin 
and blood glucose concentrations and a large increase in plasma FFA.  
These metabolic alterations were not associated with changes in the 
mRNA or protein expression of calpain-10 or -3 in skeletal muscle.  
However, as an insulin tolerance test (ITT) was employed in the 
previous chapter, it is not known whether the reduction in whole body 
insulin sensitivity seen was significant at the level of skeletal muscle, or 
was primarily an indication of hepatic insulin resistance.   
 
Several studies have shown that when FFA availability was profoundly 
increased by Intralipid infusions, impaired whole-body insulin sensitivity 
was observed in humans.  However, more physiological high-fat feeding 
in humans has produced contradictory results.  Following 3 d of high fat 
feeding (73% fat content) in aerobically active human subjects, 
Pehleman and colleagues (Pehleman et al., 2005) noted a moderate 
but significant reduction in glucose disposal, as estimated using an 
OGTT.  These findings were associated with an increase in basal (pre-
OGTT) PDK activity and decreased PDH activation.  During the OGTT, 
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GS activity and PDH activity increased to the same extent from baseline 
but PDH activity remained lower following the high-fat diet (Pehleman et 
al., 2005).  Using the hyperinsulinaemic-euglycaemic clamp technique, 
3 d of high-fat feeding (55-60% fat content) was also associated with a 
very moderate but significant reduction in insulin sensitivity (Bachmann 
et al., 2001).  High-fat feeding for 11–21 d  does not induce whole-body 
insulin resistance in healthy (Bisschop et al., 2001) and exercise-trained 
subjects (Cutler et al., 1995), although the partitioning of glucose 
metabolism is altered with decreased oxidation and increased 
nonoxidative glucose disposal.  Therefore, more detailed in vivo studies 
are needed to investigate the potential changes in insulin mediated 
muscle metabolism and the underlying mechanisms that are associated 
with high dietary fat intake in humans.   
 
It has been suggested that calpain-10 may be one gene that contributes 
to diabetes risk under certain environmental conditions, such as a 
switch to a diet high in fat.  Pima Indians with the at-risk calpain-10 
genotype at SNP-43 (G/G) have lower levels of total calpain-10 mRNA 
(Baier et al., 2000).  Subjects with the at-risk allele at SNP-43 oxidised 
more lipid over a 24 h period (using a respiratory chamber) than those 
with the G/A and A/A genotype but the changes in the carbohydrate 
oxidation were not significant in this study.  During the respiratory 
chamber studies, the subjects were fed calories to maintain energy 
balance during the 24 h period and therefore these data represent the 
total 24 h energy expenditure.  Of particular interest, therefore, was that 
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basal (fasting) rates of carbohydrate and fat oxidation were no different 
between the two groups.  During a hyperinsulinaemic-euglycaemic 
clamp, those with the at risk allele did oxidise significantly less 
carbohydrate than those without this genotype and had lower rates of 
glucose disposal as a result.  Therefore, when provided with exogenous 
substrate, including lipid, carbohydrate and protein, subjects with the at 
risk allele (and lower calpain-10 mRNA expression) preferentially 
oxidise lipid.   It was suggested by the authors that historically this 
reflects altered nutrient partitioning and allowed for an easier switch to 
ketone production in times of limited carbohydrate supply.  It is also 
proposed that today (ample food supply) this phenotype is 
disadvantageous and “excludes” glucose oxidation and thus may 
contribute to insulin resistance and type 2 diabetes.  On the contrary, 
recent preliminary data from transgenic mice lacking calpain-10 suggest 
that these mice are protected from a high fat diet mediated insulin 
resistance (Ye et al., 2006).  These findings appear to contradict those 
of Baier et al. (2000), where a lower calpain-10 is associated with 
insulin resistance.  However, on closer inspection, lower calpain-10 is 
associated with an increase in 24 h fat oxidation in that study and, from 
the discussions in chapter 1 (see 1.4), it is becoming clear that an 
impairment in fat utilisation is a major prerequisite for the development 
of insulin resistance.  It is possible, therefore, that a reduced calpain-10 
expression is beneficial during high fat feeding, although this has not 
been tested in humans.  The mechanisms whereby calpain-10 may 
affect fat mediated insulin resistance are currently unknown but it is 
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possible that cleavage and activation of the calpain substrate PKC 
(1.3.1.4 and 1.8.2.5) and GLUT4 translocation (1.3.1.3) may be 
involved.    
 
The predominantly muscle specific calpain-3 has also been linked to 
measures of insulin resistance in human and animal models.  Walder et 
al. (2002) showed that in humans calpain-3 gene expression was 
negatively correlated with total and central abdominal fat mass and with 
blood glucose concentrations in non-obese subjects.  In Psammomys 
obesus, an animal model of obesity, calpain 3 gene expression was 
negatively correlated with body fat mass and indirect calorimetry 
revealed associations between calpain 3 gene expression and 
carbohydrate oxidation and energy expenditure.  
 
This study investigated the effect of 6 d isoenergetic high-fat/low 
carbohydrate diet (HF/LC) on insulin mediated whole body and muscle 
metabolism.  In this study, a glucose tracer was used to accurately 
determine glucose turnover (including hepatic glucose output (Ra), 
glucose disposal (Rd) and non-oxidative disposal (NOD) during basal 
and insulin mediated states.  To develop an understanding of nutrient 
gene interactions further, the impact of a HF diet on calpain-10 and -3 
mRNA and protein expression was also investigated as these genes 
have been linked to insulin resistance associated with impaired fat 
metabolism.  Based on the findings of Baier et al. (2000), it was 
hypothesised that the HF diet would induce insulin resistance and that 
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this would be associated with reduced skeletal muscle expression of 
calpain-10.  Similarly, as calpain-3 mRNA has been negatively 
correlated with FFA, it was hypothesised that the HF/LC diet would 
reduce calpain-3 expression.      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 164 
4.2 Subjects and Methods 
 
4.2.1 Study protocol 
 
Ten healthy male volunteers (age 25 ± 3 yr, body mass 78 r 3 kg, BMI 
24 ± 1 kg.m2) were recruited from amongst university students.  
Subjects were informed of all procedures and risks associated with the 
experimental procedures prior to obtaining informed consent.  The 
subjects were medically screened as described in the general 
methods (2.2.1), and were in good health prior to commencement of 
the study. 
      
The study design is summarised in Fig 4.1.  Subjects reported to the 
laboratory at approximately 8 am after an overnight fast and after 
recording the subjects’ body weight, a baseline blood sample was taken 
for measurement of fasting glucose, serum insulin, plasma free fatty 
acids and ketone bodies (general methods, 2.2.2).  Under local 
anaesthetic, the vastus lateralis muscle was then biopsied as described 
(2.2.7) (pre diet biopsy).  Subjects were then randomised to either 
control (CON) or high fat (HF) diet described below for 6 days.  
Following the diet, on day 7, subjects reported to the laboratory again at 
8 am after an overnight fast.  Subjects were again weighed and a 
baseline urine sample was collected, before the subjects were allowed 
to rest on a bed.  Resting V
.
CO2 and V
.
O2 was measured using a 
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metabolic cart for approximately 30 min as described (general 
methods, 2.2.4), before a second muscle biopsy sample was taken 
(post diet biopsy).  
 
At approximately 9 am, a Teflon catheter was inserted into the 
antecubital vein of one arm for glucose tracer, 20% glucose (spiked with 
glucose tracer, 1%) and insulin infusions.  Another catheter was placed 
into a dorsal hand vein in a retrograde fashion and placed in heated 
chamber at 55°C  to obtain arterialized blood samples.  Subjects were 
infused with [6, 6-2H2]-glucose in a primed (4 mg/kg body mass)-
continuous (2.5 mg/kg) fashion for 2 h before (basal period) and during 
a 4 h hyperinsulinaemic (serum insulin ~70 mU/l) euglycaemic 
(4.5mmol/l) clamp for the determination of glucose disposal (Rd) and 
glucose appearance (Ra).  A second V. CO2 and 
 
V
.
O2 measurement was 
made during the last 30 min of the insulin glucose clamp (steady state) 
and a second muscle biopsy was obtained at the end of the insulin 
clamp (post insulin biopsy).  Seven to eight millilitre blood samples were 
collected at 20 min intervals during the study for determination of serum 
insulin, plasma free fatty acids and ketone bodies and 5 ml arterialised 
venous blood samples were obtained at 105, 110, 115 and 120 min into 
the [6,6-2H2]-glucose infusion and every 5 min during the last 20 min of 
the 4 h clamp for the determination of isotope enrichment (4.2.6).  Urine 
samples were collected during the entire study day for the 
determination of glucose and nitrogen excretion.  
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4.2.2 Dietary intervention 
 
Each subject consumed a HF and a CON diet for 6 days on two 
separate occasions with a minimum two-week interval between each 
diet.  The HF and CON diets were designed based on the subjects’ 
usual daily dietary habits and energy intake in order to increase the 
palatability of the diets and to maximise adherence to the study 
protocol.  The HF diet was designed to provide 75% of the total energy 
from fat (35% of energy from saturated fat) and 10% of energy as 
carbohydrate.  The CON diet on the other hand was designed to 
provide 50% of energy from carbohydrate and 35% of energy from fat.  
Each diet and its associated daily menu for the 6 day period was 
designed using a dietary analysis program (Microdiet, Version 1.1, April 
2000, Downlee Systems Limited) and all food, beverages (non-
caffeinated) and snacks for each diet were purchased and delivered to 
the door of the study participants.   Written instructions on cooking 
methods and ingredients were also provided if the subject required 
them and ready-made meals with known nutritional content were 
provided to subjects who were unfamiliar with the cooking methods 
required.  Subjects were asked to adhere strictly to the items on the 
menu and to record intake thoroughly, and they were also requested to 
abstain from alcohol consumption, smoking and intense exercise during 
both diet interventions.  Post diet food records were analysed using the 
dietary analysis program. 
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Figure 4.1  Schematic representation of the high fat study protocol.   
 
Skeletal muscle biopsies were taken before each diet and before and after the insulin 
clamps following each diet.  Rates of CHO oxidation (COX) and fat oxidation (FOX) 
were determined for 30 min before and at the end of the clamp.  Blood samples were 
collected at 20 min intervals for determination of blood metabolites and at 105, 110, 
115 and 120 min into the [6,6-2H2]-glucose infusion and during the last 30 min of the 4 
h clamp for the determination of isotope enrichment.   
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4.2.3 Blood and urine analysis 
 
Collected blood samples were analysed for blood glucose, lactate and 
ketone bodies and serum insulin and plasma FFA as described under 
the general methods (2.2.2).  Urine was also analysed for nitrogen, 
also as previously described (general methods, 2.2.3).  Plasma [6,6-
2H2]-glucose enrichment was determined by electron ionization gas 
chromatography-mass spectrometry analysis of the penta-acetate 
derivatives on a Finnigan INCOS-XL (Bremen, Germany).  Glucose 
concentrations in the infusates were determined with the COBAS FARA 
semi-automatic analyzer.  This work was performed by Dr Luc Van 
Loon at Maastricht University, The Netherlands).    
 
4.2.4 Skeletal muscle biopsy analysis 
 
Skeletal muscle biopsies were analysed for calpain-10 and -3 mRNA 
and protein expression using RT-PCR and western blotting procedures, 
as described in the general materials (2.2.7.4).   
 
4.2.5 Substrate oxidation rates 
 
Rates of carbohydrate (COX) and fat oxidation (FOX) were obtained 
prior to the insulin clamps from the V
.
CO2 and V
.
O2 measurements as 
described in the general methods (2.2.4).  Insulin mediated oxidation 
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rates were calculated at steady state during the insulin clamp (last 30 
min) in the same way.   
 
4.2.6 Glucose disposal calculations 
 
Calculations of glucose disposal from the glucose tracer data were 
performed at steady state during the last 30 min of the insulin clamp.  
Stable isotopes are non-radioactive atoms of the same chemical 
element which differ only in their number of neutrons.  Following 
administration, the tracer is metabolically indistinguishable from the 
equivalent unlabelled compound of interest (tracee).  The metabolic fate 
of the compound can be assessed quantitatively by measuring the 
relative abundance of tracer and tracee with time. The detectable mass 
difference of tracer and tracee allows for analysis of compounds, 
extracted from plasma, by gas chromatography-mass spectrometry.  
The glucose stable isotope dilution technique was used to determine 
glucose turnover during basal and insulin stimulated states.   
 
Modified Steele equations were used to calculate glucose disposal (Rd) 
and glucose appearance (Ra) as described by Finegood et al. (1987).  
Hepatic glucose output was calculated as the difference between Ra 
and glucose infusion rate (GIR) during the clamp. Non-oxidative 
glucose disposal was calculated as the difference between Rd and 
COX.   
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4.2.7 Statistics 
 
Data were analysed as described in the general methods (2.6).  
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4.3 Results 
 
4.3.1 High fat dietary analysis 
 
The subjects maintained detailed food records and analysis of food 
intake revealed a small but significant excess energy intake in the HF 
group when compared to CON (P<0.01, Table 4.1), although this did 
not lead to changes in body mass or resting energy expenditure.  The 
mean daily proportion of energy as CHO was 7.4 ± 0.2% in the HF diet 
and 49.8 ± 0.8% in the CON diet (P<0.01), whereas the fat intake was 
76.7 ± 0.4 vs. 32.3 ± 0.7% (P<0.01), respectively. There was no 
difference in protein intake between the two diets. All subjects 
experienced symptoms of lethargy and hunger during the HF dietary 
treatment.  
 
4.3.2 Blood metabolites and hormones 
 
Fasting blood glucose and insulin concentrations before (pre) and after 
(post) each diet were not significantly different (Table 4.2).  Whilst 
plasma FFA concentrations were similar before and after the CON diet, 
high fat feeding increased fasting FFA concentrations, although this 
LQFUHDVH GLG QRW UHDFK VLJQLILFDQFH 7DEOH   )DVWLQJ ȕ-
Hydroxybutyrate concentrations were unchanged by the CON diet but 
were increased following the HF diet (P=0.05) (Table 4.2).  Insulin 
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(CON 71.8 ± 3.5 vs. HF 70.0 ± 3.5 mU/L, Fig 4.2C) and glucose 
concentrations (CON 4.43 ± 0.05 vs. HF 4.44 ± 0.04 mmol/L, Fig 4.2A) 
were similar, and plasma FFA concentrations (CON 0.01 ± 0.003 vs. HF 
0.01 ± 0.006 mmol/L, Fig 4.2B) were suppressed to a similar extent in 
both trials at steady state during the hyperinsulinaemic clamp (Fig 4.2).  
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Table 4.1  Energy and nutrient intake following CON and HF diets (n = 
10). 
 
 
**P<0.01 compared to control values. 
 
 
 
 
 
 
 
CON 
 
HF 
 
Energy Intake 
(Kcal/kg/day) 
 
34.4 ± 1.5 
 
 
39.9 ±1.9** 
Carbohydrate (g) 
% of total 
351 ± 12 
49.8 ± 0.8 
62 (3) 
7.4 ± 0.2** 
Protein (g) 
% of total 
116 ± 3 
17.9 ± 0.6 
121± 4 
15.9 ± 0.4 
Fat (g) 
% of total 
95 ± 3 
32.3 ± 0.5 
259 ± 6 
76.7 ± 0.4** 
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Table 4.2  Blood metabolite concentrations before (pre) and after (post) 
the CON and HF diets (n = 10).   
 
 
*P=0.05 vs. pre diet values. 
 
 
 
 
 
  
CON 
 
HF 
Pre Post Pre Post 
 
Blood Glucose 
(mmol/l) 
 
4.8 ± 0.1 
 
4.5 ± 0.1 
 
4.5 ± 0.1 
 
4.4 ± 0.2 
Serum Insulin 
(mU/l) 
7.4 ± 1.3 6.4 ± 0.8 6.1 ± 0.6 5.1 ± 0.7 
Plasma FFA 
(mmol/l) 
0.47 ± 0.08 0.48 ± 0.04 0.42 ± 0.04 0.53 ± 0.04 
Blood ȕ-
hydroxybutyrate 
(mmol/l) 
0.08 ± 0.02 0.13 ± 0.03 0.07 ± 0.01 0.56 ± 0.19* 
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Figure 4.2  Blood glucose (A), plasma FFA (B) and serum insulin 
concentrations (C) during the insulin clamp before and after the CON 
and HF diets (n = 10).  
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4.3.3 Whole body substrate metabolism 
 
There was no difference in glucose disposal (Rd) between diets under 
basal, non-insulin-stimulated conditions (CON 10.6 ± 2.6 vs. HF 8.8 ± 
 ȝPRONJPLQ, Fig 4.3A).  However, under insulin clamp conditions 
there was an increase in Rd during the last 30 min of the 4 h clamp 
(CON YV+)ȝPRONJPLQ3)LJB).  On 
the other hand, COX was impaired after HF when compared to CON 
under basal (CON 8.0 ± 1.2 vs. HF 4.6 ± 1.4, P<0.05) and insulin 
VWLPXODWHGFRQGLWLRQV&21YV+)ȝPRONJPLQ
P<0.05) (Fig 4.3).  High fat feeding increased non-oxidative glucose 
disposal (NOD) under basal (CON 2.98 ± 1.07 vs. HF 4.39 ± 1.19 
µmol/kg/min) and insulin stimulated conditions (CON 36.0 ± 2.5 vs. HF 
ȝPRONJPLQ3)LJHepatic glucose output was 
comparable under basal conditions following both diets (CON 10.9 ± 0.9 
YV+)ȝmol/kg/min) and was completely suppressed during 
insulin infusion in both trials (Fig 4.3).   
 
Subjects were found to oxidise significantly more fat during the insulin 
clamp following the HF diet compared to CON (CON 3.3 ± 0.5 vs. HF 
5.3 ± 0.3 µmol/kg/min, P<0.05, Fig 4.3B).  However, whilst there was a 
trend for increased fat oxidation under basal conditions following HF, 
this did not reach significance (CON 7.2 ± 0.2 vs. HF 8.7 ± 0.7 
µmol/kg/min, P=0.06) (Fig 4.3). 
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Figure 4.3  The effect of CON and HF diets on whole body glucose and 
fat metabolism (µmol/kg/min) under basal (pre clamp) (A) and insulin 
stimulated conditions (B) (n = 10).  
Hepatic glucose output (HGO), glucose disposal (Rd), glucose oxidation (COX), fat 
oxidation (FOX) non-oxidative disposal (NOD) under basal and insulin stimulated 
conditions following the CON and HF diets. *P<0.05 vs. CON value. 
* 
A 
* 
* 
* 
B 
* 
* 
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4.3.4 Calpain-10 expression  
 
Analysis of calpain-10 mRNA revealed no effect of diet (PRE CON 1.2 ± 
0.2 vs. POST CON 1.3 ± 0.4 and PRE HF 1.2 ± 0.2 vs. POST HF 1.2 ± 
0.2) or insulin infusion following each diet (POST CON 1.3 ± 0.4 vs. 
POST INSULIN CON 1.1 ± 0.2 and POST HF 1.2 ± 0.2 vs. POST 
INSULIN HF 0.9 ± 0.1) (mixed model analysis: diet effect, P=0.893; time 
effect, P=0.238; diet*time interaction, P = 0.880) (Fig 4.5).  A small 
statistical trend towards reduced full length 75 kDa calpain-10 protein 
was observed with insulin infusion (POST CON 0.75 ± 0.12 vs. POST 
INSULIN CON 0.40 ± 0.09 and POST HF 0.62 ± 0.13 vs. POST 
INSULIN HF 0.55 ± 0.12) (mixed model analysis: insulin effect, 
P=0.110) and this was independent of any diet effect (Fig 4.6).  There 
was no effect of diet or insulin on the density of the 60 kDa 
immunoreactive band (Fig 4.6).   
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Figure 4.4  The effect of the CON and HF diets and insulin infusion on 
skeletal muscle calpain-10 mRNA expression (n = 10). 
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Figure 4.5  Effect of the CON (n = 10) and HF diets (n = 9) and insulin 
infusion on skeletal muscle calpain-10 (75 kDa) protein expression 
 
A representative Western blot for calpain-10 (75 and 60 kDa) and the corresponding 
blot for the control protein (desmin, 55 kDa) is shown. Calpain-10 and desmin were 
determined on the same Western blot. 
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4.3.5 Calpain-3 expression  
 
Calpain-3 mRNA was not affected by either diet (PRE CON 1.2 ± 0.3 
vs. POST CON 1.0 ± 0.2 and PRE HF 0.9 ± 0.1 vs. POST HF 1.0 ± 0.2) 
or insulin infusion following each diet (POST CON 1.0 ± 0.2 vs. POST 
INSULIN CON 1.0 ± 0.2 and POST HF 1.0 ± 0.2 vs. POST INSULIN HF 
0.9 ± 0.1) (Fig 4.8).  Similarly, there was no effect of diet (PRE CON 1.8 
± 0.3 vs. POST CON 1.1 ± 0.2 and PRE HF 1.2 ± 0.1 vs. POST HF 1.0 
± 0.1) or insulin (POST CON 1.1 ± 0.2 vs. POST INSULIN CON 1.4 ± 
0.4 and POST HF 1.0 ± 0.1 vs. POST INSULIN HF 1.7 ± 0.4) on 
calpain-3 protein expression (Fig 4.9).  There was no significant 
accumulation of calpain-3 autolysis products as shown in Fig 4.9 and 
quantification of any visible autolysis products was not performed due to 
their very low abundance.   
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Figure 4.6  Effect of the CON and HF diets and insulin infusion on 
skeletal muscle calpain-3 mRNA expression (n = 10). 
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Figure 4.7  Effect of the CON and HF diets and insulin infusion on 
skeletal muscle calpain-3 protein expression (n = 10). 
 
A representative blot for calpain-3 (94 kDa) and calpain-3 autolysis products (55 – 60 
kDa) is shown.  Autolysis products of calpain-3 were not quantified due to their very 
low abundance in the present study. 
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4.4 Discussion 
 
The main findings in this chapter are that high fat feeding did not affect 
the expression of calpain-10 or-3 mRNA and protein expression.  Whilst 
this is the first study to examine the effect of a 6 d high fat diet on 
calpain-10 and -3 expression in skeletal muscle, the diet employed in 
the current study did not have a significant negative impact on basal or 
insulin mediated glucose disposal.  Instead, the high-fat diet tended to 
increase the insulin mediated Rd and led to only moderate reductions in 
basal and insulin stimulated COX and FOX.  Crucially, these findings 
may explain the lack of effect of the HF diet on calpain expression.     
 
High fat feeding studies in humans have produced contradictory results.  
Studies employing a HF diet for shorter periods of time have 
documented small reductions in glucose disposal when using the oral 
glucose tolerance test (OGTT) to estimate insulin sensitivity.  For 
example, 3 d of a high-fat (73% fat content), low carbohydrate diet 
reduced whole body glucose disposal during an OGTT (Pehleman et 
al., 2005).  A similar increase in the blood glucose-area under the curve 
(AUC) during an OGTT has been documented following a 5 d diet high 
in fat (53% fat content) (Anderson and Herman, 1975).  Whilst these 
studies suggest that short-term high fat diets induce insulin resistance, 
the OGTT is an index of whole body glucose disposal and includes a 
component made up of hepatic glucose output and hepatic glucose 
disposal.  During an OGTT, hepatic glucose disposal can account for 
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~25% of the glucose disposal and hepatic glucose output is only 
reduced by ~50% (Katz et al., 1983).  As such, the results from these 
studies cannot be readily compared to the data obtained using the 
hyperglycaemic-euglycaemic clamp in the present study.  One study 
that did employ a hyperinsulinaemic-euglycaemic clamp following a 
short-term high-fat diet did report a small but significant decrease in 
glucose disposal (~85% of control) (Bachmann et al., 2001).    
 
On the other hand, high fat dietary treatment for 11 to 21 days does not 
induce whole body insulin resistance, although the partitioning of 
glucose metabolism is altered with decreased oxidation and increased 
non-oxidative glucose disposal (Bisschop et al 2001; Cutler et al., 
1995).  Furthermore, a study employing a high fat diet for 16 days 
reported no effect on glucose infusion rate (GIR) during a 3 h 
hyperinsulinaemic-euglycaemic clamp (Yost et al., 1998).  This is 
consistent with data from the present study as a slight increase in Rd 
during the last 30 min of the clamp was observed after the HF diet when 
compared to the CON.  It is possible that acute changes in dietary fat 
availability (several hours up to 3 days) might induce insulin resistance 
because of a greater imbalance between plasma FFA availability and 
their muscle oxidation, whereas after several days an increase in FFA 
availability can be compensated by a greater intramuscular lipid storage 
and/or utilisation.  Alternatively, methodological differences in 
determining insulin resistance (i.e. OGTT vs. hyperinsulinaemic-
euglycaemic clamp, clamp duration and insulin concentrations) could 
 186 
explain the difference between these studies.  Further studies are 
required to elucidate the precise sequence of adaptations to high-fat 
diets in humans.  
 
These minor physiological effects of the high fat diet in the present 
study were not associated with changes in the expression of genes 
calpain-10 and -3 and these results are consistent with those in chapter 
3.  Previous studies have suggested a link between calpain expression 
and carbohydrate metabolism in human and rodent models (Baier et al., 
2000; Walder et al., 2002; Carlsson et al., 2005).  In Pima Indians, 
genetic variation in the calpain-10 gene at SNP-43 is linked to 
considerably lower levels (>50%) of skeletal muscle calpain-10 mRNA 
(Baier et al., 2000).  The individuals with lower levels of calpain-10 were 
found to oxidise more lipid and less protein over a 24 h period when 
compared to those individuals with higher levels of calpain-10 mRNA.  
Moreover, a statistical trend towards reduced COX in those with lower 
levels of skeletal muscle calpain-10 was seen over the same 24 h 
period (Baier et al., 2000).  Whilst the small reduction in COX seen in 
the present study was not associated with a reduction in calpain-10 
mRNA and protein levels, it is possible that the physiological insult was 
not significant enough to drive a transcriptional/translational change in 
calpain-10.  Thus it is currently difficult to rule out a role for calpain-10 in 
the physiological adaptation to a high-fat diet.         
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Whilst the exact metabolic adaptations to a high-fat diet are currently 
unknown, it is unlikely that the diet in the present study elicited a 
significant effect on insulin signalling and GLUT4 translocation, 
although this was not determined here.  In support of this, 3 d of high-fat 
diet did not effect glycogen synthase (GS) activity under basal 
conditions or during an OGTT, suggesting that insulin signalling 
remained intact following the dietary intervention and is not an early 
adaptation to high-fat availability.  On the contrary, as with the 
metabolic adaptation to starvation, a number of studies have 
demonstrated an effect of high fat feeding on regulatory enzymes 
controlling carbohydrate oxidation.  In a study performed by Peters et 
al. (2001), six male subjects were fed a eucaloric, high-fat diet 
consisting of 73% fat for 3 d and PDK2 and PDK4 mRNA and protein 
expression and PDK activity was determined.  High-fat feeding 
increased PDK activity in a linear fashion from 1 to 3 d post high-fat diet 
and this was accompanied by an increase in PDK4 mRNA and protein 
within 1 d of high fat feeding (Peters et al., 2001).  Similarly, a 56 h 
high-fat diet led to a increase in PDK activity and a reduction in basal 
PDH (Pehleman et al., 2005); the activation of PDH during an OGTT 
was also blunted following the high-fat diet (Pehleman et al., 2005).  
Together these studies suggest that the early adaptation to a short-term 
high-fat diet is characterised by an impairment in glucose oxidation 
pathways possibly preceded by changes in the expression and activity 
of enzymes important in the regulation of substrate utilisation.  These 
findings have implications for the present study as it was hypothesised 
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that high-fat feeding would lead to insulin resistance characterised by a 
reduction in insulin mediated glucose uptake and this was clearly not 
seen in the present study.  Considering this, it is perhaps not surprising 
that no change in calpain-10 expression was observed in the current 
study.   
 
In order to observe a significant effect on glucose uptake and insulin 
signalling pathways, based on the present data, it is likely that exposure 
to a high-fat diet would need to be increased considerably.  In support 
of this, animal models of high fat feeding have shown that insulin 
receptor function is normal in rats after 8-weeks of high fat feeding 
(Hansen et al., 1998).  Shorter periods of high fat feeding (4-5 weeks) 
were also shown to have little or no effect on insulin binding (Boyd et 
al., 1990) and insulin stimulated autophosphorylation or tyrosine kinase 
activity of purified receptors (Boyd et al., 1990).  However, recent 
studies have investigated the effect of high-fat feeding on downstream 
insulin signalling molecules in rats.  Four weeks of high-fat feeding 
downregulated insulin stimulated PI3K activity and AKT/PKB 
phosphorylation and impaired GLUT4 translocation (Tremblay et al., 
2001).  The same study showed that the reduction in insulin stimulated 
GLUT4 translocation was associated with a complete failure of insulin to 
activate aPKC (see 1.2.1.5) (Tremblay et al., 2001).  These studies 
suggest that longer periods of exposure to high-fat diets in rodents are 
associated with impairments in distal steps in the insulin signalling 
cascade.       
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The present study shows that calpain-3 mRNA and protein expression 
is unaffected by high fat feeding and insulin infusion in the skeletal 
muscle of healthy humans.  There was also no increase in the 
accumulation of calpain-3 autolysis products.  These data are in 
contrast to the only report to document an association of calpain-3 
mRNA with phenotypes related to insulin resistance in humans and 
rodents (Walder et al., 2002).  As with calpain-10, it remains possible 
that calpain-3 may play a posttranslational role in signalling 
mechanisms that are important for glucose/FFA utilisation; however 
investigations into the role of calpain-3 in this respect have been almost 
impossible due to the unstable nature (half life of minutes) of the protein 
as soon as it is purified in the absence of its associated myofibrillar 
structures.  Using cell culture, human biopsies and mouse models, it 
has been possible to show that calpain-3 may be involved in processes 
as diverse as apoptosis, muscle cell differentiation and remodelling and 
regulation of the cytoskeleton (Kramerova et al., 2006).       
   
4.5 Conclusions 
 
In the present study, 6 d of high-fat feeding had no effect on calpain-10 
and -3 mRNA and protein expression in human skeletal muscle.  It was 
hypothesised that high-fat feeding would lead to significant insulin 
resistance and that this would be associated with reduced expression of 
calpain-10 and -3 expression.  However, the dietary intervention was 
characterised by early physiological adaptations manifesting in only 
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small changes in carbohydrate and fat oxidation and not by defects in 
insulin stimulated glucose disposal, as hypothesised.  These findings 
currently make it difficult to rule out a role for calpain-10 and -3 in lipid 
induced insulin resistance in the present study and further human in 
vivo studies that produce a larger physiological insult are needed to 
clarify the role of these proteases in the adaptation to high lipid 
availability.             
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5 Lipid infusion, insulin resistance and skeletal muscle 
calpain expression in healthy humans 
 
5.1 Introduction 
 
In chapter 4, a one-week high fat diet led to a modest increase in 
plasma FFA but did not lead to significant reductions in insulin 
sensitivity.  More acute elevation of FFA availability, on the other hand, 
results in severe insulin resistance in healthy humans (Ferrannini et al., 
1983; Boden et al., 1991).  Acute elevations of plasma FFA are usually 
achieved via the simultaneous infusion of a triglyceride emulsion and 
heparin, which activates lipoprotein lipase activity and promotes 
intravascular lipoylsis of the triglyceride emulsion.  The effect of FFA on 
glucose disposal occurs well within the physiological range of FFA 
concentrations seen in, for example, obesity and has been shown to be 
dose dependent (Belfort et al., 2005).  In contrast to short-term fasting 
and high-fat diets, acute elevation of FFA concentrations leads to a 
downregulation of the insulin signalling pathway and is associated with 
reduced insulin receptor and IRS-1 tyrosine phosphorylation, reduced 
PI3K activity associated with IRS-1 and impaired AKT/PKB serine 
phosphorylation (Belfort et al., 2005).   
 
Carlsson et al. (2005) were the first to document the effect of intralipid 
infusion on skeletal muscle calpain-10 mRNA levels.  In this study, 
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seven male subjects with impaired glucose tolerance (IGT) and family 
history of type 2 diabetics and eight control subjects with normal 
glucose tolerance (NGT) were infused with Intralipid for 0, 2 and 24 h 
on three separate occasions.  These infusions were followed by a 
standard (40 mU/m2/min) 2 h hyperinsulinaemic-euglycaemic clamp in 
the continued presence of the Intralipid infusion.  The authors found that 
calpain-10 mRNA was no different between the two groups prior to the 
insulin clamp.  However, their main finding was that calpain-10 mRNA 
was increased with insulin infusion for 2 h following 24 h of Intralipid 
infusion in the NGT group when compared to the IGT group.  Intralipid 
infusion alone had no effect on calpain-10 mRNA levels.  Moreover, 
infusion of Intralipid for shorter periods of time (0 and 2 h) did not have 
the same effect and was no different before or after the insulin clamp in 
both groups.   
 
This chapter extends this previously published work and the work in 
chapter 4 of this thesis by investigating the effects of a 6 h infusion of a 
triglyceride emulsion (Intralipid) on insulin sensitivity and calpain-10 
mRNA and protein levels.  A change in calpain-10 expression with 
insulin resistance in the present study may be linked to changes in the 
GLUT4 expression and/or translocation, as both have been shown to be 
downregulated by elevated lipid availability (Vettor et al., 2002; Zierath 
et al., 1997).  Therefore, the expression of skeletal muscle calpain-10 
mRNA and protein and GLUT4 mRNA was determined in the present 
study and It was hypothesised that Intralipid infusion would lead to 
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insulin resistance and that this would be associated with a reduction in 
the expression of calpain-10 mRNA and protein and a reduction in 
GLUT4 mRNA content.    
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5.2 Subjects and Methods 
 
5.2.1 Study protocol 
 
Ten healthy men (age 22 ± 1 yr, body mass 78 r 3 kg, BMI 24 ± 1 
kg.m2) were recruited from the students of the University of Nottingham 
to take part in this study. 
 
The study protocol is summarised in Fig 5.1.  On two separate 
occasions, interspersed by a minimum of two weeks, subjects 
underwent hyperinsulinaemic-euglycaemic clamps for 6 h with or 
without the intravenous infusion of a 20% Intralipid emulsion (a 
commercial emulsion of soya bean oil) at 90 ml/h and heparin (200 U 
prime and 600 U/h).  Subjects reported to the laboratory at 
approximately 8 am and after baseline measurements were made, a 
baseline muscle biopsy was taken, as described previously (general 
methods, 2.2.7).  At approximately 9 am, a Teflon catheter was 
inserted into the antecubital vein of one arm for the infusion of 20% 
glucose, insulin and 20% intralipid plus heparin.  Another catheter was 
placed into a dorsal hand vein in a retrograde fashion and placed in 
heated chamber at 55°C  to obtain arterialized blood samples as before.  
Infusions were continued for 6 h and measurements of FOX and COX 
were taken every 45 minutes.  Additional skeletal muscle biopsies were 
obtained half way through (3 h clamp biopsy) and at the end of the 
intravenous infusions (6 h clamp biopsy).  As before for the high fat 
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study, blood samples were collected every 20 min for determination of 
serum insulin, plasma FFA and ketone bodies.  
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Figure 5.1  Schematic representation of the intralipid study protocol.   
 
Skeletal muscle biopsies were taken before, during and at the end of the insulin 
clamp.  Substrate oxidation rates were determined every 45 minutes during the clamp 
using indirect calorimetry.  Blood samples were taken every 20 min for determination 
of blood metabolites.  
 
 
6 h hyperinsulinaemic euglycaemic clamp with or without 20% 
Intralipid + heparin (200 U prime, 600 U/h) 
0 h 3 h  6 h 
Pre clamp 
 
3 h clamp 
 
6 h clamp 
 
Muscle biopsies 
 
Substrate oxidation 
(45 min intervals) 
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5.2.2 Blood and urine analysis 
 
Collected blood samples were analysed for blood glucose, serum 
insulin, plasma FFA and ketones as described in the general methods 
(2.2.2).  Urine was also analysed for urea, also as previously described 
(general methods).  
 
5.2.3 Dual energy x-ray absorptiometry (DEXA) 
 
Measurements of lean body mass and fat mass were determined for the 
whole body by DEXA scanning using an extended analysis program for 
body composition (Hologic QDR-2000, Waltham, MA, USA).  The 
procedure was performed each time by the same trained technician 
(Elizabeth Simpson, School of Biomedical Sciences, University of 
Nottingham) who positioned the subjects, performed the scans, and 
completed the scan analysis according to the operator’s manual using 
the standard analysis protocol.  Quality-assurance tests were performed 
each morning of assessment.  
 
5.2.4 Skeletal muscle biopsy analysis 
 
Skeletal muscle biopsies were analysed for calpain-10 mRNA and 
protein expression and GLUT4 mRNA using RT-PCR and western 
blotting procedures, as described in the general methods (2.2.7).  
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Skeletal muscle protein was extracted using the new extraction buffer 
B, as discussed in the general methods (2.2.7).  All mRNA results 
were normalised to actin expression as this is expressed in the 
supernatant fraction when using buffer B (see 2.2.7.6).       
 
5.2.5 Substrate oxidation rates 
 
Rates of COX and FOX were obtained prior to insulin clamps from the  
V
.
CO2 and 
 
V
.
O2 measurements as described (general methods, 2.2.4).  
During both insulin clamps, rates of COX and FOX were determined in 
the same way every 45 min as described in the general methods 
(2.2.4) chapter.  
5.2.6 Glucose disposal calculations 
 
Glucose disposal was calculated from the glucose infusion rate and 
normalised to the total lean body mass of each subject, as described 
previously in chapter 4 (4.2.6). 
 
5.2.7 Statistics 
 
Data were analysed as described in the general methods (2.6).   
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5.3 Results 
 
5.3.1 Blood metabolites 
 
At baseline, prior to infusions, plasma FFA (CON 0.46 ± 0.07 vs. LIPID 
0.63 ± 0.11 mmol/L, Fig 5.2B), serum insulin (CON 8.7 ± 0.2 vs. LIPID 
8.3 ± 0.2 mU/L, Fig 5.2C) and blood glucose (CON 4.6 ± 0.1 vs. LIPID 
4.6 ± 0.1 mmol/L, 5.2A) were not different between the CON and LIPID 
trials.   
 
FFA were elevated throughout the clamp in the LIPID trial (2.3 ± 0.3 
mmol/L) but were completely suppressed in the CON trial (0.02 ± 0.003 
mmol/L) (Fig 5.2B).  The average blood glucose concentration during 
the clamp was similar in the two trials (CON 4.5 ± 0.02 vs. LIPID 4.6 ± 
0.02 mmol/L, Fig 5.2A) and in each case was similar to the fasting 
glucose concentration.  The mean serum insulin concentration during 
the clamp was not different between trials (CON 89.5 ± 2.7 vs. LIPID 
96.5 ± 1.8 mU/L, Fig 5.2C).   
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Figure 5.2  Blood glucose (A), plasma FFA (B) (n = 10) and serum insulin 
concentrations (C) (n = 9) during the insulin clamp with (LIPID) or 
without (CON) the simultaneous infusion of Intralipid. 
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5.3.2 Whole body substrate metabolism 
 
Glucose disposal as calculated from the glucose infusion rate was 
reduced by approximately 50% in the LIPID trial (Fig 5.3A).  During the 
last 30 min of the clamp, at steady state, glucose disposal was 79.6 ± 
4.0 µmol/kg lean mass/min in the CON trial compared to 37.8 ± 4.4 
µmol/kg lean mass/min in the LIPID trial (P<0.001).  Post-hoc analysis 
revealed that the reduction in glucose disposal began 210 min into the 
insulin clamp (P<0.05) (Fig 5.3A).       
 
The effect of Intralipid on glucose disposal was preceded by an 
increase in FOX starting at 90 min during the LIPID clamp (CON 6.7 ± 
0.0 vs. LIPID 9.3 ± 0.8 µmol/kg lean mass/min, P<0.05, Fig 5.3C) and 
later by a reduction in COX, which began at 150 min (CON 23.9 ± 0.0 
vs. LIPID 17.8 ± 1.0, P<0.05, Fig 5.3B).  From these time points 
onwards, both FOX and COX continued to increase and decrease, 
respectively, until beginning to plateau at the end of the clamp at 360 
min (Fig 5.3B and 5.3C).  At the end of the clamp, FOX was over 2.5 
fold higher (CON 4.9 ± 0.0 vs. LIPID 12.8 ± 0.7 µmol/kg lean mass/min, 
P<0.001, Fig 5.3C) and COX was over 3 fold lower (CON 23.4 ± 0.0 vs. 
LIPID 7.6 ± 1.6 µmol/kg lean mass/min, P<0.001, Fig 5.3B) in the LIPID 
than the CON trial. 
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Figure 5.3  Glucose disposal (A), carbohydrate oxidation (COX) (B) and 
fat oxidation (FOX) (C) during the insulin clamp with (LIPID) or without 
(CON) the simultaneous infusion of Intralipid (n = 10). 
*P<0.05, **P<0.01, ***P<0.001 vs. corresponding CON/LIPID value 
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5.3.3 Calpain-10 and GLUT4 expression  
 
Calpain-10 mRNA was significantly reduced in both CON (PRE CLAMP 
0.93 ± 0.08 vs. 6 h POST CLAMP 0.68 ± 0.06) and LIPID (PRE CLAMP 
0.87 ± 0.12 vs. 6 h POST CLAMP 0.66 ± 0.02) trials after 6 h (P < 0.05) 
of insulin infusion (mixed model analysis: insulin effect, P = 0.016), and 
the addition of Intralipid in the LIPID trial did not modify this response 
(Fig 5.4A). 
 
To more clearly differentiate the effect of insulin and lipid on calpain-10 
mRNA expression, a separate group of subjects (n=6) were infused with 
Intralipid infusion alone for 3 h in the absence of insulin.  Consistent 
with the findings above, Intralipid infusion alone had no effect on 
calpain-10 expression (Fig 5.6).      
 
Protein levels of full length 75 kDa calpain-10 were not different with 
insulin infusion in either the CON (PRE CLAMP 0.64 ± 0.13 vs. 3 h 
POST CLAMP 0.58 ± 0.10 vs. 6 h POST CLAMP 0.55 ± 0.09) or LIPID 
trials (PRE CLAMP 0.46 ± 0.09 vs. 3 h POST CLAMP 0.39 ± 0.08 vs. 6 
h POST CLAMP 0.43 ± 0.07) (Fig 5.5).  There was a borderline 
significant effect of the LIPID treatment on calpain-10 protein levels 
(P=0.05) but this was most likely due to the slightly lower values prior to 
the commencement of the infusions (Fig 5.5).  In terms of calpain-10 
isoforms, additional immunoreactive bands were observed at 
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approximately 60, 48 and 35 kDa in the supernatant fraction using the 
new extraction buffer (Fig 5.5). 
 
Measurement of GLUT4 mRNA revealed no significant effect of insulin 
(PRE CLAMP 1.2 ± 0.1 vs. 3 h POST CLAMP 1.2 ± 0.1 vs. 6 h POST 
CLAMP 1.2 ± 0.1) or insulin and Intralipid infusion (PRE CLAMP 1.2 ± 
0.1 vs. 3 h POST CLAMP 1.1 ± 0.1 vs. 6 h POST CLAMP 1.1 ± 0.1) on 
skeletal GLUT4 mRNA levels (Fig 5.4B). 
 
5.3.4 Calpain-3 expression  
 
Calpain-3 mRNA was not affected by insulin infusion alone in the CON 
trial (PRE CLAMP 2.3 ± 0.2 vs. 6 h POST CLAMP 2.0 ± 0.2) or by 
intralipid and insulin infusion in the LIPID trial (PRE CLAMP 2.1 ± 0.1 
vs. 6 h POST CLAMP 2.0 ± 0.1) (Fig 5.6).  
 
 
 
 
 
 
 
 
 
 
 205 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4  The effect of insulin infusion with or without Intralipid 
infusion on skeletal muscle calpain-10 (A) and GLUT4 (B) mRNA levels (n 
= 10). 
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Figure 5.5  The effect of insulin infusion with or without Intralipid 
infusion on skeletal muscle full length calpain-10 (n = 10). 
 
Representative blots showing all observed calpain-10 immunoreactive bands in 
addition to the control protein (actin, 45 kDa). Only the results for the full length 
calpain-10 protein (75 kDa) are shown.  Calpain-10 and actin were analysed on the 
same Western blot.    
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Figure 5.6  The effect of Intralipid infusion alone for 3 h on calpain-10 
mRNA expression (n=6). 
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5.4 Discussion 
 
The main finding from this chapter is that 6 h of insulin infusion 
significantly downregulated calpain-10 mRNA.  The addition of Intralipid 
to the insulin clamp did not modify the response of calpain-10 to insulin 
infusion despite a significant reduction in glucose disposal 3 h after the 
commencement of the Intralipid infusion.  Infusion of Intralipid alone in a 
separate group of subjects for 3 h did not affect calpain-10 expression, 
strengthening the finding that insulin and not Intralipid was responsible 
for the reduction in calpain-10 mRNA in the present study.  GLUT4 
mRNA levels were not affected by either insulin or Intralipid and insulin 
infusion.  These data suggest that calpain-10 may be regulated by 
hyperinsulinaemia per se and is not influenced by changes in insulin 
mediated glucose uptake.  This is interesting since no previous studies 
have investigated the effect of insulin infusion on skeletal muscle 
calpain-10 expression.  Moreover, in the previous studies in this thesis, 
the effect of insulin on calpain-10 was not investigated nor controlled 
for.  Whilst in chapter 4 a small trend for reduced calpain-10 protein 
expression was observed with 4 h of insulin infusion following both CON 
and HF diets, it is not clear what impact each diet had on this response.        
 
Intralipid infusion has been shown to reduce insulin mediated glucose 
disposal in humans and previous studies have indicated that the 
skeletal muscle is the primary site of the fatty acid mediated insulin 
resistance (Ferrannini et al., 1983).  More recent studies have shown 
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that this insulin resistance is associated with impairments in insulin 
receptor and insulin receptor substrate (IRS-1) tyrosine 
phosphorylation, phosphatidylinositol 3-kinase (PI3K) activity 
associated with IRS1 and AKT/PKB serine phosphorylation in skeletal 
muscle (Belfort et al., 2005; Dresner et al., 1999; Kruszynska et al., 
2002) indicating significant impairments in the insulin signalling pathway 
with Intralipid infusion in humans.   
 
Carlsson et al. (2005) were the first group to investigate the effect of 
insulin and insulin plus Intralipid infusion on skeletal muscle calpain-10 
mRNA levels.  In this study the response of calpain-10 mRNA to 2 h of 
insulin infusion following lipid infusion for 0, 2 and 24 h in normal 
glucose tolerant (NGT) and impaired glucose intolerant (IGT) individuals 
was investigated.  Firstly, a 2 h insulin infusion alone had no effect on 
calpain-10 mRNA levels in NGT or IGT group.  However, following 24 h 
of Intralipid infusion, calpain-10 mRNA was increased 3-fold in 
response to 2 h of insulin infusion in the NGT but not the IGT subjects.  
The data in the current study do not confirm the findings of Carlsson et 
al. (2005) as 1) insulin infusion alone downregulated calpain-10 mRNA 
expression and 2) the addition of lipid to the insulin clamp procedure did 
not affect the response of calpain-10 mRNA to insulin infusion alone.  
This was despite significant reductions in glucose disposal and 
alterations in COX and FOX with the addition of lipid to the insulin 
clamp.  Extending the work of Carlsson et al. (2005) further to include 
the analysis of calpain-10 protein levels revealed that calpain-10 protein 
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levels were not affected by insulin infusion or by intralipid and insulin 
infusion.      
 
The possible explanation for these discrepancies between the present 
study and that of Carlsson et al. (2005) are not entirely clear but could 
be due to a number of factors.  Most importantly, however, the study 
protocols were significantly different.  For example in the present study, 
lipid and insulin were infused together for the same period of time  (6 h) 
where as Carlsson and co-authors infused Intralipid alone for the 
required times (up to 24 h) and then performed a 2 h insulin clamp 
whilst the lipid infusion continued.  Infusion of lipid alone for 24 h might 
be expected to profoundly affect the subsequent physiological response 
to insulin infusion and therefore may substantially alter the effect of 
insulin on calpain-10 mRNA.     
 
Carlsson et al. (2005) suggested that the increase in calpain-10 mRNA 
in the NGT but not the IGT group with insulin following lipid infusion 
may be related to an interaction between calpain-10 and GLUT4 and on 
the involvement of calpain-10 in a novel apoptosis pathway originally 
LGHQWLILHG LQSDQFUHDWLF ȕ-cells and which may be initiated by the fatty 
acid palmitate (Johnson et al., 2004).  Whilst it is not possible to rule out 
any potential interaction between GLUT4 and calpain-10 post-
translationally, GLUT4 mRNA was unchanged by lipid and insulin 
infusion in the present study.   
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It is not clear how a calpain-10 mediated ordered lysis of muscle cells, 
possibly initiated by palmitate, would protect NGT but not IGT subjects 
from FFA mediated insulin resistance.  Palmitate has been shown to 
induce insulin resistance in myotubes in vitro (Storz et al., 1999) but has 
not been linked to apoptosis in muscle cells (Johnson et al., 2004).  
Regardless it is not possible to reach the conclusion that increased 
calpain-10 expression per se protects subjects from FFA mediated 
insulin resistance in the present study as glucose disposal was 
significantly downregulated after 210 min of the clamp and was 50% 
lower at the end of the clamp when lipid was present.  This occurred 
without any change in calpain-10 mRNA or protein levels and it 
therefore seems unlikely that calpain-10 expression plays any role in 
modifying the physiological response to FFA.  Interestingly, no data was 
reported on the effect of the increase in calpain-10 on insulin mediated 
glucose disposal in the study by Carlsson et al. (2005).  If a protective 
role for calpain-10 was to be envisaged in this pathway, one hypothesis 
could be that increased calpain-10 activity (not expression) would 
attenuate the protein kinase C (PKC) mediated insulin resistance in 
response to elevated FFA (Itani et al., 2002).           
 
The observation that calpain-10 mRNA but not protein expression was 
significantly downregulated by 6 h insulin infusion in both trials suggests 
the possibility that calpain-10 expression is regulated by 
hyperinsulinaemia.  In chapter 4, 4 h of insulin infusion tended to lead 
to a reduction in calpain-10 protein.  This finding is consistent with the 
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present study as calpain-10 mRNA was only reduced at the end of the 
clamp (6 h) and was no different between 0 h and 3 h of the clamp.  
This observation also provides an additional explanation as to why 
Carlsson et al. (2005) did not see any effect of a 2 h insulin infusion on 
calpain-10 mRNA levels.  It seems likely that the reduction in calpain-10 
mRNA was indeed the result of the hyperinsulinaemia and was not 
important for the increase in glucose uptake during the insulin infusions 
as the reduction was seen in both arms of the trial.  This is 
strengthened because the change in calpain-10 occurred only towards 
the end of the 6 h clamp and a similar effect was not seen with only 4 h 
of insulin infusion (Chapter 4).  Moreover, lipid infusion alone in the 
absence of insulin had no effect on calpain-10 expression in the present 
study.  What is particularly interesting is that a reduction in calpain-10 
mRNA with hyperinsulinaemia might provide a link between calpain-10 
and diabetes.  Chronic hyperinsulinaemia, which is characteristic of 
some insulin resistant states, may lead to a similar reduction in calpain-
10 mRNA levels in skeletal muscle.  Because calpain-10 protein levels 
were unaffected by insulin infusion it is unclear what impact, if any, the 
observed change in calpain-10 mRNA would have on skeletal muscle 
metabolism.  Further studies in human subjects with long-term 
hyperinsulinaemia are needed to clarify the role of insulin on the 
expression of calpain-10 in skeletal muscle.      
 
A number of immunoreactive bands were observed in the supernatant 
fraction for calpain-10 following extraction with the new protein 
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extraction buffer (see general methods, 2.2.7.6).  The intensity of all of 
these bands was unchanged with insulin infusion, however, and this is 
consistent with the findings from chapter 4, where 4 h of insulin infusion 
had no effect on calpain-10 protein levels.  The impact of the 
determination of calpain-10 protein in the supernatant fraction on the 
interpretation of the data and on comparisons with earlier chapters of 
this thesis is likely to be minimal as it was shown in chapter 2 that when 
using buffer A and B, the majority of calpain-10 is detected in the pellet 
and supernatant fractions, respectively, indicating that in both cases the 
majority of calpain-10 protein is detected.   
 
5.5  Conclusions 
 
The major finding in the present study is that 6 h of insulin infusion 
downregulated calpain-10 mRNA in human skeletal muscle.  This effect 
of insulin on calpain-10 was not altered by the simultaneous infusion of 
Intralipid – which lead to marked reductions in insulin mediated glucose 
uptake and COX and a large increase in FOX.  Moreover, Intralipid 
infusion alone had no effect on calpain-10 suggesting that 
hyperinsulinaemia per se regulates calpain-10 mRNA expression.  
There was no effect of insulin on calpain-10 protein levels and the 
impact of the observed reduction in calpain-10 mRNA with insulin on 
skeletal muscle metabolism is therefore unclear.  Further studies 
examining the long-term effect of hyperinsulinaemia on calpain-10 
mRNA and protein expression in skeletal muscle will be needed to more 
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clearly define the role of insulin mediated regulation of calpain-10 and 
its relationship to the development of insulin resistance and type 2 
diabetes.   
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6 Exercise mediated glucose uptake and the expression 
of genes involved in glucose transport and oxidation 
 
6.1 Introduction 
 
The expression of calpain-10 and -3 was not altered in induced states 
of insulin resistance in healthy humans as shown in the previous 
chapters of this thesis.  This chapter, therefore, set out to investigate 
the effect of an increase in insulin sensitivity on the expression of these 
genes.  A single bout of moderate intensity exercise has been shown to 
lead to significant improvements in skeletal muscle insulin sensitivity 
and glucose uptake (e.g., Mikines et al., 1988; Richter et al., 1989) and 
this effect can last for up to 48 h post exercise bout (Mikines et al., 
1988).  The precise mechanisms responsible for 1) the immediate effect 
of exercise on muscle glucose uptake and 2) the increase in insulin 
stimulated glucose uptake during recovery from exercise are not well 
understood.  During exercise calcium induced activation of calcium-
calmodulin-dependent protein kinase (CaMKII) (Wright et al., 2004) 
and/or AMP-activated protein kinase (AMPK) (Winder and Hardie, 
1996) is thought to be responsible for the contraction mediated increase 
in the translocation of GLUT4 in an insulin independent fashion (Ploug 
et al., 1984).   
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Following exercise, the exact mechanisms responsible for the 
enhancement in insulin mediated glucose uptake are unknown.  One 
hypothesis is that exercise potentiates the insulin signalling pathway.  
Immediately after exercise in vivo, insulin mediated activity of IRS-2 
associated with PI3K is increased in the exercise leg versus the control 
leg (Howlett et al., 2002).  It has been suggested that this could lead to 
an increase in aPKC mediated GLUT4 translocation (Wojtaszewski and 
Richter, 2006).   This potential enhancement in insulin signalling 
pathways following exercise could be linked to the glycogen lowering 
effect of exercise; reduced glycogen levels have been shown to activate 
GS (Nielson et al., 2001).  Moreover, prior exercise is known to 
increase GS activity in response to stimulation by insulin (Wojtaszewski 
et al., 2000).  This in turn could be related to the effect of glycogen on 
the insulin stimulated activation of AKT/PKB as insulin mediated 
AKT/PKB activity is enhanced by lowering glycogen levels (Derave et 
al., 2000).   
 
The increase in insulin sensitivity following a bout of exercise could also 
be the result of adaptive changes in the expression of genes important 
in the regulation of glucose transport into skeletal muscle.  Some 
studies have suggested that GLUT4 mRNA is increased immediately 
after exercise (Kraniou et al., 2006) whilst others have demonstrated no 
effect of exercise on the GLUT4 message (Vissing et al., 2005).  The 
hypothesised link between calpain-10 and GLUT4 trafficking has been 
discussed previously in this thesis and this interaction, combined with 
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the elevated intracellular calcium concentrations during exercise, 
provides a potential mechanisms whereby calpain-10 may contribute to 
exercise mediated GLUT4 translocation.  It is possible that an increase 
in insulin sensitivity with exercise will be associated with an increase in 
calpain-10 expression.  An inhibition of general calpain expression and 
activity in calpastatin overexpressing mice leads to an increase in 
CaMKII and AMPK expression (Otani et al., 2006) and it is possible that 
calpain-10 mediates an increase in insulin sensitivity following exercise 
via these pathways.  Calpain-3 expression following both eccentric and 
concentric exercise bouts in humans has previously been investigated.  
Muscular damage as a result of 30 min of downhill running was 
associated with a decrease in skeletal muscle calpain-3 mRNA 
(Feasson et al., 2002), whilst no significant autolysis of calpain-3 was 
observed with exhaustive bicycling exercise (Murphy et al., 2006).    
 
Adaptive changes in other genes important for glucose phosphorylation 
and oxidation in skeletal muscle may also be important for the increase 
in insulin sensitivity following exercise.  For example, during recovery 
from a single bout of exercise, the transcriptional activity and mRNA 
content of PDK4 is increased (Pilegaard et al., 2000), although this 
effect was not apparent 24 h following the exercise bout.  Similarly, the 
expression of HKII has been shown to be upregulated during recovery 
from exercise in humans (Pilegaard et al., 2005) and rats (O’Doherty et 
al., 1994).  The peroxisome proliferator-activated receptor-Ȗ (33$5 Ȗ
FRDFWLYDWRUĮ3*&Į has been linked to transcriptional regulation of 
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GLUT4 and therefore has also been associated with the metabolic 
adaptation to exercise.  For example, in rats, low intensity swimming 
exercise leads to an increase in PG&Į H[SUHVVLRQ 7HUDGD HW DO
2002), and similar results have been found in humans (Pilegaard et al., 
2003b).       
 
The aim of the present chapter was to investigate the effects of a single 
bout of moderate intensity one-legged cycling exercise, followed by an 
insulin clamp 24 h later, on skeletal muscle gene expression in order to 
gain a better understanding of the metabolic adaptations to a single 
bout of exercise in humans.  To achieve this aim, the expression of 
genes potentially important for glucose uptake (GLUT4, calpain-10 and 
3*&Į DQG R[LGDWLRQSKRVSKRU\ODWLRQ +.,, 3'. DQG 3'. ZHUH
determined.  It was hypothesised that an increase in insulin sensitivity 
as a result of exercise would be associated with alterations in the 
expression of all of these genes.  In particular, as the previous chapter 
demonstrated that calpain-10 was decreased with insulin infusion, it 
was hypothesised that exercise would increase calpain-10 expression 
(with increased insulin sensitivity) and that insulin infusion following 
exercise would augment this response.     
 
 
 
 
 
 219 
6.2 Subjects and Methods 
 
6.2.1 Study protocol 
 
Eight healthy men (age 24 ± 2 yr, body mass 79 r 4 kg, BMI 24 ± 1 
kg.m2) were recruited from the students of the University of Nottingham 
as described previously.  
    
The study protocol is summarised in Fig 6.1.  Each individual underwent 
a 4 h hyperinsulinaemic-euglycaemic clamp 24 h after completing 90 
min of one-legged moderate intensity (60% of maximal oxygen uptake) 
exercise.  Prior to the commencement of the study, subjects were 
asked to complete an incremental exercise test on a cycle ergometer to 
establish their two-legged V
.
O2 max as described in the general 
methods (2.2.5).  The corresponding one-legged V. O2 max was 
calculated as 75% of the two-legged value, as previously described 
(Pernow and Saltin, 1971).  Linear regression was then used to 
estimate the work load required for a given percentage of the V
.
 
O2 max.   
On day 1 of the study, subjects reported to the laboratory at 
approximately 8 am after an overnight fast and a catheter was placed 
into a dorsal hand vein in a retrograde fashion and placed in heated 
chamber at 55°C  to obtain arterialized blood samples as described 
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previously (general methods, 2.2.2).  To ensure that the first post 
exercise biopsy was obtained as quickly as possible after the cessation 
of exercise, the biopsy site on the leg to be exercised (EX) was 
prepared and anaesthetised prior to the exercise bout as described in 
the general methods (2.2.7).  Subjects were then asked to perform the 
90 min of one-legged exercise on the cycle ergometer.  Briefly, two 
stationary exercise bicycles were placed either side of an electrically 
braked cycle ergometer and the seats were adjusted to allow for 
comfortable peddling of the ergometer whilst the subject remained 
seated on the stationary bicycle.  The non-exercising leg (CON) was 
rested on the stationary bicycle and care was taken to ensure that this 
leg remained as inactive as possible.  The opposing side of the 
ergometer was peddled by the same helper on all occasions.  Four 
subjects exercised with their left leg and the remaining four with their 
right leg. Heart rate monitors were placed on each participant to monitor 
workload throughout the exercise period and oxygen consumption 
measurements were taken every 30 min to ensure that the subject was 
performing the work required.  Blood samples were also taken at 15 min 
intervals during the exercise period.  Following the 90 min of exercise, 
the subject was quickly moved to the bed and placed in a supine 
position where the first biopsy was taken from the EX leg and then the 
CON leg, which was used as the baseline sample.  The subject was 
then fed a mixed meal and was prescribed additional mixed meals (55% 
CHO, 30% fat, 15% protein) to consume for the remainder of the 24 h 
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recovery period, which was based on the subjects usual dietary habits 
which were obtained for three days prior to the study using food diaries.         
 
On day 2, subjects reported to the laboratory at approximately 8 am 
after an overnight fast and after baseline measurements were made, 
muscle biopsies were taken from both the CON and EX leg, as 
described previously (general methods, 2.2.7).  A standard 4 h 
hyperinsulinaemic-euglycaemic clamp was then started at 
approximately 9 am as described in the general methods (2.2.6).  
Determinations of substrate oxidation rate were obtained before and at 
steady state during the last 30 min the insulin clamp.      
 
6.2.2 Blood and urine analysis 
 
Collected blood samples were analysed for blood glucose, serum 
insulin and plasma FFA as described under the general methods 
(2.2.2) section.  
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Figure 6.1  Schematic representation of the exercise study protocol.   
 
Skeletal muscle biopsies were taken immediately following the exercise bout in the 
CON and EX leg on day 1, and before and after the insulin clamp 24 h later on day 2.  
Estimates of substrate oxidation were taken at 30 min intervals during the exercise 
protocol on day 1 and before and at the end of the insulin clamp on day 2.      
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6.2.3 Substrate oxidation rates 
 
Rates of carbohydrate (COX) and fat oxidation (FOX) were calculated 
prior to the exercise on day 1, and before and at steady state during the 
insulin clamp, from the V
.
CO2 and V
.
O2 measurements which were 
obtained using the open-circuit indirect calorimeter, as described in the 
general methods (2.2.4).  During the exercise period, rates of oxidation 
were similarly determined from the V
.
CO2 and 
 
V
.
O2 measurements 
obtained using an alternative machine (Vmax, Sensor Medics, Yorba 
Linda, CA) which was attached to a mouthpiece and valve.                
6.2.4 Whole body glucose disposal calculations 
 
Whole body glucose disposal values were calculated from the glucose 
infusion rate (GIR) during the clamp on day 2 as described in chapter 4 
(4.2.6). 
 
6.2.5 Skeletal muscle biopsy analysis  
 
Skeletal muscle biopsies were analysed for calpain-10 and -3, GLUT4, 
3'. 3'. +.,, DQG 3*&Į P51$ H[SUHVVLRQ XVLQJ 57-PCR, as 
described in the general methods (2.2.7).  
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6.2.6 Statistics 
 
Data were analysed as described in the general methods (2.6).  
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6.3 Results 
 
6.3.1 Blood metabolites 
 
Exercise decreased circulating insulin (PRE EX 7.1 ± 0.8 vs. 90 min EX 
3.6 ± 0.4 mU/L, P<0.01) (Fig 6.2A) and increased plasma FFA (PRE EX 
0.3 ± 0.1 vs. 90 min EX 0.7 ± 0.1 mmol/L, P<0.05) (Fig 6.2B).  These 
values returned to their pre exercise values prior to the insulin clamp on 
day 2 as shown in Fig 6.2.  During the insulin clamp on day 2 
physiological serum insulin concentrations were achieved (78.0 ± 6.0 
mU/L) and plasma FFA were suppressed (PRE CLAMP 0.3 ± 0.04 vs. 
240 min CLAMP 0.02 ± 0.004 mmol/L) at the end of the clamp period 
during steady state. 
 
6.3.2 Substrate oxidation 
 
Carbohydrate oxidation was elevated 30 min into the exercise period 
(PRE EX 11.6 ± 1.5 vs. 30 MIN EX 94.8 ± 10.2 µmol/kg/min, P<0.001) 
and remained at this level until the exercise had ceased (Fig 6.2C).  
Similarly FOX increased after 30 min of exercise (PRE EX 5.5 ± 0.7 vs. 
30 MIN EX 28.3 ± 4.5 µmol/kg/min, P<0.01) and remained essentially 
unchanged until the exercise period was over (Fig 6.2C).  On the 
morning of day 2, both COX (13.1 ± 0.8 µmol/kg/min) and FOX (5.6 ± 
0.5 µmol/kg/min) had returned to their pre exercise values (Fig 6.2C).      
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Figure 6.2  Serum insulin (A), plasma FFA (B) and substrate oxidation 
rates (C) before and during (day 1) and 24 h after (day 2) 90 min of one-
legged exercise (n = 8). 
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6.3.3 Gene expression 
 
The mRNA expression of calpain-10 and -3 and GLUT4 were not 
different between the EX and CON leg at any time point (Fig 6.4).  The 
mRNA levels of PDK4 were also investigated in this chapter and the 
expression of PDK4 was significantly reduced immediately after 
exercise in the EX leg (POST EX 1.4 ± 0.3) versus the CON leg (POST 
EX 2.1 ± 0.4) (P<0.05) (Fig 6.5A).  In contrast, mRNA levels of PDK2 
were not altered immediately after exercise (POST EX (CON) 0.7 ± 0.1 
vs. POST EX (EX) 0.8 ± 0.03) (Fig 6.5B).  24 h after the exercise 
period, PDK4 mRNA levels were significantly reduced in the CON leg 
(POST EX 2.1 ± 0.4 vs. 24 h POST EX 1.0 ± 0.2, P<0.05), and were 
almost identical to the EX leg (24 h POST EX 1.0 ± 0.2).  PDK2 mRNA 
was higher in the EX (24 h POST EX 0.9 ± 0.1) but not the CON (24 h 
POST EX 0.7 ± 0.04) leg 24 h after exercise (P<0.01).  Insulin infusion 
reduced PDK4 mRNA further to the same extent in both legs (POST 
CLAMP (CON) 0.2 ± 0.03 vs. POST CLAMP (EX) 0.2 ± 0.03, P<0.01), 
whereas insulin did not have any additional effect on PDK2 mRNA 
levels (Fig 6.5B).    
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Figure 6.3  The effect of a 90 min one-legged exercise bout on calpain-10 
(A) and calpain-3 (B) and GLUT4 (C) mRNA immediately after and 24 h 
post exercise and following a 4 h insulin clamp (n = 8).   
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Figure 6.4  The effect of a 90 min one-legged exercise bout on PDK4 (A) 
and PDK2 (B) mRNA immediately after and 24 h post exercise and 
following a 4 h insulin clamp (n = 8).  
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The expression of hexokinase-II was similarly increased in the EX leg 
immediately following exercise (POST EX (CON) 1.0 ± 0.1 vs. POST 
EX (EX) 1.3 ± 0.2, P<0.05) and 24 h after the exercise bout (24 h POST 
EX (CON) 0.8 ± 0.2 vs. 24 h POST EX (EX) 1.3 ± 0.2, P<0.05), and was 
also higher in the EX leg following insulin infusion (P<0.05) (Fig 6.6A).  
7KHP51$OHYHOVRI3*&ĮZHUHVLgnificantly elevated in the exercise 
leg 24 h following the exercise bout when compared to the control leg 
(P<0.05) (Fig 6.6B). 
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Figure 6.5  The effect of a 90 min one-legged exercise bout on HKII (A) 
DQG 3*&Į (B) mRNA immediately after and 24 h post exercise and 
following a 4 h insulin clamp (n = 8).    
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6.4 Discussion    
 
The present study investigated the effect of a single bout of exercise on 
the expression of genes thought important for glucose transport and 
oxidation/phosphorylation using a one-legged cycling model.  Gene 
expression was measured immediately following and 24 h after cycling 
exercise under basal and insulin stimulated conditions during a 4 h 
hyperinsulinaemic-euglycaemic clamp.  The main findings from this 
chapter are that an exercise mediated increase in glucose uptake is not 
associated with changes in the mRNA expression of genes believed to 
be important for glucose transport (calpain-10 and GLUT4), but is 
associated with significant alterations in genes that are important for 
glucose oxidation (PDK2 and PDK4) and phosphorylation (HKII).  
 
Calpains and exercise 
 
In the previous chapter of this thesis (chapters 5), insulin sensitivity 
and glucose uptake into skeletal muscle was altered in a negative 
fashion via an increase in FFA availability.  The results from this study 
indicated that FFA mediated insulin resistance was not associated with 
any significant changes in calpain-10 mRNA and protein expression in 
skeletal muscle.  However, it was also shown that hyperinsulinaemia 
negatively regulated calpain-10 mRNA.  In this chapter, the ability of 
exercise to regulate calpain-10 expression was tested.  It was 
hypothesised that an exercise mediated increase in insulin sensitivity 
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and glucose uptake both during and 24 h after exercise might be 
associated with an adaptive increase in calpain expression.  Moreover, 
calpain-3 is intricately linked to skeletal muscle via interaction with titin, 
a giant protein which spans the muscle half-sarcomere from the M to 
the Z line (Sorimachi et al., 1995).  Previous studies have implicated a 
role for calpain-3 during eccentric muscle contraction (Feasson et al., 
2002) and the present study examined whether a single bout of 
exercise leads to changes in the expression of calpain-3 mRNA in 
humans.   
 
Exercise leads to a significant increase in glucose uptake into skeletal 
muscle which has been shown to occur independently of insulin (Ploug 
et al., 1984; Richter et al., 1985; Wallberg-Henriksson and Holloszy, 
1985).  The translocation of GLUT4 to the plasma membrane is 
increased with exercise via as yet unknown mechanisms, but is thought 
to occur via calcium release from the sarcoplasmic reticulum resulting in 
the activation of Ca2+/calmodulin-dependent protein kinase (CaMKII) 
and/or an AMPK related mechanism linked to the energy status of the 
cell (see Wojtaszewski and Richter, 2006 for review).  Whilst the 
downstream mechanisms linking increased calcium release to GLUT4 
translocation are currently unknown, it was hypothesised in this chapter 
that calpains may be important in this putative pathway.  This may be 
especially true given the proposed link between calpain-10 and GLUT4 
in skeletal muscle and that calpains are activated in states of elevated 
intracellular calcium concentrations, such as those seen during 
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exercise.  A potential link between calpain-10 and GLUT4 translocation 
during exercise involving calcium is CaMKII and this has been shown to 
be increased markedly following calpain inhibition in rodents (Otani et 
al., 2006).  Changes in calpain-10 expression during exercise may 
mediate an increase in GLUT4 translocation via CaMKII.  However, in 
the present study, exercise had no effect on calpain-10 expression 
suggesting that this pathway, at least at the level of mRNA, is not 
important during muscle contraction.  Indeed, this is consistent with the 
studies of Otani et al. (2006) as they reported no change in contraction 
mediated glucose uptake or GLUT4 translocation following calpain 
inhibition despite the observed increase in CaMKII expression.  Insulin 
infusion 24 h after an exercise bout for 4 h did not effect calpain-10 
expression and this is consistent with the results in chapters 4 and 5 
suggesting that prior exercise (and an increase in insulin sensitivity) 
does not affect the ability of insulin to regulate calpain-10 mRNA.      
          
A recent study has examined more closely the effect of exhaustive 
cycling exercise on skeletal muscle calpain-3 and µ-calpain protein 
expression and autolysis in humans (Murphy et al., 2005).  The results 
from this study showed that cycling exercise to exhaustion at 70% V
.
O2 
peak did not result in significant autolysis of calpain-3 or µ-calpain, 
which is in agreement to the data in the current study.  The authors 
suggested that their exercise model did not produce an increase in 
intracellular calcium of sufficient duration to lead to increased calpain 
activity.  In the present study, it is also possible that the intracellular 
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calcium concentrations were not elevated long enough to activate 
calpain, and this may have prevented any feedback induced changes in 
calpain expression.  Given that the calcium induced activity of calpain-
10, and to some extent calpain-3, has yet to be characterised and that 
calpain-10 activity cannot be measured directly or indirectly, it is 
currently unclear whether calpain-10 is activated by elevated calcium 
concentrations in cells.  This would seem unlikely as calpain-10 lacks 
the typical calcium binding EF-hand motifs found in the ubiquitous 
calpains, as discussed in chapter 1 (1.8).  Nevertheless, it would be 
interesting to investigate the effects of an exercise bout of longer 
duration to that employed in this study (and therefore more sustained 
elevations in calcium concentrations) on calpain-10 and -3 expression. 
 
GLUT4 and exercise 
 
The finding that GLUT4 mRNA was not altered either immediately 
following exercise or 24 h after exercise may be surprising given that 
many studies have documented such a change in rodents.  For 
example, Ren et al. (1994) showed that GLUT4 mRNA was upregulated 
two-fold 16 h after one prolonged swimming exercise session.  In 
humans however, only a few studies have examined the effect of a 
single bout of exercise on GLUT4 mRNA expression.  Kraniou et al. 
(2006 and 2000) have showed on two occasions that a single exercise 
bout increases GLUT4 mRNA in humans, although the mRNA data 
from the earlier publication has been called into question due to their 
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alleged inappropriate use of quantitative real-time PCR internal controls 
(Schjerling, 2001).  There remains some controversy therefore in 
regards to the effect of a single bout of exercise on GLUT4 mRNA 
levels in humans.  The data from the present study is in agreement with 
recent work which investigated the effect of a one-legged exercise bout 
on GLUT4 mRNA expression and found no effect (Vissing et al., 2005).  
In that study, subjects performed 3 h of one-legged cycling exercise at 
50% V
.
 
O2 peak and biopsy samples were taken immediately after 
exercise and during recovery from exercise.  GLUT4 mRNA levels were 
found to be unchanged with the exercise bout or during 20 h of recovery 
when compared to resting controls (Vissing et al., 2005).  
These results indicate that changes in the mRNA levels of GLUT4 in 
humans may not be associated with the increase in glucose uptake with 
exercise or the adaptive increase in insulin mediated glucose uptake 
during recovery from an exercise bout.  In the short term therefore, 
increased GLUT4 translocation to the plasma membrane during 
exercise and during insulin infusion following exercise may play a more 
important role in the immediate and short term increases in glucose 
uptake into skeletal muscle.  In the longer term and with repeated 
training, adaptive changes in the expression of GLUT4 in skeletal 
muscle may become more important and this has been demonstrated 
previously in humans (Helge et al., 2006; Kim et al., 2004; Dela et al., 
1994).   
 
 237 
Exercise regulation of pyruvate dehydrogenase kinase (PDK) 
 
The pyruvate dehydrogenase complex plays a pivotal role in the 
entrance of pyruvate into the TCA cycle and thus is a major regulator of 
glucose oxidation in skeletal muscle.  In this chapter, PDK4 mRNA was 
downregulated in the exercise leg immediately after the exercise bout 
when compared to the non-exercising leg.  For the first time, this study 
also demonstrates the downregulation of PDK4 mRNA by insulin 
infusion.  An additional isoform of PDK, PDK2, was also shown to be 
differentially expressed between the two legs with exercise; exercise led 
to an increase in PDK2 mRNA 24 h after the exercise bout and 
remained unchanged during the insulin clamp.   
 
A number of studies have investigated the effects of a single bout of 
cycling exercise of various intensities and durations on PDK 
transcription and expression in human skeletal muscle (e.g., Pilegaard 
et al., 2000; Pilegaard and Neufer, 2004; Watt et al., 2004; Mourtzakis 
et al., 2006; Cluberton et al., 2005).  In the first such study, PDK4 gene 
transcription was induced by both 75 min and 4 h of exhaustive 
exercise (Pilegaard et al., 2000).  Both PDK4 transcription and mRNA 
expression was elevated at the end of each exercise bout and remained 
so throughout 4 h of recovery.  However, both transcription and mRNA 
had returned to their pre-exercise levels 24 h following each exercise 
bout.  Studying the time-course of PDK4 mRNA changes during 
moderate intensity exercise to exhaustion in more detail revealed that 
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PDK4 mRNA is not upregulated until 2 h into the exercise period 
(Pilegaard and Neufer, 2004).  The current results show that 90 min of 
one-legged cycling exercise led to reduced PDK4 mRNA expression in 
the exercise leg versus the control leg.  At the end of the exercise, 
whole body COX was substantially higher than FOX and therefore a 
reduced expression of PDK4 mRNA might be expected, as it would 
permit increased activation of the PDH complex and presumably 
increased COX.  This idea was strengthened when, during the insulin 
infusion, PDK4 mRNA was reduced even further.  The reason for the 
discrepancy between this and previous studies is not clear.  In much of 
the previous work, the transcription rate of PDK4 was measured rather 
than mRNA content per se and this may account, at least in part, for the 
differences in the results and also in the interpretations.  The duration 
and intensity of the exercise protocol is also likely to have a significant 
impact on substrate utilisation, PDK levels and PDH activity and this 
makes comparisons between studies difficult.  Moreover, the pre 
exercise muscle glycogen content has been shown to blunt the effects 
of exercise on the metabolic gene expression and this may have been a 
contributing factor in the current study (Pilegaard et al., 2002). 
     
PDK4 mRNA was reduced in both legs to the same extent 24 h after 
exercise in the current study and this is consistent with an increase in 
whole body glucose utilisation seen following exercise (Mikines et 
al.1988).  These data suggest that a serum factor possibly linked to 
increased whole body insulin sensitivity may be responsible for the 
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reduction in PDK4 mRNA in both legs 24 h following exercise.  The 
requirement for a serum factor in the improvements in insulin sensitivity 
with exercise has been demonstrated in vitro (Gao et al., 1994).  It is 
currently not clear what this serum factor is but it is unlikely to be 
insulin, glucose or circulating FFA as these were no different 24 h after 
the exercise bout in the present study, but additional hormonal factors 
(which were not measured in this study) could also play a role.  Other 
factors could also contribute to the reduction in PDK4 mRNA 24 h 
following exercise.  For example, a change in pyruvate concentration 
and/or cellular energy status (NADH/NAD+, ATP/ADP) could affect PDK 
activity in the hours during recovery from exercise.  A change in a 
number of transcription factors (FOXO1, PGC1Į PPARs) have been 
previously documented during recovery from a single bout of endurance 
exercise (Mahoney et al., 2005) and it is possible that these factors 
could have contributed to the reduction in PDK4 mRNA expression.  
,QWHUHVWLQJO\ 3*&Į P51$ H[SUession was increased 24 h following 
the exercise bout but only in the exercised leg.  It is also possible that 
substrate availability and metabolic recovery (e.g. glycogen restoration) 
following exercise is regulating PDK4 mRNA expression in the present 
study.  Some studies have noted an increase in PDK4 mRNA during 
recovery from exercise (Pilegaard et al., 2000; Pilegaard et al., 2005) 
and the difference between these studies and the present one is 
possibly a result of diet composition.  It has been shown that altering 
the carbohydrate composition of the diet following exercise can have a 
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significant impact on PDK4 mRNA and transcription (Pilegaard et al., 
2005).  
 
The PDK4 mRNA data raise some interesting questions regarding the 
experimental protocol.  Muscle biopsies were taken from both legs 
following the exercise period and the biopsy from the control leg, which 
was completely inactive during the exercise period, was used as a 
baseline.  This was done to differentiate the effects of circulating 
hormonal factors (i.e. adrenaline) and exercise per se on gene 
expression.  However, in so doing, both legs were exposed to the same 
circulating factors during the exercise bout and this could have had an 
impact on muscle metabolism and subsequent gene expression in the 
control leg.  An important consideration in this is the effect of exercise 
on muscle glycogen levels in the control leg.  Whilst this was not 
measured in the present study, previous studies using the one-legged 
cycling model have shown that muscle glycogen is unaffected in the 
control leg following exhaustive exercise in humans (Casey et al., 
1995).         
  
In contrast to PDK4, PDK2 mRNA was upregulated 24 h after the 
exercise bout and was not affected by insulin infusion in current study 
suggesting that the two isoforms are regulated by different 
mechanisms.  One possible explanation for these results is that the 
relative amounts of each PDK isoform may determine the total PDK 
activity in certain physiological states.  As PDK2 is more sensitive to 
 241 
inhibition by pyruvate (Bowker-Kinley et al., 1998), a relative increase in 
PDK2 over PDK4 might be expected to increase the sensitivity of the 
PDK complex to inhibition by pyruvate and thus lead to an increase in 
PDH activity when carbohydrate is readily available.    
 
Hexokinase II DQG3*&Į 
 
Finally, in this chapter it has been demonstrated that exercise increases 
the expression of HKII and 3*&Į7KHILQGLQJWKDW+.,,LVXSUHJXODWHG
with exercise and during recovery from exercise is consistent with 
previous reports in humans (Koval et al., 1998; Pilegaard et al., 2005) 
and rats (O’Doherty et al., 1994).  The maintenance of elevated mRNA 
levels of HKII in the exercised leg versus the control leg, combined with 
the alterations in PDK gene expression, may account for the relative 
increase in glucose uptake that occurs during recovery from exercise.  
Whilst the activity of HKII was not measured, it has been shown that 
exercise similarly increases the activity of HKII (Koval et al., 1998).  In 
rats, low intensity swimming exercise increase the expression of 
3*&Į 7HUDGD et al., 2002) and similar findings have been 
demonstrated in humans (Pilegaard et al., 2003) and the results of the 
present study are consistent with these findings.  It is thought that 
3*&Į ELQGV WR DQG PRGXODWHV WKH Dctivity of specific transcription 
factors that are already bound to their target sequences.  Elevated 
3*&ĮH[SUHVVLRQLVWKRXJKWWRFRQWULEXWHWRPLWRFKRQGULDOELRJHQHVLV
via marked increases in the expression of a number of key metabolic 
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genes, including GLUT4 (Micheal et al., 2001).  As mentioned 
previously, an increase in GLUT4 mRNA may not be necessary for the 
immediate or short term adaptations of skeletal muscle to a single bout 
RI H[HUFLVH  7KLV PD\ H[SODLQ ZK\ 3*&ĮP51$ ZDV LQFUHDVHG EXW
GLUT4 mRNA was unchanged in the present.  The present data also 
LQGLFDWH WKDW 3*&Į PD\ FRQWURO WKH H[SUHVVLRQ RI RWKHU PHWDEROLF
genes that are important for the exercise mediated increase in insulin 
sensitivity but which were not measured in this study.      
 
6.5 Conclusions      
 
In conclusion, this study demonstrates that a single bout of exercise is 
associated with changes in the expression of genes important for 
glucose oxidation (PDK2, PDK4) and phosphorylation (HKII) but not 
glucose transport (GLUT4, calpain-10).  This study also confirms the 
recent finding that the skeletal muscle specific calpain-3 is not affected 
by a concentric exercise protocol.  These results provide novel insight 
into the molecular mechanisms behind not only the immediate effects of 
exercise on glucose uptake but also the pathways involved in the 
adaptive increase in insulin mediated glucose uptake seen during 
recovery from a single bout of exercise.  Exercise is beneficial in the 
treatment of diabetes and an understanding of the molecular 
mechanisms responsible for the improvement in glucose uptake and 
insulin sensitivity during and after exercise may lead to novel strategies 
to combat diabetes that may be independent of insulin.    
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7 Calpain-10 single nucleotide polymorphisms and 
calpain-10 expression in type 2 diabetics 
 
7.1 Introduction 
 
Calpain-10 was one of the first genes to be identified as contributing to 
type 2 diabetes risk in Mexican Americans using a positional cloning 
approach (Horikawa et al., 2000).  The risk could be most readily 
defined in terms of specific haplotypes of three polymorphisms: SNP-
43, Indel-19 and SNP-63.  The association of these SNPs and their 
haplotypes with type 2 diabetes has not been consistently replicated in 
other populations.  Importantly for this thesis, this has particularly been 
the case in the UK (Evans et al., 2001) and other European populations 
(Fingerlin et al., 2002; Malecki et al., 2002; Orho-Melander et al., 2002).  
Evans et al. (2001) studied calpain-10 in white subjects of British/Irish 
ancestry using family based case control study designs.  They 
examined the three SNPs mentioned above (SNP-43, Indel-19 and 
SNP-63) and an additional SNP (SNP-44) and did not find any 
association between risk for type 2 diabetes and SNP-43, Indel-19 and 
SNP-63 either individually or as part of the previously described risk 
haplotypes (Evans et al., 2001).  They did observe increased 
transmission of the rare C risk allele at SNP-44 to affected offspring 
suggesting the possible involvement of alternative calpain-10 SNPs in 
UK populations (Evans et al., 2001).  Lynn et al. (2002) investigated the 
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effects of variation in the calpain-10 gene on blood glucose and insulin 
levels in 285 nondiabetic British subjects following a 75 g oral glucose 
tolerance test.  Their results indicated that those subjects with the at-
risk genotype at SNP-43 had higher 2 h plasma glucose levels (Lynn et 
al., 2002).  In addition, those with the at-risk haplotype also had 
increased fasting and 2 h plasma glucose and a reduced insulin 
secretory response (Lynn et al., 2002).  The first part of this final 
chapter combines the data from all subjects used in this thesis and 
investigates the relationship between SNP-43, Indel-19 and SNP-63 
and baseline measurements including blood glucose, serum insulin and 
plasma FFA levels and substrate oxidation rates.  Where possible, data 
from insulin clamps was also combined to investigate the effect on 
glucose disposal.       
 
Since the initial publication describing that variation within calpain-10 
was associated with type 2 diabetes, there have not been any reports of 
investigations of the expression of calpain-10 in type 2 diabetics.  This 
is surprising given that it is over 6 years since this initial finding.  Given 
that reduced calpain-10 expression has been linked to insulin 
resistance in Pima Indians and is reduced with hyperinsulinaemia in this 
thesis, one would expect type 2 diabetics to have reduced levels of 
calpain-10.  In the second part of this chapter, therefore, and as the 
final experiment in this thesis, the expression of skeletal muscle 
calpain-10 was measured for the first time in type 2 diabetics and 
compared to age, sex and activity matched control subjects.   
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7.2 Subjects and methods 
 
7.2.1 Calpain-10 SNP study protocol 
 
Every individual that participated in a study presented in this thesis was 
genotyped at SNP-43, Indel-19 and SNP-63 (general methods, 2.5) 
and these data were combined to allow for investigation into the effect 
of this SNP on blood metabolites, substrate oxidation rates and glucose 
disposal.  It was not possible to examine the effect of the at-risk 
haplotype combination on these measurements due to the expected 
very low frequency of this haplotype.  An extra group of subjects which 
were not used in any of the previous chapters described in this thesis 
were also genotyped and included in the subsequent analysis for this 
chapter (designated chapter 7).  This group consisted of seven healthy 
men who underwent a standard 4 h hyperinsulineamic-euglyceamic 
clamp with measurements of fasting blood metabolites and basal and 
insulin mediated rates of COX and FOX.  A summary of the 
combination of subjects and their characteristics is shown in table 7.1.    
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Table 7.1  Subject characteristics used for the analysis of calpain-10 
SNPs 
 
  
Chapter 
3 
 
Chapter 
4 
 
Chapter 
5 
 
Chapter 
6 
 
Chapter 
7 
 
Total 
 
n 
 
10 
 
11* 
 
10 
 
8 
 
7 
 
46 
Age 
(yrs) 
26 ± 1 26 ±3 22 ± 1 24 ± 2 22 ± 2 24 ± 1 
Body 
mass 
(kg) 
81 ± 4 78 ± 3 78 ± 3 79 ± 4 79 ± 4 79 ± 2 
BMI 
(kg.m2) 
26 ± 1 24 ± 1 24 ± 1 24 ± 1 25 ± 1 24 ± 0.4 
 
Subjects from each chapter were combined with the additional group of subjects 
(designated chapter 7) for the analysis of calpain-10 SNPs.  The characteristics of the 
combined group that was used in this chapter is shown in the last column (total). *An 
extra subject who did not complete the high fat study was also included in the present 
study. 
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7.2.1.1 Calpain-10 SNP determination 
 
Each individuals genotype at SNP-43, Indel-19 and SNP-63 was 
determined as described in the general methods (2.5) chapter.   
 
7.2.1.2 Blood metabolites  
 
Blood glucose, serum insulin and plasma FFA concentrations were 
determined for each individual in each chapter as described in the 
general methods (2.2.2).  Plasma FFA were not determined in the 
additional group.  Fasting data for blood metabolites were combined 
and analysed in terms of SNP genotype.   
 
7.2.1.3 Substrate oxidation   
 
Estimates of basal and insulin mediated substrate oxidation rates were 
obtained in chapters 4 and 5 and in the additional group of subjects 
(chapter 7) using exactly the same equipment and procedure as 
described in the general methods (2.2.4).  In chapter 6, only fasting 
data was included in the analysis.  Data were expressed as 
µmol/kg/min in each case and then combined and analysed in terms of 
the SNP genotype.    
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7.2.1.4 Glucose disposal   
 
Data from baseline insulin clamps, that is prior to any intervention, in 
chapters 4 and 5 and from the additional group of subjects (chapter 7) 
were combined and analysed in terms of the SNP genotype.  A 6 h 
clamp was performed in chapter 5, and to allow for combination with 
the additional data, only the 4 h clamp data were used in the 
subsequent analysis.        
 
7.2.2 Type 2 diabetes study protocol 
 
7.2.2.1 Subjects 
 
This study was performed in collaboration with Dr L.J.C. van Loon and 
colleagues at Maastricht University, The Netherlands.  All physiological 
procedures described in the following section were performed by Dr 
L.J.C van Loon and colleagues.  Briefly, a total of 10 sedentary, 
overweight type 2 diabetes patients (60.0 ± 2.0 yr), 10 sedentary, 
weight-matched, normoglycaemic controls (60.0 ± 2.0 yr) and 10 age-
matched endurance trained cyclists (57.0 ± 1.0 yr) were selected to 
participate in this study (Table 7.3).  All type 2 diabetes patients were 
using oral blood glucose lowering medication (metformin with or without 
sulfonylurea derivatives).  Type 2 diabetic status was verified with an 
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oral glucose tolerance test (OGTT) according to World Health 
Organisation (WHO) criteria.   
 
7.2.2.2 Subject screening 
 
All subjects performed an oral glucose tolerance test (OGTT). After an 
overnight fast, subjects arrived at the laboratory at approximately 8 am 
and a catheter (Baxter BV, Utrecht, the Netherlands) was inserted into 
an antecubital vein and a resting blood sample was drawn.   Following 
this, 75 g of glucose dissolved in 250 ml water was ingested and blood 
samples were taken at 2 h post glucose ingestion.  Blood glucose 
concentrations were measured to obtain an index of glucose tolerance 
according to the American Diabetes Association (ADA) guidelines of 
2003.  Maximal power output (Wmax) and maximal oxygen uptake 
capacity (V. O2 max) were determined on an electronically braked cycle 
ergometer (Lode Excalibur, Groningen, The Netherlands) during an 
incremental exhaustive exercise test 2 weeks before obtaining a muscle 
biopsy sample.  Oxygen uptake (V. O2) and carbon dioxide production (V
.
CO2) were measured continuously (Oxycon ß, Mijnhart, Breda, The 
Netherlands).  Residual lung volume was measured by the helium-
dilution technique using a spirometer (Volugraph 2000, Mijnhart, 
Bunnik, The Netherlands).  Body composition was assessed using the 
hydrostatic weighing method in the morning after an overnight fast and 
body weight was measured with a digital balance with an accuracy of 
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0.001 kg (E1200, August Sauter GmbH, Albstadt, Germany).  Body fat 
percentage was calculated using Siri’s equation and fat free mass 
(FFM) was calculated by subtracting fat mass (FM) from total body 
weight. 
 
7.2.2.3 Muscle sampling and analysis 
 
A fasting muscle biopsy was obtained from all patients as described in 
the general methods (2.2.7).  Calpain-10 mRNA and protein levels 
were determined also as previously described in the general methods 
(2.2.7).   
 
7.2.2.4 Calpain-10 immunohistochemistry 
 
This procedure was performed by Rene Koopman at Maastricht 
University, The Netherlands.  Briefly, muscle samples were dissected 
and frozen in liquid nitrogen.  Approximately 15 mg of muscle were 
frozen in nitrogen-cooled isopentane and embedded in Tissue-Tek 
(Sakura Finetek, Zoeterwoude, The Netherlands).  Multiple serial 
sections (5 µm) were thaw mounted on uncoated, pre-cleaned glass 
slides, fixed in formaldehyde and incubated overnight with calpain-10 
primary antibody (N7) at a concentration of 1:100.  After washing with 
TBS-T, the slides were incubated with a secondary IgG antibody 
labelled with FITC for 30 min followed by 3 wash steps with TBS-T.  
 251 
Slides were examined using a Nikon E800 fluorescence microscope 
(Uvikon, Bunnik, The Netherlands) coupled to a Basler A113 C 
progressive scan colour charge-coupled device (CCD) camera.  The 
antibody 4'-6-Diamidino-2-phenylindole (DAPI) was used as control for 
nuclear staining.  
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7.3 Results 
 
7.3.1 Calpain-10 SNP analysis 
 
As shown in Fig 7.1, genotyping each individual at SNP-43, Indel-19 
and SNP-63 was carried out successfully using the RFLP method.  The 
frequency of each allele is given in Table 7.2 and the numbers of each 
particular genotype are given in Table 7.3.  In total, 46 individuals were 
included in this study (Table 7.1) and all could be genotyped except for 
one subject at SNP-43 and two individuals for both Indel-19 and SNP-
63.   
 
7.3.1.1 SNP and subject characteristics 
 
There was no significant effect of the SNP-43, Indel-19 or SNP-63 
genotype individually on blood metabolites, rates of carbohydrate and 
fat oxidation or insulin stimulated glucose disposal, as summarised in 
Table 7.4.  There was not sufficient numbers of subjects to analyse the 
effect of the at-risk haplotype combination; only a single subject had the 
at-risk genotype in this study.          
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Figure 7.1  Representative agarose gels of digested PCR products for 
SNP-43 (A), SNP-63 (B) and Indel-19 (C).   
 
PCR products were digested with the appropriate restriction enzyme and run on 3% 
(w/v) agarose gels.  For SNP-43, the G and A alleles are seen as bands of 254 bp and 
223 and 31 bp, respectively.  Allele 1 (C) of SNP-63 is seen as a product of 162 bp 
and allele 2 (T) is observed as a band of 192 bp.  Indel-19 is seen as bands of 187 bp 
(three repeats) and 155 bp (two repeats).    
254 bp 
223 bp 
192 bp 
162 bp 
187 bp 
155 bp 
A 
B 
C 
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Table 7.2  Allele frequencies for SNP-43, Indel-19 and SNP-63 
 
 
SNP-43 
 
Indel-19 
 
SNP-63 
 
Allele 1 
 
0.77 
 
0.44 
 
0.93 
Allele 2 0.23 0.56 0.07 
 
SNP-43: allele 1 (G), allele 2 (A). Indel-19: allele 1 (two repeats), allele 2 (three 
repeats). SNP-63: allele 1 (C), allele 2 (T) 
 
 
Table 7.3  Number of each genotype at SNP-43, Indel-19 and SNP-63 
 
 
SNP-43 
 
Indel-19 
 
SNP-63 
 
1/1 
 
26 
 
10 
 
39 
1/2 17 19 4 
2/2 2 15 1 
 
Total 
 
45 
 
44 
 
44 
 
A total of 46 subjects were included in this study.  45 could be genotyped at SNP-43 
and 44 at Indel-19 and SNP-63.  Genotype 1/1 and 2/2 refers to those homozygous 
for allele 1 and allele 2, respectively, and 1/2 refers to those heterozygous for these 
alleles. A description of the alleles is given in Table 7.2.
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Table 7.4  The effect of SNP-43, Indel-19 and SNP-63 on blood metabolites, substrate oxidation and glucose disposal. 
  
 
SNP-43 
  
Indel-19 
  
SNP-63 
  
1/1 
 
1/2 + 2/2  
 
1/1 
 
2/2 
 
1/2  
 
1/1 
 
2/2 
 
1/2 
 
Glucose 
(mmol/L) 
 
 
4.47 ± 0.05 
(26) 
 
4.39 ± 0.07 
(19) 
  
4.39 ± 0.09 
(10) 
 
4.49 ± 0.10 
(15) 
 
4.46 ± 0.05 
(19) 
  
4.48 ± 0.05 
(39) 
 
4.16 
(1) 
 
4.33 ± 0.15 
(4) 
Insulin 
(mU/L) 
 
6.45 ± 0.49 
(26) 
 
6.15 ± 0.50 
(19) 
 5.36 ± 0.61 
(10) 
6.97 ± 0.68 
(15) 
 
6.92 ± 0.62 
(19) 
 
 6.72 ± 0.42 
(39) 
7.25 
(1) 
4.57 ± 0.65 
(4) 
FFA 
(mmol/L) 
0.39 ± 0.05 
(18) 
 
0.36 ± 0.04 
(16) 
 0.42 ± 0.09 
(7) 
0.41 ± 0.10 
(9) 
0.39 ± 0.05 
(11) 
 0.39 ± 0.04 
(31) 
0.19 
(1) 
0.34 ± 0.07 
(3) 
 
COXbasal 
 
COXinsulin 
(µmol/kg/min) 
 
10.6 ± 1.4 
(23) 
22.9 ± 2.8 
(20) 
 
9.63 ± 0.9 
(14) 
20.4 ± 1.5 
(8) 
  
9.3 ± 1.6 
(8) 
20.7 ± 3.2 
(7) 
 
9.13 ± 1.3 
(12) 
19.2 ± 2.7 
(9) 
 
10.9 ± 1.3 
(17) 
22.7 ± 1.7 
(13) 
  
10.3 ± 0.8 
(35) 
21.2 ± 1.4 
(26) 
 
ND 
 
5.0 ± 0.8 
(2) 
20.9 ± 1.7 
(2) 
 
FOXbasal 
 
FOXinsulin 
(µmol/kg/min) 
 
5.8 ± 0.6 
(23) 
1.9 ± 0.8 
(20) 
 
6.0 ± 0.4 
(14) 
2.8 ± 0.5 
(8) 
  
6.2 ± 0.4 
(8) 
3.2 ± 0.7 
(7) 
 
6.1 ± 0.4 
(12) 
2.9 ± 0.8 
(9) 
 
5.7 ± 0.6 
(17) 
2.0 ± 0.6 
(13) 
  
5.9 ± 0.3 
(35) 
2.6 ± 0.5 
(26) 
 
ND 
 
7.7 ± 0.4 
(2) 
2.5 ± 0.1 
(2) 
 
CHO  
disposal 
(µmol/min/kg) 
 
 
59.5 ± 3.3 
(18) 
 
60.4 ± 4.5 
(9) 
  
60.4 ± 4.9 
(7) 
 
57.2 ± 3.1 
(9) 
 
60.3 ± 4.2 
(11) 
  
58.3 ± 2.3 
(28) 
 
ND 
 
62.3 ± 2.3 
(2) 
Blood glucose, serum insulin and plasma FFA, rates of carbohydrate (COX) and fat (FOX) oxidation and insulin mediated glucose disposal were analysed in 
terms of each subjects’ genotype at SNP-43, Indel-19 and SNP-63 as described.  The number of subjects in each category is shown in brackets. Where there 
were no subjects in a category, results were not determined (ND). Refer to Table 7.3 for genotype information. Data are mean ± SEM.  
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7.3.2 Type 2 diabetes and calpain-10 expression 
 
In this chapter, the expression of calpain-10 mRNA and protein in the 
skeletal muscle of type 2 diabetics and was compared to the expression 
in healthy age matched and endurance trained control subjects (Table 
7.3).  Calpain-10 mRNA was no different between the three groups 
(CON 0.89 ± 0.05 vs. DIABETICS 0.82 ± 0.05 vs. TRAINED 0.90 ± 
0.04) (Fig 7.2A).  For calpain-10 protein, immunoreactive bands were 
seen at 75, 60, 48 and 35 kDa as in chapter 5 (5.3.3) and these were 
quantified in each group.  Whilst there was no significant difference in 
the expression of any of the bands individually between each group, 
interesting trends in the expression of the 60 and 48 kDa bands were 
observed on the Western blot in some subjects and this is shown in Fig 
7.2B.  This led to the quantification of all of the observed calpain-10 
bands for the analysis of total calpain-10 protein.  When the expression 
of the bands was combined there was a strong trend towards reduced 
calpain-10 protein in the diabetic group compared to the trained 
subjects (DIABETICS 0.55 ± 0.05 vs. TRAINED 0.67 ± 0.10, P=0.06) 
(Fig 7.2B).  There was no significant difference in total calpain-10 
protein between the sedentary control and diabetic group, or between 
the control and trained group (Fig 7.2B).  Immunohistochemistry of 
control muscle showed that calpain-10 was highly localised to the 
nucleus, cell membrane and vasculature in skeletal muscle (Fig 7.4). 
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Table 7.5  Subjects’ characteristics in the type 2 diabetic trial 
 
 
 
Type 2 
Diabetes 
n = 10 
Sedentary 
Controls 
n = 10 
Trained 
Controls 
n = 10 
 
Age (yrs) 
 
58.9 ± 2.5 
 
60.0 ± 1.9 
 
57.4 ± 0.8 
Height (m) 1.79 ± 0.02 1.76 ± 0.01 1.75 ± 0.01 
Body mass (kg) 93.0 ± 4.4 86.9 ± 1,9 77.7 ± 1.8 # 
BMI (kg.m2) 28.9 ± 1.2 27.5 ± 0.5 25.5 ± 0.7 # 
Body fat (%) 30.4 ± 1.8 28.9 ± 1.4 17.2 ± 11.2 *# 
Fat free mass (kg) 64.5 ± 2.4 61.7 ± 1.6 64.2 ± 11.2 
Basal plasma glucose (mM) 9.0 ± 0.4 5.5 ± 0.2 # 5.7 ± 0.1 # 
Plasma glucose 120min  (mM) 16.81 ± 1.0 5.34 ± 0.49 # 5.28 ± 0.4 # 
Basal plasma insulin (mU/L) 8.70 ± 1.01 7.86 ± 1.58 5.13 ± 0.56 
Plasma insulin 120min 47.24 ± 9.61 48.40 ± 8.04 29.40 ± 6.34 
HbA1c (%) 7.30 ± 0.3 5.83 ± 0.2 # 5.78 ± 0.1 # 
VO2max (L/min) 2.9 ± 0.2 3.2 ± 0.2 3.8 ± 0.1 # 
Wmax (W) 205 ± 16 206 ± 18 300 ± 9 *# 
Maximal heartrate (bpm) 161 ± 4 164 ± 7 172 ± 3 
Diagnosed with diabetes (yrs) 7 ± 1 - - 
 
 
Plasma glucose/insulin120min represents plasma glucose/insulin concentrations at t = 
120 min during the OGTT.  *P<0.05 vs. sedentary control group, #P<0.05 vs. type 2 
diabetes group.  
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Figure 7.2  Calpain-10 mRNA (A) and protein expression (B) in type 2 
diabetics and healthy control and trained subjects.   
A representative Westerm blot shows the detection of multiple immunoreactive bands 
for calpain-10 (B), some of which were differentially expressed (arrows). All of these 
bands were quantified and expressed as total calpain-10 protein (B). †P<0.1 vs. 
diabetic group. 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
Control Diabetic Trained
Ca
lp
a
in
-
10
 
m
R
N
A
 
(re
la
tiv
e
 
to
 
H
M
B
S)
0.0
0.2
0.4
0.6
0.8
1.0
Control Diabetic Trained
To
ta
l c
a
lp
a
in
-
10
 
pr
o
te
in
 
(re
la
tiv
e
 to
 
a
lp
ha
-a
c
tin
)
A 
B 
Calpain-10 (75 kDa)  
Calpain-10 (60 kDa)  
Calpain-10 (48 kDa)  
Calpain-10 (35 kDa)  
Di
a
be
tic
 
Co
n
tr
o
l 
Tr
a
in
e
d 
Di
a
be
tic
 
Co
n
tr
o
l 
Tr
a
in
e
d 
† 
 259 
          
          
          
          
          
          
          
          
          
          
          
          
          
     
 
Figure 7.3  Immunohistochemistry of calpain-10 in human skeletal 
muscle. 
 
Panels A and D show calpain-10 staining in red using the N7 antibody (1:100) and 
panel B shows nuclear staining in blue.  Panel C merges both calpain-10 (A) and 
DAPI (B) signals and demonstrates calpain-10 localisation at the nucleus and plasma 
membrane.   
 
 
A B 
D C 
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7.4 Discussion 
 
This study examined the effect of the common calpain-10 
polymorphisms SNP-43, Indel-19 and SNP-63 on blood metabolites, 
insulin mediated glucose disposal and basal and insulin mediated COX 
and FOX in healthy subjects.  The expression of calpain-10 in the 
skeletal muscle of type 2 diabetics and age matched healthy and 
trained control subjects and the immunolocalisation of calpain-10 was 
also investigated.  The main findings from this final chapter are that the 
none of the SNPs, including the at-risk SNP-43 G/G genotype, were 
associated with fasting blood glucose, serum insulin or plasma FFA 
levels, insulin stimulated glucose disposal or rates of COX and FOX.  In 
the second part of this chapter, it was shown for the first time that total 
calpain-10 protein levels were lower in type 2 diabetic patients when 
compared to age matched endurance trained, but not sedentary, control 
subjects.   
 
A number of studies have previously shown that SNP-43 is associated 
with a number of diabetes related traits, such as elevated blood glucose 
(Lynn et al., 2002), serum cholesterol (Daimon et al., 2002), plasma 
FFA (Orho-Merlander et al., 2002; Carlsson et al., 2004) serum insulin 
concentrations (Orho-Merlander et al., 2002) and recently abdominal 
obesity (Pihlajamaki et al., 2006).  The same polymorphism has been 
linked to reduced calpain-10 mRNA, lower rates of postabsorptive and 
insulin stimulated glucose turnover (Baier et al., 2001; Tripathy et al., 
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2004) and a reduced ability to oxidise carbohydrate (Baier et al., 2001).  
On the other hand, other studies have failed to demonstrate such an 
association and this is particularly the case in the UK and other 
European populations.  For example, Evans et al. (2001) did not show 
an association between SNP-43 and type diabetes in the UK 
population, but were able to show an association with the C allele at an 
additional SNP-44.  The present study would appear to strengthen 
these findings for SNP-43 as no association between this SNP and type 
2 diabetes related traits was seen, but the role of SNP-44 in this study 
remains unknown.  
 
It is not at all clear how SNP-43 would affect any of the physiological 
parameters outlined in this chapter.  Elucidating the role of this 
polymorphism has been confounded further by the fact that SNP-43 is 
located within intron-3 (a region of DNA that is spliced out after 
transcription) of calpain-10.  Horikawa and colleagues considered the 
possibility that there was a gene embedded in intron-3 and whether 
intron-3 influenced calpain-10 transcription as a result (Horikawa et al., 
2000).  However, they were not able to detect a signal on northern blots 
probed using intron-3 suggesting that intron-3 is not part of another 
gene.  In separate experiments the G allele displayed much lower 
binding to a factor present in nuclear extracts from HepG2 and human 
pancreatic cells when compared to the A allele.  Cloning of fragments of 
intron-3 containing SNP-43 (and also SNP-44) upstream of an SV40 
promoter-luciferase gene transcriptional unit revealed that intron-3 and 
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the SNP-43 (and SNP-44) were able to differentially regulate the 
expression of the SV40 reporter gene (Horikawa et al., 2000).  Others 
have since shown that calpain-10 mRNA is reduced considerably in 
human skeletal muscle of subjects homozygous for the G allele at SNP-
43 (Baier et al., 2000; Carlsson et al., 2005).  It was not possible in the 
present study to examine the effect of SNP-43 on calpain-10 mRNA 
and protein expression due to the difficulties in comparing across 
Taqman real-time PCR plates and Western blots.  When looking at the 
effect of SNP-43 on calpain-10 mRNA in the individual chapters, 
however, there was no differences between the G/G and G/A and A/A 
group in any chapter.  The link between calpain-10 SNP-43, calpain-10 
expression and phenotypes relating to type 2 diabetes therefore 
remains unknown.  
 
In general, a low number of subjects in this thesis made it difficult to 
investigate the role of all of the calpain-10 SNPs in detail, although this 
is the first study to examine the role of calpain-10 SNPs on substrate 
oxidation and glucose disposal in healthy UK subjects.  Despite the fact 
that all subjects were combined in the present study, it is important to 
consider that the present study is likely to be underpowered as it was 
calculated that to detect a significant effect of the SNP-43 genotype on 
insulin mediated glucose disposal, a total of 20 subjects was required in 
each group.  To detect a difference in insulin mediated COX, one would 
require in excess of 40 subjects per genotype group.  A lack of 
statistical power was particularly evident for the at-risk polymorphisms 
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which were much less abundant, for example the rare alleles at SNP-63 
and also SNP-44, which was not genotyped in this thesis due to the 
very rare occurrence of the risk C allele.  This also made it difficult to 
examine the role of the risk haplotype combination as only a single 
subject was positive for this haplotype.  It is tempting to speculate, 
however, that the subjects’ response (i.e. calpain-10 expression) to the 
physiological interventions in this thesis may have been governed by 
their genotype at particular loci, so-called environment-gene 
interactions.  Interestingly, in the high fat study of this thesis (chapter 
4), it was observed that subjects who were homozygous for the at-risk 
G allele at SNP-43 were more profoundly affected by the high fat diet 
intervention and had lower basal glucose disposal and reduced COX 
compared to those who had at least one copy of the A allele.  These 
results did not reach statistical significance, most likely because of the 
low number of subjects in each group.  Therefore, future investigations 
in vitro and in vivo with more subjects whose genotype would be 
predetermined would be beneficial for studies into calpain-10, type 2 
diabetes and calpain-10 nutrient-gene interactions.     
 
This chapter includes the first measurement of calpain-10 mRNA and 
protein in the skeletal muscle of type 2 diabetics.  There was no 
significant difference in calpain-10 mRNA between either the control 
group or the diabetic group.  This result was perhaps surprising in the 
context of the currently available literature and given that this gene has 
been closely linked to type 2 diabetes, but perhaps not surprising in the 
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context of the findings of this thesis.  Whilst it has been shown in this 
thesis that hyperinsulinaemia can downregulate calpain-10 expression, 
the type 2 diabetic patients included in this chapter were not 
hyperinsulinaemic and this may partly explain why calpain-10 mRNA 
levels were not different in the diabetics when compared to the control 
subjects.  Interestingly, however, there was a strong trend towards 
reduced total calpain-10 protein in the skeletal muscle of the diabetic 
patients, when compared to the endurance trained control subjects.  
Although there was no significant difference in the expression of any of 
the immunoreactive bands individually, most of the difference in the 
total calpain-10 protein was accounted for by reductions in the 
expression of smaller bands.  This may indicate a potential role for 
calpain-10 isoforms in the development of type 2 diabetes.  It has been 
stressed previously in this thesis that consideration of calpain-10 
isoforms is important but results from isoform expression studies 
(including the present study) must be interpreted with caution given that 
none of the bands have been sequenced and no information is 
available regarding the regulation and protein expression of calpain-10 
isoforms.  Nevertheless, this is an interesting observation given that 
endurance trained athletes have elevated expression of genes that are 
important for glucose transport (e.g. GLUT4) (Richter et al., 1998; Kim 
et al., 2004; Short et al., 2003; Langfort et al., 2003; Dela et al., 1993; 
Gulve and Spina, 1995) and oxidation (e.g. PDH) (Pilegaard et al., 
2000; LeBlanc et al., 2004).  Endurance training is also well known to 
increase insulin mediated glucose uptake (Dela et al., 1992) and it is 
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possible that the elevated calpain-10 and GLUT4 protein levels may, in 
part, govern this muscle adaptation to training.  The endurance trained 
subjects used in the present study may also have had differences in 
muscle fibre type composition when compared to the diabetic subjects 
and this may partly explain the difference in calpain-10 expression.  
Interestingly, the expression of calpain-3 has been shown to be 
increased in type II fast fibres (Jones et al., 1999).  In support of this 
idea, immunohistochemistry of calpain-10 in the present study 
suggested that calpain-10 expression may be regulated by muscle fibre 
type as some muscle fibres clearly stained more intensely than others.  
Whilst these are interesting preliminary observations, further studies are 
needed to examine more closely the effect of fibre type on calpain-10 
expression.      
 
Another interesting and novel observation in the present study is that 
calpain-10 protein appears to be localised to the nucleus and 
sarcolemma in human skeletal muscle.  This finding is in close 
agreement with the results of Ma et al. (2001) who demonstrated that 
calpain-10 was localised to the sarcolemma in skeletal muscle fibres 
from young mice and in the nucleus of lens epithelial cells (Ma et al., 
2001).  These results are also consistent with computer-aided PSORT 
analysis for nuclear localisation signals in domain III of calpain-10 (Ma 
et al., 2001) and findings from Gafni et al. (2004) who demonstrated the 
nuclear localisation of calpain-10 isoforms in human kidney 293T cells 
in vitro.  Together these findings are in contrast to a more recent study 
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suggesting that calpain-10 is located in rat and rabbit kidney 
mitochondria (Arrington et al., 2006).  Attempts to detect calpain-10 in 
human skeletal muscle mitochondria during the course of this thesis 
have repeatedly failed indicating that calpain-10 is not located in the 
mitochondria in humans.  An unexpected finding in the present study 
was that calpain-10 appeared to be highly localised to the skeletal 
muscle microvasculature.  Whilst also a preliminary observation, this 
finding could have important implications for the future study of calpain-
10 in muscle.  The proposed association between skeletal muscle 
insulin resistance and calpain-10 could be a result of the role of calpain-
10 in insulin resistance at the level of the vasculature.  Insulin can exert 
control over capillary surface area via activation of nitric oxide synthase 
(NOS) and an increase in nitric oxide (NO) release and can therefore 
increase total blood flow and blood volume in skeletal muscle.  
Microvascular dysfunction has been linked to insulin resistance and it 
has been suggested that it may form the basis of the metabolic 
syndrome (Serne et al., 2006).  This is based on the fact that the ability 
of insulin to dilate skeletal muscle vasculature is impaired in insulin 
resistant states (Serne et al., 2006).  Any disruption to the correct 
delivery of insulin and glucose to muscle will have implications for 
insulin mediated glucose uptake; thus the vasodilatory and metabolic 
actions of insulin may be coupled (Serne et al., 2006).  Interestingly, the 
vascular actions of insulin that stimulate NO production are PI3K 
dependent and are very similar to metabolic insulin signalling pathways 
providing a potential mechanism for this coupling (Serne et al., 2006).  
 267 
A role for calpain-10 in these pathways could be one way in which it 
exerts an influence on insulin sensitivity.  Clearly more work is needed 
to define the subcellular localisation of calpain-10 in skeletal muscle 
and other insulin sensitive tissues that are important for insulin 
resistance and type 2 diabetes.           
 
7.5 Conclusions     
 
This chapter demonstrates that in healthy male subjects calpain-10 
polymorphisms are not associated with alterations in fasting blood 
metabolite concentrations, basal and insulin mediated substrate 
oxidation rates or insulin stimulated glucose disposal.  It is also shown 
that type 2 diabetic subjects do not have reduced levels of calpain-10 
mRNA or protein when compared to age matched controls.  Endurance 
trained athletes, however, tended to have elevated levels of calpain-10 
protein when compared to the type 2 diabetic group indicating that 
calpain-10 may be important for the skeletal muscle adaptations that 
occur with endurance training.  This is the first study to measure the 
expression of calpain-10 in type 2 diabetics and athletes and more work 
is needed to more fully understand the regulation of calpain-10 
expression in these populations. 
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8 Final discussion 
 
The major aim of this thesis was to test the hypothesis that skeletal 
muscle calpain-10 and -3 gene and protein expression would be 
affected in states of altered insulin sensitivity in healthy humans given 
their proposed role in skeletal muscle metabolism, type 2 diabetes and 
insulin resistance.  In order to test this hypothesis, a number of human 
in vivo experiments were performed, all of which were designed to 
either reduce or increase whole body insulin sensitivity and assess the 
mRNA and protein expression of calpain-10 and -3 in skeletal muscle.  
This thesis also set out to investigate the role of genetic variation in the 
calpain-10 gene on carbohydrate utilisation in healthy humans.  In the 
final chapter the expression of calpain-10 in type 2 diabetic patients was 
compared to control and endurance trained subjects. 
 
In summary, the major finding of this thesis is that calpain-10 and -3 
expression is not altered when insulin sensitivity is negatively or 
positively regulated.  Short-term fasting (Chapter 3) and Intralipid 
infusion (Chapter 5) led to insulin resistance but had no effect on 
calpain-10 or -3 mRNA and protein expression.  This was despite the 
fact that short-term hyperinsulinaemia (achieved by insulin clamps) 
resulted in reduced skeletal muscle calpain-10 mRNA expression 
(Chapter 5).  This effect appeared to be independent of the reduction in 
insulin sensitivity and glucose uptake during the insulin clamp as lipid 
infusion for 6 h markedly reduced insulin mediated glucose uptake but 
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did not modify the response of calpain-10 mRNA to insulin.  Moreover, 
an Increase in insulin sensitivity with a single bout of moderate intensity 
exercise led to increased skeletal muscle glucose uptake but had no 
effect on calpain-10 or -3 mRNA expression (Chapter 6).  This thesis 
also demonstrates that variation in the calpain-10 gene, previously 
linked to type 2 diabetes in some populations, was not associated with 
insulin mediated carbohydrate disposal or oxidation in healthy British 
subjects (Chapter 7).  Neither was any difference found in the mRNA 
expression of calpain-10 in type 2 diabetic patients when compared to 
sedentary and endurance trained control subjects (Chapter 7).  
Interestingly, the protein expression of calpain 10 was found to be lower 
in the diabetic patients when compared to the trained, but not the 
sedentary, controls (Chapter 7). 
 
At the commencement of this thesis project and in the years following 
the publication of the initial association (Horikawa et al., 2000), there 
was considerable interest in calpain-10 as it was the first gene to be 
associated with type 2 diabetes using a positional cloning approach.  A 
genome wide linkage study with affected sib-pairs for type diabetes 
genes in a Mexican American population localised a type 2 diabetes 
susceptibility gene (NIDDM1) to chromosome 2 (Hanis et al., 1996; Cox 
et al., 1999).  Single nucleotide polymorphisms (SNPs) were identified 
in this region and initially SNPs were surveyed in eight patients of 
families with evidence of linkage at NIDDM1 and in two patients of 
families without evidence for linkage.  Those SNPs with minor allele 
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frequencies of more than 10% or those showing a unique pattern were 
genotyped in a patient group of 110 Mexican Americans with type 2 
diabetes and a control group of 112 subjects to compare allele and 
haplotype frequencies between the two groups.  No single SNP was 
significantly associated with type 2 diabetes but when three SNPs were 
combined (SNP-43, Indel-19 and SNP-63) a significant association with 
type 2 diabetes was found.  This combination was also associated with 
diabetes in Finnish and German populations (Horikawa et al., 2000).    
 
Whilst most studies then focused on confirming this association in a 
variety of populations using molecular genetic approaches, on close 
examination of the literature, a number of potential obstacles became 
apparent.  Firstly, the “at-risk” SNPs were all located in intronic regions 
of the calpain-10 gene (Horikawa et al., 2000).  In other words, the 
SNPs that were associated with type 2 diabetes were located in genetic 
regions that did not code for, or alter, the calpain-10 protein.  It was 
shown in the original association study that intron 3, which contained 
SNP-43, may contribute to calpain-10 splicing generating calpain-10f 
(Horikawa et al., 2000).  However, this is probably a rare event and in 
any case calpain-10f is one of the smallest calpain-10 isoforms and 
lacks a complete domain II, which is the critical catalytic domain in the 
ubiquitous calpains.  Whilst it was also shown that the SNP-43 region 
could affect calpain-10 transcription in vitro (Horikawa et al., 2000), a 
direct relationship between SNP-43 (and the other SNPs for that matter) 
and calpain-10 transcription has not been demonstrated in vivo; only 
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SNP-43 has been associated with reduced calpain-10 mRNA levels 
since the initial association study (Baier et al., 2000; Carlsson et al., 
2005).  No study up to the end point of this thesis had even attempted 
to measure calpain-10 protein in human skeletal muscle (a major site of 
insulin resistance) and therefore it has not been demonstrated that any 
of the risk SNPs can affect calpain-10 protein levels.   
 
Another drawback with the initial association study findings was that 
there was no obvious mechanism whereby calpain-10 could affect 
metabolism in such a way as to have a major impact on diabetes risk.  
Calpain-10 was a completely unknown gene and its function was not 
immediately apparent.  As outlined in chapter 1, the calpains had been 
linked to a variety of functions, including skeletal muscle growth and 
differentiation, but not glucose utilisation or any other role that would 
have an obvious impact on insulin resistance and type 2 diabetes.  
What was also unknown was whether calpain-10 was actually a 
protease and/or whether it was activated by calcium.  Calpain-10 lacks 
typical calcium binding domains of the ubiquitous calpains but the active 
site triad is conserved in calpain-10.  
 
Only a handful of functional studies were performed following the initial 
association and, to date, these studies are extremely limited in nature.  
Most have been performed using cell cultures in vitro and have used 
general non-specific calpain inhibitors to examine the role of calpain-10 
primarily in glucose uptake in the adipocyte (e.g. Paul et al., 2003) and 
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in insulin release from the pancreas (e.g. Marshall et al., 2005).  Of the 
few studies that focused on glucose uptake suggested that calpain-10 
may have some role in GLUT4 mediated pathways of glucose uptake in 
vitro.  More convincing evidence currently exists for a role for calpain-10 
in insulin release in the pancreas (Marshall et al., 2005).  Nevertheless, 
evidence continued to mount from the association studies with many 
reporting positive links between calpain-10 genetic variants and type 2 
diabetes.  Meta-analyses of many of the population studies appeared to 
confirm that calpain-10 was associated with type 2 diabetes (Weedon et 
al., 2003; Song et al., 2004; Tsuchiya et al., 2006).  This was even the 
case in the UK population where studies had indicated that calpain-10 
variants affect blood glucose levels (Evans et al., 2001).   
 
The important point is that at the time of this thesis, there was good 
evidence to suggest that calpain-10 may play a role in the development 
of insulin resistance and type 2 diabetes.  At the very least, this 
evidence existed at the level of association studies with some 
additional, albeit indirect, evidence coming from the limited functional in 
vitro data.  What was clearly lacking was studies performed in vivo in 
humans demonstrating that states of insulin resistance were functionally 
linked to changes in calpain-10 mRNA and protein expression in 
skeletal muscle, which is the major site for insulin mediated glucose 
disposal.  The hypothesis of this thesis was therefore relatively simple – 
that changes in whole body and skeletal muscle insulin sensitivity in 
 273 
otherwise healthy humans would alter the expression of calpain-10 
mRNA and protein in skeletal muscle.  
 
In the first two experimental chapters of this thesis, it can be argued that 
part of this aim was not achieved, i.e. that insulin resistance at the level 
of skeletal muscle was not achieved or that the magnitude in the 
reduction in skeletal muscle insulin sensitivity was relatively small and 
short lived.  In the first experimental chapter, short-term fasting did lead 
to whole body insulin resistance but the contribution of skeletal muscle 
to this insulin resistance was uncertain as an insulin tolerance test was 
used to estimate insulin sensitivity.  Previous studies using an almost 
identical fasting protocol in humans did demonstrate skeletal muscle 
insulin resistance (Mansell and Macdonald et al., 1990) and, combined 
with the reduction in skeletal muscle GLUT4 content, it seems likely that 
skeletal muscle insulin resistance was achieved, although the extent of 
this insulin resistance is unknown.  In the following chapter, however, a 
one-week high-fat diet led to a slight increase in insulin mediated 
glucose disposal and only mild reductions in carbohydrate and fat 
oxidation.  It is probable that the lack of insulin resistance seen in this 
chapter was due to the relatively short duration of the high-fat feeding 
protocol.  In these two studies, therefore, it was perhaps not surprising 
that calpain-10 mRNA and protein expression was not affected, 
particularly in chapter 4 where no reduction in insulin mediated glucose 
disposal was seen at all.  The first two interventions in this thesis were 
probably associated with early adaptations in the expression and 
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activity of enzymes important in the regulation of carbohydrate 
metabolism and not necessarily reductions in insulin signalling 
pathways.  This may be an additional explanation for the lack of effect 
of these interventions on skeletal muscle calpain-10 expression as 
there is currently no evidence to suggest that calpain-10 may play a role 
in these early physiological adaptations. 
 
However, in chapter 5 there was a more pronounced reduction in insulin 
mediated glucose disposal with Intralipid infusion.  Previous studies 
have also demonstrated that this intervention is associated with 
significant alterations of the insulin signalling pathway (Belfort et al., 
2005).  In this study, infusion of Intralipid alone had no effect on calpain-
10 expression but infusion of insulin for 6 h with or without the 
simultaneous infusion of Intralipid significantly reduced calpain-10 
mRNA expression.  This finding was unexpected in the context of 
chapter 4, in which insulin was infused for only 4 h, but is also 
consistent with these clamps as the reduction in calpain-10 mRNA was 
only significant at the end of the clamp in chapter 5 (6 h) and not half 
way through the clamp (3 h).  The level of the hyperinsulinaemia seen 
in chapter 5 may also have contributed to the significant reduction in 
calpain-10 expression as in chapter 5, insulin concentrations during the 
clamp were higher than in previous chapters (~90 mU/L in chapter 5 vs. 
70 mU/L in chapter 4).  Whilst the reason for this difference is unknown, 
but are most likely due to subject variability, these data suggest that 
calpain-10 is regulated by hyperinsulinaemia per se and may not be 
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regulated by states of insulin resistance or changes in substrate 
utilisation at rest as Intralipid infusion also led to marked reductions in 
carbohydrate oxidation. 
 
It is therefore tempting to speculate that the regulation of calpain-10 by 
hyperinsulinaemia may explain, in part, the finding of reduced calpain-
10 in insulin resistant states as many of these (i.e. obesity, type 2 
diabetes) are associated with hyperinsulinaemia.  In the two studies 
which have investigated calpain-10 mRNA expression in human 
skeletal muscle, both reported a significant reduction in calpain-10 
expression in subjects with the G/G genotype at SNP-43 (Baier et al., 
2000; Carlsson et al., 2005).  In the first of these studies, subjects with 
the G/G genotype had higher insulin levels at baseline which reached 
significance during a 2 h OGTT (Baier et al., 2000).  In the second study 
it is not known whether the G/G subjects had higher insulin but in a 
separate experiment in that study, calpain-10 mRNA expression was 
determined in subjects with normal (NGT) and impaired glucose 
tolerance (IGT) before and after an insulin clamp.  Interestingly, 
subjects with hyperinsulinaemia (IGT group) appeared to have lower 
levels of basal and insulin stimulated calpain-10 mRNA, although this 
data was not significant.  When these subjects were infused with 
Intralipid for 24 h prior to the insulin clamp, the NGT subjects had 
increased calpain-10 mRNA following the insulin infusion, whereas the 
IGT subjects did not.  These data suggest the possibility that 
hyperinsulinaemia may negatively regulate calpain-10 expression and 
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perhaps prevent a protective increase in calpain-10 mRNA in response 
to stimuli which induce insulin resistance.  It should be noted that in that 
study, the authors did not detect a significant affect of the 2 h insulin 
clamp procedure on calpain-10 mRNA levels, but this is consistent with 
the data in this thesis demonstrating that up to 6 h of insulin infusion is 
required to downregulate calpain-10 mRNA.       
 
It is important to put the finding that insulin downregulates calpain-10 
mRNA into perspective and to consider alternative explanations.   For 
example, insulin infusion for just 3 h has been shown to regulate the 
expression of approximately 800 genes in healthy human skeletal 
muscle (Rome et al., 2003) and has been shown to lead to an increase 
in the mRNA expression of other proteolytic genes, e.g. many 
proteasome components and ubiquitin-conjugating enzymes (Rome et 
al., 2003).  It is generally accepted that physiological hyperinsulinaemia 
promotes muscle protein anabolism, possibly via inhibition of protein 
breakdown (Gelfand and Barrett, 1987) and/or stimulation of protein 
synthesis (Biolo et al., 1995).  Therefore, perhaps the effect of insulin 
infusion on calpain-10 expression seen in this thesis reflects the 
potential role of calpain-10 in skeletal muscle protein turnover, rather 
than its proposed role in carbohydrate metabolism.  This idea would be 
consistent with the effects of insulin infusion on the expression of other 
protease components (Rome et al., 2003) and would also be consistent 
with the role of the ubiquitous calpains in skeletal muscle, as outlined in 
chapter 1 (1.7.2).   
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The results from chapter 7 of this thesis also suggest the possibility 
that calpain-10 is involved in skeletal muscle protein turnover.  In this 
chapter, there was no difference in the expression of calpain-10 
between mRNA and protein between type 2 diabetic and the sedentary 
control subjects but calpain-10 protein was lower when compared to 
endurance trained control subjects.  The relative increase in calpain-10 
protein in the endurance trained subjects was confined to smaller 
calpain-10 isoforms and immunohistochemistry analysis revealed that 
this may be related to the muscle fibre type.  Staining of skeletal muscle 
for calpain-10 revealed an interesting pattern of calpain-10 distribution 
and demonstrated regions of more intense staining which appeared to 
correspond to different fibre types.  Endurance trained subjects tend to 
have a greater proportion of type I, or slow oxidative fibres (Andersson 
et al., 2000) whereas the skeletal muscle from obese and type 2 
diabetic subjects has been shown to contain a reduced proportion of 
type I fibres (Nyholm et al., 1997).  Therefore, differences in calpain-10 
expression between diabetic and trained subjects may be related to the 
muscle fibre type composition.  Whilst more investigation is needed to 
more accurately quantify calpain-10 expression in different muscle fibre 
types, fibre type specific expression of calpain-3 has been 
demonstrated in porcine skeletal muscle (Jones et al., 1999) suggesting 
that this may be an interesting line of future investigation.  
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The human in vivo evidence outlined in this thesis therefore suggests 
that the initial association between calpain-10 and diabetes is not 
confirmed.  Critically, this highlights the difference between the 
presence of an environment-gene association, which might not 
necessarily imply a cause and effect relationship, and a functional 
environment-gene interaction under conditions of altered nutrient supply 
and insulin sensitivity.   
 
For example, one of the initial studies on calpain-10 showed that lower 
skeletal muscle calpain-10 expression in Pima Indians with the risk 
SNP-43 genotype was associated with reduced rates of insulin 
stimulated glucose disposal and carbohydrate oxidation (Baier et al., 
2001).  This finding, however, does not prove that calpain-10 
expression is either the cause of these metabolic alterations or the 
result of them – instead it merely demonstrates a statistical association 
between the two.  It is possible that the lower levels of calpain-10 in 
these subjects was completely unrelated to their metabolic 
characteristics and instead was the result of an alternative factor.  This 
factor could be the SNP-43 genotype per se, for example.  In other 
words, the SNP-43 genotype may well reduce calpain-10 transcription 
but this does not necessarily mean that this is the cause of the 
reduction in carbohydrate utilisation in these subjects.  This thesis 
extends the work from these association studies and demonstrates that 
in healthy human subjects, skeletal muscle calpain-10 expression is not 
important in states of altered nutrient supply and insulin sensitivity and 
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therefore provides strong evidence against a role for calpain-10 in the 
physiological adaptations that occur following these interventions.    
 
One of the major limitations of this thesis was that analysis of calpain-
10 was limited to the mRNA and protein expression only and the 
measurements in this thesis do not provide any insight into the potential 
post-translational roles of calpain-10.  These may include specific 
proteolytic activity towards a number of substrates that are important for 
skeletal muscle metabolism.  It is possible that altered calpain-10 
activity, rather than expression, underlie the association of calpain-10 
with insulin resistance and type 2 diabetes.   This is impossible to rule 
out in the present thesis without parallel measurements of calpain-10 
activity in the studies in this thesis.  The activity of calpain-10 has not 
been measured in any of the previous literature and it is not clear 
whether calpain-10 is proteolytically active at all.  Looking at its protein 
structure (chapter 1, 1.8) it would appear that the active site triad found 
in the ubiquitous calpains is intact in calpain-10, indicating the potential 
for calpain-10 to demonstrate proteolytic activity.  However, it lacks the 
typical calcium binding sites of µ- and m-calpain indicating that any 
potential activity may not be regulated by intracellular calcium 
availability.   
 
The potential proteolytic substrates for calpain-10 are unknown but one 
strong candidate in the literature is the specific glucose transporter, 
GLUT4, as any interaction between GLUT4 and calpain-10 might be 
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expected to have a significant impact on glucose uptake into cells.  
GLUT4 can be cleaved by m-calpain in vitro (Otani et al., 2004) and 
specific inhibition of calpain-10 reduces insulin stimulated translocation 
of GLUT4 to the plasma membrane in adipocytes (Paul et al., 2003).  
The expression of GLUT4 was measured in chapters 3 and 5 in an 
attempt to detect an interaction between GLUT4 and calpain-10.  In 
chapter 3, short term fasting reduced GLUT4 mRNA significantly as 
insulin sensitivity was reduced but had no effect on calpain-10 mRNA or 
protein expression suggesting a divergence between these two 
proteins.  Similarly, in chapter 5, insulin infusion downregulated calpain-
10 mRNA but did not regulate GLUT4 mRNA levels.  A potential 
drawback of this analysis is that GLUT4 expression may not be an ideal 
marker for insulin resistance and it is likely that GLUT4 translocation 
plays a more direct role in determining insulin mediated glucose uptake 
into skeletal muscle.  Calpain-10 may mediate GLUT4 translocation 
only indirectly via effects on the insulin stimulated actin reorganisation 
required for GLUT4 translocation, although this effect has only been 
demonstrated in adipocytes in vitro (Paul et al., 2003).  There is 
therefore little evidence currently to suggest that calpain-10 plays a 
direct role in GLUT4 pathways of glucose uptake into skeletal muscle.  
 
It therefore follows that if calpain-10 is involved in insulin resistance and 
type 2 diabetes via proteolytic modification of key protein substrates, 
then what are these potential substrates aside from GLUT4 that are 
important in the relevant pathways?  It was outlined in chapter 1 that 
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calpains are capable of cleaving a number of proteins involved in a wide 
range of cellular processes ranging from gene transcription to skeletal 
muscle cell differentiation.  One interesting but speculative candidate is 
the signalling intermediate PKC as this has previously been shown to 
be cleaved by calpains in vitro (Kishimoto et al., 1983, 1989).  A role for 
calpain-10 in PKC related pathways may link calpain-10 to insulin 
stimulated GLUT4 translocation and FFA mediated pathways of insulin 
resistance.  Other speculative candidates may be the proteins that are 
involved in vesicle fusion and docking and which may be important in 
GLUT4 exocytosis.  It has previously been shown that an isoform of 
calpain-10 binds to a number of proteins (e.g. SNAP-25, VAMP-2 and 
syntaxin-1) important for insulin-containing vesicle fusion in pancreatic 
cells in vitro (Marshall et al., 2005) but this has yet to be demonstrated 
in muscle cells.  Recent data from the calpastatin overexpressing mice 
also suggests that CaMKII and AMPK may be calpain substrates as the 
protein content of these was increased in the skeletal muscle with 
calpain inhibition (Otani et al., 2006).  Pathways utilising these 
signalling intermediates may link calpain, and possibly calpain-10, with 
exercise mediated glucose uptake although the data from chapter 6 of 
this thesis suggests that calpain-10 and -3 may not be important in such 
pathways.      
 
An additional limitation in this thesis is that calpain-10 expression in 
skeletal muscle was examined in skeletal muscle only and this is just 
one of the key tissues in carbohydrate and fat metabolism.  Therefore 
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the results in this thesis do not exclude a role for calpain-10 in the 
pancreas and in the adipocyte, two important tissues in the 
development of diabetes.  Indeed in vitro studies have demonstrated a 
potential role for calpain-10 in these tissues as discussed in chapter 1 
(1.8.2) and as a result a “two-hit” model whereby calpain-10 expression 
in the pancreas and insulin sensitive tissues (muscle and adipose 
tissue) together could affect glucose utilisation has been proposed.  In 
addition, some interesting novel data from chapter 7 in the present 
thesis suggests that calpain-10 expression is highly localised to the 
skeletal muscle microvasculature and it is possible that a role for 
calpain-10 in this tissue underlies the association of calpain-10 and 
insulin resistance.  More in vitro and in vivo work is needed to better 
understand these potential models.   
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9 Reflections and future work 
 
In summary, based on the present observations and on reflections on 
the previously published literature on calpain-10, it appears unlikely at 
this point that calpain-10 is involved in skeletal muscle insulin 
resistance.  A number of key questions regarding the function of 
calpain-10 and -3 in skeletal muscle, however, still remain.  Much more 
is known about calpain-3, but problems with the purification are 
hindering detailed studies into its activation and substrate specificity.  It 
has been shown that calpain-3 is calcium sensitive and it is clearly 
capable of self-autolysis, but the significance of this autolysis is not 
clear.  Its location in skeletal muscle and the fact that loss of function 
mutations in its gene lead to LGMD2A indicates that calpain-3 must 
play a critical functional role in skeletal muscle, but how does a lack of 
calpain-3 activity lead to muscular dystrophy?  It seems likely that its 
function is more in keeping with the traditional calpains and that it is 
important for skeletal muscle protein turnover.  Its effects on LGMD2A 
would certainly indicate this.  Whether its activity is also important for 
glucose utilisation pathways however, remains to be seen, but the 
results in this thesis would indicate otherwise.   
 
Clearly, much less is known about calpain-10.  To date, the purification 
of the full length protein has not been possible due to its almost 
complete insolubility and this is clearly an important step.  Moreover, it 
is not known whether it is calcium activated, or indeed whether it 
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possesses any activity at all.  The regulation of its expression and the 
functional significance of the observed calpain-10 isoforms also are not 
clear.  Much speculation has surrounded calpain-10 since the initial 
publication but elucidating the mechanisms whereby it may affect 
insulin resistance and type 2 diabetes has been an immense challenge.  
Future work must first focus on the calpain-10 protein in vitro and 
attempt to decipher its complex regulation of expression, its mechanism 
of activation and its specific substrates, if indeed there are any.  
Calpain-10 KO mice have been produced and the phenotypic effects of 
this KO are currently being investigated and these mice will 
undoubtedly yield novel and very important data.  Future human studies 
need to be performed with larger number of subjects to allow for 
detailed investigations into the complex role of genetic variation in the 
calpain-10 gene and of potential nutrient gene interactions. 
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Appendix 1 
 
Determination of serum insulin concentration 
 
For the determination of serum insulin, polypropylene tubes coated with 
anti-insulin antibodies were incubated overnight with 200 µl of serum or 
standard and 1000 µl of 125I-insulin.  Supernatants were then decanted 
and left over tissue paper for 2-3 minutes to remove all remaining liquid.  
The tubes were then counted in a Ȗ-radioactivity counter (Cobra II auto-
gamma-counter, Canberra-Packard, Melbourne, Australia), and results 
were calculated from a standard curve of known concentrations of 
insulin. 
 
Determination of plasma FFA 
 
In a 96-well plate, 4 µl of sample was added to each well in duplicate, 
and for the standard curve, 0-9 µl of a 1 mM oleic acid solution was 
added to each well in duplicate to give a standard concentration range 
of 0-0.0291 mM FFA.  Following this, 75 µl of colour reagent A was 
added to each well before incubating the plate at 37°C for 10 min.  
Next, 150 µl of reagent B was added to each well and the plate was 
incubated for a further 10 min at 37°C.  The absorbance of each sample 
and standard was measured at 550 nm.  To calculate the FFA 
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concentration of each unknown sample, the standard curve was plotted 
and used to obtain the FFA concentration in each well, and this figure 
was multiplied by 61 to account for the dilution of the sample in the well 
by the other reagents used throughout the assay. 
 
DetermLQDWLRQRIEORRGNHWRQHVȕ-hydroxybutyrate)  
 
This assay was based on that described by Williamson et al. (1962) and 
was performed by Sally Cordon at the School of Biomedical Sciences, 
University of Nottingham.  Briefly, 150 µl of whole blood was added to 
300 µl of 10% perchloric acid, mixed and allowed to precipitate.  The 
sample was then centrifuged at 1000 g for 5 minutes and the 
supernatant was removed to a fresh tube and the sample was frozen at 
-20°C.  A set of standards ranging from 0 – 100 µM was prepared in 
advance in the same way as the samples (i.e. PCA precipitation).  
Samples were neutralised with the addition of 110 µl of 20% KOH and 
the pH of the resulting supernatant was checked with pH indicator 
paper.  A pH of 7-8 was optimal.  The samples were then centrifuged 
for 5 minutes at 1000 g.  The standards were neutralised with 65 µl of 
20% KOH and 45 µl of H2O (to make up the volume to 110 µl) and 
processed in the same way as the samples.  Either 100 µl of sample or 
standard was added to a well in a 96-well plate in triplicate and 55 µl of 
nicotinamide-adenine dinucleotide (NAD) solution (200 µl of NAD 
solution with 2 ml of hydrazine tris buffer) was added to each well.  The 
NAD (2 mg) was reconstituted in 200 ȝO7KHK\GUD]LQHWULVEXIIHUZDV
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prepared by the addition of 2 mg of EDTA to 100 µl hydrazine hydrate, 
500 µl of 1 N HCl and 1.4 ml 0.1 M tris buffer (pH 8.5).  A plate reader 
was set to 30°C and the plate was read at 340 nm.  One microlitre of 
enzyme was then added to each well except one of each standard, 
which served as a sample blank.  The plate was incubated at 30°C for 1 
h and read at 340 nm.  To calculate the absorbance change during the 
reaction for the standards, the mean first read values were subtracted 
from the mean final read values.  The absorbance change was plotted 
DJDLQVW ȕ-hydoxybutyrate concentration and this was used as the 
standard curve.  The concentration of the sample was calculated in the 
same way from the standard curve.  
 
Determination of glucagon concentrations   
 
This assay was performed by Dr. K. Chokkalingam at the Queens 
Medical Centre, Nottingham.  Briefly, 200 µl of each sample and 
supplied standard were transferred to an individual glass tube and 100 
µl of glucagon antiserum was added.  Tubes were vortexed and 
incubated at 4°C for 24 h.  The next day 100 µl of 125I glucacon was 
added to each tube and the samples were again left for 24 h at 4°C.  
The following day, 1 ml of cold precipitating solution was added to the 
tubes and the samples were centrifuged at 1500 g for 15 minutes.  The 
supernatant was decanted and the tubes were counted for 1 min (Cobra 
auto-gamma-counter).   
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Determination of urine urea concentrations  
 
This assay was performed by Dr. K. Chokkalingam at the Queens 
Medical Centre, Nottingham.  Urine urea was quantified using a 
commercially available kit (Randox Laboratories, UK).  Briefly, urine 
samples were diluted 10-fold and 2 µl of sample was added to 200 µl of 
reagent A in well of a 96-well plate in duplicate.  Serial 2-fold dilutions of 
the provided standard solution (13.3 mM) were prepared and 2 µl were 
also added to 200 µl of reagent A in a well of a 96-well plate in 
duplicate.  The plate was incubated at 37°C for 30 min and then read at 
340 nm.     
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Appendix 2 
 
Table A.1  Real-time PCR primers and probes used in this thesis 
 
 
 
Gene Accession 
no. 
Primer/Probe Sequence 
 
 
Calpain-10 
 
 
 
  NM_023083   
 
Forward primer 
Taqman probe 
Reverse primer 
 
5’-GTGCCTTGCAGGGAGACTCT-3’  
5’ (FAM)-TGTTCTGGCTCCCCTTACTGGAAAAGGTCTAC-(TAMRA) 3’  
5’-CGTAGGACCCATGGACCTTG-3’ 
 
GLUT4 
  
NM_001042 
 
Forward primer 
Taqman probe 
Reverse primer 
 
5’-GCTGTGGCTGGTTTCTCCAA-3’ 
5’ (FAM)-CAACTTCATCATTGGCATGGGTTTCCA-(TAMRA) 3 
5’-CCCATAGCCTCCGCAACATA-3’ 
 
Calpain-3 
 
  
NM_000070 
 
Forward primer 
Taqman probe 
Reverse primer 
 
5’-GGCGGAAGGACCGGAAGCT -3’ 
5’ (FAM)-TCGCCATCTACGAGGTTCCCAAAGAGAT-(TAMRA) 3’  
5’-TCCTTCTGCAGGTGCTGC T-3’ 
 
PDK4 
 
 
 
 
NM_002612 
 
Forward primer 
Taqman probe 
Reverse primer 
 
5’-CAAGGATGCTCTGTGATCAGTATTATTT-3’ 
 5’ (FAM)- CATCTCCAGAATTAAAGCTTACACAAGTGAATGGA-(TAMRA) 3’ 
5’-TGTGAATTGGTTGGTCTGGAAA-3’ 
 
 
PDK2 
 
NM_002611 
 
 
Forward primer 
Taqman probe 
Reverse primer 
 
5’-CATCATGAAAGAGATCAACCTGCTT-3’ 
 5’ (FAM)- CCGACCGAGTGCTGAGCACACCC-(TAMRA) 3’ 
5’-CAGGAGGCTCTGGACATACCA-3’ 
 
 
˞-Actin 
 
 
NM_001100 
 
Forward primer 
Taqman probe 
Reverse primer 
 
5’-GAGCGTGGCTACTCCTTCGT-3’ 
 5’ (FAM)-ACCACAGCTGAGCGCGAGATCGT-(TAMRA) 3’ 
 5’-GTAGCACAGCTTCTCCTTGATGTC-3’ 
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Table A.2  Real-time PCR primers and probes used in this thesis (contd)   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Accession 
no. 
Primer/Probe Sequence 
 
HKII 
 
NM_000189 
 
Forward primer 
Taqman probe 
Reverse primer 
 
5’-AAGTTCTTGTCTCAGATTGAGAGTGACT-3’  
5’ (FAM)-CTGCAACACTTAGGGCTTGAGAGCACCTG-(TAMRA) 3’  
5’-CAGTGCACACCTCCTTAACAATG-3’ 
 
3*&Į 
  
NM_013261 
 
Forward primer 
Taqman probe 
Reverse primer 
 
5’-GGTGCAGTGACCAATCAGAAATAA-3’ 
5’ (FAM)-ATCCAATCAGTACAACAATGAGCCTTCAAACATAT-(TAMRA) 3’ 
5’-TTGCCTCATTCTCTTCATCTATCTTC-3’ 
